id	sid	tid	token	lemma	pos
dti-3213	1	1	dti	dti	PROPN
dti-3213	1	2	drug	drug	PROPN
dti-3213	1	3	target	target	NOUN
dti-3213	1	4	insights	insight	NOUN
dti-3213	1	5	2024	2024	NUM
dti-3213	1	6	;	;	PUNCT
dti-3213	1	7	18	18	NUM
dti-3213	1	8	:	:	SYM
dti-3213	1	9	105	105	NUM
dti-3213	1	10	-	-	SYM
dti-3213	1	11	111	111	NUM
dti-3213	1	12	issn	issn	PROPN
dti-3213	1	13	1177	1177	NUM
dti-3213	1	14	-	-	SYM
dti-3213	1	15	3928	3928	NUM
dti-3213	1	16	|	|	ADV
dti-3213	1	17	doi	doi	NOUN
dti-3213	1	18	:	:	PUNCT
dti-3213	1	19	10.33393	10.33393	NUM
dti-3213	1	20	/	/	SYM
dti-3213	1	21	dti.2024.3213	dti.2024.3213	PRON
dti-3213	1	22	original	original	ADJ
dti-3213	1	23	research	research	NOUN
dti-3213	1	24	article	article	NOUN
dti-3213	1	25	drug	drug	NOUN
dti-3213	1	26	target	target	NOUN
dti-3213	1	27	insights	insight	NOUN
dti-3213	1	28	issn	issn	VERB
dti-3213	1	29	1177	1177	NUM
dti-3213	1	30	-	-	SYM
dti-3213	1	31	3928	3928	NUM
dti-3213	1	32	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-3213	1	33	©	©	PROPN
dti-3213	1	34	2024	2024	NUM
dti-3213	1	35	the	the	DET
dti-3213	1	36	authors	author	NOUN
dti-3213	1	37	.	.	PUNCT
dti-3213	2	1	this	this	DET
dti-3213	2	2	article	article	NOUN
dti-3213	2	3	is	be	AUX
dti-3213	2	4	published	publish	VERB
dti-3213	2	5	by	by	ADP
dti-3213	2	6	aboutscience	aboutscience	NOUN
dti-3213	2	7	and	and	CCONJ
dti-3213	2	8	licensed	license	VERB
dti-3213	2	9	under	under	ADP
dti-3213	2	10	creative	creative	ADJ
dti-3213	2	11	commons	common	NOUN
dti-3213	2	12	attribution	attribution	NOUN
dti-3213	2	13	-	-	PUNCT
dti-3213	2	14	noncommercial	noncommercial	ADJ
dti-3213	2	15	4.0	4.0	NUM
dti-3213	2	16	international	international	NOUN
dti-3213	2	17	(	(	PUNCT
dti-3213	2	18	cc	cc	NOUN
dti-3213	2	19	by	by	ADP
dti-3213	2	20	-	-	PUNCT
dti-3213	2	21	nc	nc	PROPN
dti-3213	2	22	4.0	4.0	NUM
dti-3213	2	23	)	)	PUNCT
dti-3213	2	24	.	.	PUNCT
dti-3213	3	1	commercial	commercial	ADJ
dti-3213	3	2	use	use	NOUN
dti-3213	3	3	is	be	AUX
dti-3213	3	4	not	not	PART
dti-3213	3	5	permitted	permit	VERB
dti-3213	3	6	and	and	CCONJ
dti-3213	3	7	is	be	AUX
dti-3213	3	8	subject	subject	ADJ
dti-3213	3	9	to	to	ADP
dti-3213	3	10	publisher	publisher	NOUN
dti-3213	3	11	’s	’s	PART
dti-3213	3	12	permissions	permission	NOUN
dti-3213	3	13	.	.	PUNCT
dti-3213	4	1	full	full	ADJ
dti-3213	4	2	information	information	NOUN
dti-3213	4	3	is	be	AUX
dti-3213	4	4	available	available	ADJ
dti-3213	4	5	at	at	ADP
dti-3213	4	6	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3213	4	7	faricimab	faricimab	NOUN
dti-3213	4	8	versus	versus	ADP
dti-3213	4	9	the	the	DET
dti-3213	4	10	standard	standard	NOUN
dti-3213	4	11	of	of	ADP
dti-3213	4	12	care	care	NOUN
dti-3213	4	13	for	for	ADP
dti-3213	4	14	neovascular	neovascular	NOUN
dti-3213	4	15	age	age	NOUN
dti-3213	4	16	-	-	PUNCT
dti-3213	4	17	related	relate	VERB
dti-3213	4	18	macular	macular	ADJ
dti-3213	4	19	degeneration	degeneration	NOUN
dti-3213	4	20	in	in	ADP
dti-3213	4	21	italy	italy	PROPN
dti-3213	4	22	:	:	PUNCT
dti-3213	4	23	an	an	DET
dti-3213	4	24	indirect	indirect	ADJ
dti-3213	4	25	treatment	treatment	NOUN
dti-3213	4	26	comparison	comparison	NOUN
dti-3213	4	27	carlotta	carlotta	PROPN
dti-3213	4	28	galeone	galeone	NOUN
dti-3213	4	29	1,2	1,2	NUM
dti-3213	4	30	,	,	PUNCT
dti-3213	4	31	federica	federica	PROPN
dti-3213	4	32	turati3	turati3	PROPN
dti-3213	4	33	,	,	PUNCT
dti-3213	4	34	massimo	massimo	PROPN
dti-3213	4	35	nicolò	nicolò	PROPN
dti-3213	4	36	4	4	NUM
dti-3213	4	37	,	,	PUNCT
dti-3213	4	38	mariacristina	mariacristina	NOUN
dti-3213	4	39	parravano	parravano	PROPN
dti-3213	4	40	5	5	NUM
dti-3213	4	41	,	,	PUNCT
dti-3213	4	42	stela	stela	PROPN
dti-3213	4	43	vujosevic	vujosevic	VERB
dti-3213	4	44	6,7	6,7	NUM
dti-3213	4	45	,	,	PUNCT
dti-3213	4	46	laura	laura	PROPN
dti-3213	4	47	bianchino8	bianchino8	PROPN
dti-3213	4	48	,	,	PUNCT
dti-3213	4	49	emilia	emilia	PROPN
dti-3213	4	50	sicari	sicari	PROPN
dti-3213	4	51	8	8	NUM
dti-3213	4	52	,	,	PUNCT
dti-3213	4	53	paolo	paolo	NOUN
dti-3213	4	54	lanzetta	lanzetta	NOUN
dti-3213	4	55	9,10	9,10	NUM
dti-3213	4	56	1bicocca	1bicocca	NUM
dti-3213	4	57	applied	apply	VERB
dti-3213	4	58	statistics	statistic	NOUN
dti-3213	4	59	center	center	NOUN
dti-3213	4	60	(	(	PUNCT
dti-3213	4	61	basc	basc	PROPN
dti-3213	4	62	)	)	PUNCT
dti-3213	4	63	,	,	PUNCT
dti-3213	4	64	università	università	PROPN
dti-3213	4	65	degli	degli	PROPN
dti-3213	4	66	studi	studi	PROPN
dti-3213	4	67	di	di	PROPN
dti-3213	4	68	milano	milano	PROPN
dti-3213	4	69	-	-	PUNCT
dti-3213	4	70	bicocca	bicocca	PROPN
dti-3213	4	71	,	,	PUNCT
dti-3213	4	72	milan	milan	PROPN
dti-3213	4	73	italy	italy	PROPN
dti-3213	4	74	2biostatistics	2biostatistics	NUM
dti-3213	4	75	&	&	CCONJ
dti-3213	4	76	outcome	outcome	PROPN
dti-3213	4	77	research	research	NOUN
dti-3213	4	78	,	,	PUNCT
dti-3213	4	79	statinfo	statinfo	NOUN
dti-3213	4	80	,	,	PUNCT
dti-3213	4	81	milan	milan	PROPN
dti-3213	4	82	italy	italy	PROPN
dti-3213	5	1	3department	3department	NUM
dti-3213	5	2	of	of	ADP
dti-3213	5	3	clinical	clinical	ADJ
dti-3213	5	4	sciences	science	NOUN
dti-3213	5	5	and	and	CCONJ
dti-3213	5	6	community	community	NOUN
dti-3213	5	7	health	health	NOUN
dti-3213	5	8	,	,	PUNCT
dti-3213	5	9	university	university	PROPN
dti-3213	5	10	of	of	ADP
dti-3213	5	11	milan	milan	PROPN
dti-3213	5	12	,	,	PUNCT
dti-3213	5	13	milan	milan	PROPN
dti-3213	5	14	italy	italy	PROPN
dti-3213	6	1	4clinica	4clinica	PROPN
dti-3213	6	2	oculistica	oculistica	PROPN
dti-3213	6	3	—	—	PUNCT
dti-3213	6	4	dinogmi	dinogmi	ADJ
dti-3213	6	5	,	,	PUNCT
dti-3213	6	6	irccs	ircc	VERB
dti-3213	6	7	ospedale	ospedale	PROPN
dti-3213	6	8	policlinico	policlinico	PROPN
dti-3213	6	9	san	san	PROPN
dti-3213	6	10	martino	martino	PROPN
dti-3213	6	11	,	,	PUNCT
dti-3213	6	12	genoa	genoa	PROPN
dti-3213	6	13	italy	italy	PROPN
dti-3213	6	14	5irccs	5irccs	PROPN
dti-3213	6	15	-	-	PUNCT
dti-3213	6	16	fondazione	fondazione	NOUN
dti-3213	6	17	bietti	bietti	NOUN
dti-3213	6	18	,	,	PUNCT
dti-3213	6	19	rome	rome	PROPN
dti-3213	6	20	italy	italy	PROPN
dti-3213	7	1	6department	6department	NUM
dti-3213	7	2	of	of	ADP
dti-3213	7	3	biomedical	biomedical	ADJ
dti-3213	7	4	,	,	PUNCT
dti-3213	7	5	surgical	surgical	ADJ
dti-3213	7	6	,	,	PUNCT
dti-3213	7	7	and	and	CCONJ
dti-3213	7	8	dental	dental	ADJ
dti-3213	7	9	sciences	science	NOUN
dti-3213	7	10	,	,	PUNCT
dti-3213	7	11	university	university	PROPN
dti-3213	7	12	of	of	ADP
dti-3213	7	13	milan	milan	PROPN
dti-3213	7	14	,	,	PUNCT
dti-3213	7	15	milan	milan	PROPN
dti-3213	7	16	italy	italy	PROPN
dti-3213	7	17	7eye	7eye	PROPN
dti-3213	7	18	clinic	clinic	NOUN
dti-3213	7	19	,	,	PUNCT
dti-3213	7	20	irccs	ircc	VERB
dti-3213	7	21	multimedica	multimedica	PROPN
dti-3213	7	22	,	,	PUNCT
dti-3213	7	23	milan	milan	PROPN
dti-3213	7	24	italy	italy	PROPN
dti-3213	7	25	8roche	8roche	NUM
dti-3213	7	26	s.p.a	s.p.a	PROPN
dti-3213	7	27	.	.	PROPN
dti-3213	7	28	,	,	PUNCT
dti-3213	7	29	monza	monza	PROPN
dti-3213	7	30	italy	italy	PROPN
dti-3213	8	1	9department	9department	NUM
dti-3213	8	2	of	of	ADP
dti-3213	8	3	medicine	medicine	NOUN
dti-3213	8	4	-	-	PUNCT
dti-3213	8	5	ophthalmology	ophthalmology	NOUN
dti-3213	8	6	,	,	PUNCT
dti-3213	8	7	university	university	PROPN
dti-3213	8	8	of	of	ADP
dti-3213	8	9	udine	udine	PROPN
dti-3213	8	10	,	,	PUNCT
dti-3213	8	11	udine	udine	PROPN
dti-3213	8	12	italy	italy	PROPN
dti-3213	8	13	10iemo	10iemo	PROPN
dti-3213	8	14	,	,	PUNCT
dti-3213	8	15	istituto	istituto	PROPN
dti-3213	8	16	europeo	europeo	PROPN
dti-3213	8	17	di	di	PROPN
dti-3213	8	18	microchirurgia	microchirurgia	PROPN
dti-3213	8	19	oculare	oculare	PROPN
dti-3213	8	20	,	,	PUNCT
dti-3213	8	21	udine	udine	PROPN
dti-3213	8	22	italy	italy	PROPN
dti-3213	8	23	abstract	abstract	ADJ
dti-3213	8	24	objectives	objective	NOUN
dti-3213	8	25	:	:	PUNCT
dti-3213	8	26	to	to	PART
dti-3213	8	27	assess	assess	VERB
dti-3213	8	28	through	through	ADP
dti-3213	8	29	an	an	DET
dti-3213	8	30	indirect	indirect	ADJ
dti-3213	8	31	treatment	treatment	NOUN
dti-3213	8	32	comparison	comparison	NOUN
dti-3213	8	33	(	(	PUNCT
dti-3213	8	34	itc	itc	PROPN
dti-3213	8	35	)	)	PUNCT
dti-3213	8	36	the	the	DET
dti-3213	8	37	potential	potential	ADJ
dti-3213	8	38	benefit	benefit	NOUN
dti-3213	8	39	of	of	ADP
dti-3213	8	40	faricimab	faricimab	NOUN
dti-3213	8	41	over	over	ADP
dti-3213	8	42	the	the	DET
dti-3213	8	43	anti	anti	ADJ
dti-3213	8	44	-	-	ADJ
dti-3213	8	45	vascular	vascular	ADJ
dti-3213	8	46	endothelial	endothelial	ADJ
dti-3213	8	47	growth	growth	NOUN
dti-3213	8	48	factor	factor	NOUN
dti-3213	8	49	(	(	PUNCT
dti-3213	8	50	vegf	vegf	NOUN
dti-3213	8	51	)	)	PUNCT
dti-3213	8	52	real	real	ADJ
dti-3213	8	53	-	-	PUNCT
dti-3213	8	54	life	life	NOUN
dti-3213	8	55	scenario	scenario	NOUN
dti-3213	8	56	,	,	PUNCT
dti-3213	8	57	hereby	hereby	ADV
dti-3213	8	58	defined	define	VERB
dti-3213	8	59	standard	standard	NOUN
dti-3213	8	60	of	of	ADP
dti-3213	8	61	care	care	NOUN
dti-3213	8	62	(	(	PUNCT
dti-3213	8	63	soc	soc	NOUN
dti-3213	8	64	)	)	PUNCT
dti-3213	8	65	,	,	PUNCT
dti-3213	8	66	in	in	ADP
dti-3213	8	67	italy	italy	PROPN
dti-3213	8	68	,	,	PUNCT
dti-3213	8	69	that	that	ADV
dti-3213	8	70	is	be	AUX
dti-3213	8	71	,	,	PUNCT
dti-3213	8	72	aflibercept	aflibercept	ADJ
dti-3213	8	73	,	,	PUNCT
dti-3213	8	74	bevacizumab	bevacizumab	NOUN
dti-3213	8	75	,	,	PUNCT
dti-3213	8	76	and	and	CCONJ
dti-3213	8	77	ranibizumab	ranibizumab	NOUN
dti-3213	8	78	,	,	PUNCT
dti-3213	8	79	in	in	ADP
dti-3213	8	80	patients	patient	NOUN
dti-3213	8	81	with	with	ADP
dti-3213	8	82	neovascular	neovascular	NOUN
dti-3213	8	83	age	age	NOUN
dti-3213	8	84	-	-	PUNCT
dti-3213	8	85	related	relate	VERB
dti-3213	8	86	macular	macular	ADJ
dti-3213	8	87	degeneration	degeneration	NOUN
dti-3213	8	88	(	(	PUNCT
dti-3213	8	89	namd	namd	NOUN
dti-3213	8	90	)	)	PUNCT
dti-3213	8	91	naïve	naïve	ADJ
dti-3213	8	92	to	to	ADP
dti-3213	8	93	any	any	DET
dti-3213	8	94	anti	anti	ADJ
dti-3213	8	95	-	-	ADJ
dti-3213	8	96	vegf	vegf	ADJ
dti-3213	8	97	treatment	treatment	NOUN
dti-3213	8	98	.	.	PUNCT
dti-3213	9	1	methods	method	NOUN
dti-3213	9	2	:	:	PUNCT
dti-3213	9	3	individual	individual	ADJ
dti-3213	9	4	patient	patient	NOUN
dti-3213	9	5	-	-	PUNCT
dti-3213	9	6	level	level	NOUN
dti-3213	9	7	data	datum	NOUN
dti-3213	9	8	from	from	ADP
dti-3213	9	9	the	the	DET
dti-3213	9	10	phase	phase	NOUN
dti-3213	9	11	iii	iii	NUM
dti-3213	9	12	clinical	clinical	ADJ
dti-3213	9	13	trials	trial	NOUN
dti-3213	9	14	tenaya	tenaya	PROPN
dti-3213	9	15	and	and	CCONJ
dti-3213	9	16	lucerne	lucerne	PROPN
dti-3213	9	17	(	(	PUNCT
dti-3213	9	18	faricimab	faricimab	NOUN
dti-3213	9	19	cohort	cohort	NOUN
dti-3213	9	20	)	)	PUNCT
dti-3213	9	21	and	and	CCONJ
dti-3213	9	22	the	the	DET
dti-3213	9	23	real	real	ADJ
dti-3213	9	24	-	-	PUNCT
dti-3213	9	25	world	world	NOUN
dti-3213	9	26	study	study	NOUN
dti-3213	9	27	radiance	radiance	NOUN
dti-3213	9	28	(	(	PUNCT
dti-3213	9	29	radiance	radiance	NOUN
dti-3213	9	30	cohort	cohort	NOUN
dti-3213	9	31	)	)	PUNCT
dti-3213	9	32	were	be	AUX
dti-3213	9	33	used	use	VERB
dti-3213	9	34	.	.	PUNCT
dti-3213	10	1	efficacy	efficacy	NOUN
dti-3213	10	2	was	be	AUX
dti-3213	10	3	evaluated	evaluate	VERB
dti-3213	10	4	with	with	ADP
dti-3213	10	5	changes	change	NOUN
dti-3213	10	6	in	in	ADP
dti-3213	10	7	best	well	ADV
dti-3213	10	8	corrected	correct	VERB
dti-3213	10	9	visual	visual	ADJ
dti-3213	10	10	acuity	acuity	NOUN
dti-3213	10	11	(	(	PUNCT
dti-3213	10	12	bcva	bcva	NOUN
dti-3213	10	13	)	)	PUNCT
dti-3213	10	14	and	and	CCONJ
dti-3213	10	15	central	central	ADJ
dti-3213	10	16	subfield	subfield	NOUN
dti-3213	10	17	thickness	thickness	NOUN
dti-3213	10	18	(	(	PUNCT
dti-3213	10	19	cst	cst	PROPN
dti-3213	10	20	)	)	PUNCT
dti-3213	10	21	from	from	ADP
dti-3213	10	22	baseline	baseline	NOUN
dti-3213	10	23	to	to	ADP
dti-3213	10	24	1	1	NUM
dti-3213	10	25	year	year	NOUN
dti-3213	10	26	(	(	PUNCT
dti-3213	10	27	week	week	NOUN
dti-3213	10	28	52	52	NUM
dti-3213	10	29	in	in	ADP
dti-3213	10	30	the	the	DET
dti-3213	10	31	radiance	radiance	NOUN
dti-3213	10	32	and	and	CCONJ
dti-3213	10	33	week	week	NOUN
dti-3213	10	34	48	48	NUM
dti-3213	10	35	in	in	ADP
dti-3213	10	36	the	the	DET
dti-3213	10	37	faricimab	faricimab	NOUN
dti-3213	10	38	cohorts	cohort	NOUN
dti-3213	10	39	,	,	PUNCT
dti-3213	10	40	respectively	respectively	ADV
dti-3213	10	41	)	)	PUNCT
dti-3213	10	42	.	.	PUNCT
dti-3213	11	1	propensity	propensity	NOUN
dti-3213	11	2	score	score	NOUN
dti-3213	11	3	-	-	PUNCT
dti-3213	11	4	based	base	VERB
dti-3213	11	5	inverse	inverse	NOUN
dti-3213	11	6	probability	probability	NOUN
dti-3213	11	7	of	of	ADP
dti-3213	11	8	treatment	treatment	NOUN
dti-3213	11	9	weighting	weighting	NOUN
dti-3213	11	10	was	be	AUX
dti-3213	11	11	utilized	utilize	VERB
dti-3213	11	12	to	to	PART
dti-3213	11	13	balance	balance	NOUN
dti-3213	11	14	cohorts	cohort	NOUN
dti-3213	11	15	and	and	CCONJ
dti-3213	11	16	mitigate	mitigate	VERB
dti-3213	11	17	bias	bias	NOUN
dti-3213	11	18	due	due	ADP
dti-3213	11	19	to	to	ADP
dti-3213	11	20	potential	potential	ADJ
dti-3213	11	21	confounding	confounding	NOUN
dti-3213	11	22	.	.	PUNCT
dti-3213	12	1	sensitivity	sensitivity	NOUN
dti-3213	12	2	analyses	analysis	NOUN
dti-3213	12	3	were	be	AUX
dti-3213	12	4	performed	perform	VERB
dti-3213	12	5	to	to	PART
dti-3213	12	6	evaluate	evaluate	VERB
dti-3213	12	7	treatment	treatment	NOUN
dti-3213	12	8	differences	difference	NOUN
dti-3213	12	9	adjusted	adjust	VERB
dti-3213	12	10	for	for	ADP
dti-3213	12	11	the	the	DET
dti-3213	12	12	number	number	NOUN
dti-3213	12	13	of	of	ADP
dti-3213	12	14	injections	injection	NOUN
dti-3213	12	15	.	.	PUNCT
dti-3213	13	1	results	result	NOUN
dti-3213	13	2	:	:	PUNCT
dti-3213	13	3	the	the	DET
dti-3213	13	4	itc	itc	PROPN
dti-3213	13	5	included	include	VERB
dti-3213	13	6	513	513	NUM
dti-3213	13	7	patients	patient	NOUN
dti-3213	13	8	treated	treat	VERB
dti-3213	13	9	with	with	ADP
dti-3213	13	10	faricimab	faricimab	NOUN
dti-3213	13	11	and	and	CCONJ
dti-3213	13	12	263	263	NUM
dti-3213	13	13	patients	patient	NOUN
dti-3213	13	14	treated	treat	VERB
dti-3213	13	15	with	with	ADP
dti-3213	13	16	soc	soc	NOUN
dti-3213	13	17	.	.	PUNCT
dti-3213	14	1	at	at	ADP
dti-3213	14	2	1	1	NUM
dti-3213	14	3	year	year	NOUN
dti-3213	14	4	,	,	PUNCT
dti-3213	14	5	faricimab	faricimab	NOUN
dti-3213	14	6	showed	show	VERB
dti-3213	14	7	a	a	DET
dti-3213	14	8	greater	great	ADJ
dti-3213	14	9	mean	mean	NOUN
dti-3213	14	10	bcva	bcva	NOUN
dti-3213	14	11	gain	gain	NOUN
dti-3213	14	12	(	(	PUNCT
dti-3213	14	13	treatment	treatment	NOUN
dti-3213	14	14	difference	difference	NOUN
dti-3213	14	15	+5.4	+5.4	PROPN
dti-3213	14	16	letters	letter	NOUN
dti-3213	14	17	,	,	PUNCT
dti-3213	14	18	p<0.001	p<0.001	PROPN
dti-3213	14	19	)	)	PUNCT
dti-3213	14	20	and	and	CCONJ
dti-3213	14	21	cst	cst	PROPN
dti-3213	14	22	reduction	reduction	NOUN
dti-3213	14	23	(	(	PUNCT
dti-3213	14	24	treatment	treatment	NOUN
dti-3213	14	25	difference	difference	NOUN
dti-3213	14	26	−71.8	−71.8	INTJ
dti-3213	14	27	μm	μm	INTJ
dti-3213	14	28	,	,	PUNCT
dti-3213	14	29	p<0.001	p<0.001	PROPN
dti-3213	14	30	)	)	PUNCT
dti-3213	14	31	compared	compare	VERB
dti-3213	14	32	to	to	ADP
dti-3213	14	33	soc	soc	NOUN
dti-3213	14	34	.	.	PUNCT
dti-3213	15	1	sensitivity	sensitivity	NOUN
dti-3213	15	2	analyses	analysis	NOUN
dti-3213	15	3	confirmed	confirm	VERB
dti-3213	15	4	the	the	DET
dti-3213	15	5	robustness	robustness	NOUN
dti-3213	15	6	of	of	ADP
dti-3213	15	7	results	result	NOUN
dti-3213	15	8	,	,	PUNCT
dti-3213	15	9	showing	show	VERB
dti-3213	15	10	a	a	DET
dti-3213	15	11	bcva	bcva	NOUN
dti-3213	15	12	improvement	improvement	NOUN
dti-3213	15	13	of	of	ADP
dti-3213	15	14	+4.0	+4.0	X
dti-3213	15	15	letters	letter	NOUN
dti-3213	15	16	and	and	CCONJ
dti-3213	15	17	a	a	DET
dti-3213	15	18	cst	cst	PROPN
dti-3213	15	19	reduction	reduction	NOUN
dti-3213	15	20	of	of	ADP
dti-3213	15	21	−71.5	−71.5	NOUN
dti-3213	15	22	μm	μm	NOUN
dti-3213	15	23	in	in	ADP
dti-3213	15	24	favor	favor	NOUN
dti-3213	15	25	of	of	ADP
dti-3213	15	26	faricimab	faricimab	NOUN
dti-3213	15	27	.	.	PUNCT
dti-3213	16	1	conclusions	conclusion	NOUN
dti-3213	16	2	:	:	PUNCT
dti-3213	16	3	despite	despite	SCONJ
dti-3213	16	4	the	the	DET
dti-3213	16	5	limitations	limitation	NOUN
dti-3213	16	6	due	due	ADP
dti-3213	16	7	to	to	ADP
dti-3213	16	8	the	the	DET
dti-3213	16	9	use	use	NOUN
dti-3213	16	10	of	of	ADP
dti-3213	16	11	itc	itc	PROPN
dti-3213	16	12	and	and	CCONJ
dti-3213	16	13	the	the	DET
dti-3213	16	14	comparison	comparison	NOUN
dti-3213	16	15	between	between	ADP
dti-3213	16	16	clinical	clinical	ADJ
dti-3213	16	17	trials	trial	NOUN
dti-3213	16	18	and	and	CCONJ
dti-3213	16	19	realworld	realworld	PROPN
dti-3213	16	20	cohorts	cohort	NOUN
dti-3213	16	21	,	,	PUNCT
dti-3213	16	22	the	the	DET
dti-3213	16	23	present	present	ADJ
dti-3213	16	24	analysis	analysis	NOUN
dti-3213	16	25	suggests	suggest	VERB
dti-3213	16	26	potential	potential	ADJ
dti-3213	16	27	benefits	benefit	NOUN
dti-3213	16	28	in	in	ADP
dti-3213	16	29	terms	term	NOUN
dti-3213	16	30	of	of	ADP
dti-3213	16	31	vision	vision	NOUN
dti-3213	16	32	gain	gain	NOUN
dti-3213	16	33	and	and	CCONJ
dti-3213	16	34	cst	cst	PROPN
dti-3213	16	35	reduction	reduction	NOUN
dti-3213	16	36	in	in	ADP
dti-3213	16	37	naïve	naïve	ADJ
dti-3213	16	38	namd	namd	NOUN
dti-3213	16	39	patients	patient	NOUN
dti-3213	16	40	treated	treat	VERB
dti-3213	16	41	with	with	ADP
dti-3213	16	42	faricimab	faricimab	NOUN
dti-3213	16	43	compared	compare	VERB
dti-3213	16	44	with	with	ADP
dti-3213	16	45	soc	soc	NOUN
dti-3213	16	46	in	in	ADP
dti-3213	16	47	a	a	DET
dti-3213	16	48	real	real	ADJ
dti-3213	16	49	-	-	PUNCT
dti-3213	16	50	world	world	NOUN
dti-3213	16	51	setting	setting	NOUN
dti-3213	16	52	.	.	PUNCT
dti-3213	17	1	keywords	keyword	NOUN
dti-3213	17	2	:	:	PUNCT
dti-3213	17	3	faricimab	faricimab	NOUN
dti-3213	17	4	,	,	PUNCT
dti-3213	17	5	indirect	indirect	ADJ
dti-3213	17	6	treatment	treatment	NOUN
dti-3213	17	7	comparison	comparison	NOUN
dti-3213	17	8	,	,	PUNCT
dti-3213	17	9	namd	namd	ADJ
dti-3213	17	10	,	,	PUNCT
dti-3213	17	11	vascular	vascular	ADJ
dti-3213	17	12	endothelial	endothelial	ADJ
dti-3213	17	13	growth	growth	NOUN
dti-3213	17	14	factor	factor	NOUN
dti-3213	17	15	a	a	DET
dti-3213	17	16	received	received	NOUN
dti-3213	17	17	:	:	PUNCT
dti-3213	17	18	july	july	PROPN
dti-3213	17	19	18	18	NUM
dti-3213	17	20	,	,	PUNCT
dti-3213	17	21	2024	2024	NUM
dti-3213	17	22	accepted	accept	VERB
dti-3213	17	23	:	:	PUNCT
dti-3213	17	24	november	november	PROPN
dti-3213	17	25	13	13	NUM
dti-3213	17	26	,	,	PUNCT
dti-3213	17	27	2024	2024	NUM
dti-3213	17	28	published	publish	VERB
dti-3213	17	29	online	online	ADV
dti-3213	17	30	:	:	PUNCT
dti-3213	17	31	december	december	PROPN
dti-3213	17	32	12	12	NUM
dti-3213	17	33	,	,	PUNCT
dti-3213	17	34	2024	2024	NUM
dti-3213	17	35	corresponding	correspond	VERB
dti-3213	17	36	author	author	NOUN
dti-3213	17	37	:	:	PUNCT
dti-3213	17	38	carlotta	carlotta	PROPN
dti-3213	17	39	galeone	galeone	NOUN
dti-3213	17	40	email	email	NOUN
dti-3213	17	41	:	:	PUNCT
dti-3213	17	42	carlotta.galeone@unimib.it	carlotta.galeone@unimib.it	PROPN
dti-3213	17	43	neovascular	neovascular	PROPN
dti-3213	17	44	amd	amd	PROPN
dti-3213	17	45	(	(	PUNCT
dti-3213	17	46	namd	namd	NOUN
dti-3213	17	47	)	)	PUNCT
dti-3213	17	48	is	be	AUX
dti-3213	17	49	an	an	DET
dti-3213	17	50	advanced	advanced	ADJ
dti-3213	17	51	form	form	NOUN
dti-3213	17	52	of	of	ADP
dti-3213	17	53	amd	amd	NOUN
dti-3213	17	54	characterized	characterize	VERB
dti-3213	17	55	by	by	ADP
dti-3213	17	56	the	the	DET
dti-3213	17	57	development	development	NOUN
dti-3213	17	58	of	of	ADP
dti-3213	17	59	subretinal	subretinal	ADJ
dti-3213	17	60	new	new	ADJ
dti-3213	17	61	vessels	vessel	NOUN
dti-3213	17	62	that	that	PRON
dti-3213	17	63	may	may	AUX
dti-3213	17	64	lead	lead	VERB
dti-3213	17	65	to	to	ADP
dti-3213	17	66	leakage	leakage	NOUN
dti-3213	17	67	,	,	PUNCT
dti-3213	17	68	accumulation	accumulation	NOUN
dti-3213	17	69	of	of	ADP
dti-3213	17	70	fluid	fluid	ADJ
dti-3213	17	71	intra	intra	NOUN
dti-3213	17	72	and	and	CCONJ
dti-3213	17	73	subretinally	subretinally	ADV
dti-3213	17	74	,	,	PUNCT
dti-3213	17	75	macular	macular	ADJ
dti-3213	17	76	edema	edema	NOUN
dti-3213	17	77	,	,	PUNCT
dti-3213	17	78	hemorrhage	hemorrhage	NOUN
dti-3213	17	79	,	,	PUNCT
dti-3213	17	80	and	and	CCONJ
dti-3213	17	81	serous	serous	ADJ
dti-3213	17	82	detachments	detachment	NOUN
dti-3213	17	83	of	of	ADP
dti-3213	17	84	the	the	DET
dti-3213	17	85	retinal	retinal	ADJ
dti-3213	17	86	pigment	pigment	NOUN
dti-3213	17	87	epithelium	epithelium	NOUN
dti-3213	17	88	.	.	PUNCT
dti-3213	18	1	angiogenesis	angiogenesis	NOUN
dti-3213	18	2	and	and	CCONJ
dti-3213	18	3	increased	increase	VERB
dti-3213	18	4	vascular	vascular	ADJ
dti-3213	18	5	permeability	permeability	NOUN
dti-3213	18	6	are	be	AUX
dti-3213	18	7	mainly	mainly	ADV
dti-3213	18	8	caused	cause	VERB
dti-3213	18	9	by	by	ADP
dti-3213	18	10	an	an	DET
dti-3213	18	11	abnormally	abnormally	ADV
dti-3213	18	12	high	high	ADJ
dti-3213	18	13	expression	expression	NOUN
dti-3213	18	14	of	of	ADP
dti-3213	18	15	vascular	vascular	ADJ
dti-3213	18	16	endothelial	endothelial	ADJ
dti-3213	18	17	growth	growth	NOUN
dti-3213	18	18	factor	factor	NOUN
dti-3213	18	19	(	(	PUNCT
dti-3213	18	20	vegf	vegf	PROPN
dti-3213	18	21	)	)	PUNCT
dti-3213	18	22	(	(	PUNCT
dti-3213	18	23	4	4	NUM
dti-3213	18	24	-	-	SYM
dti-3213	18	25	8)	8)	NUM
dti-3213	18	26	.	.	PUNCT
dti-3213	19	1	over	over	ADP
dti-3213	19	2	the	the	DET
dti-3213	19	3	last	last	ADJ
dti-3213	19	4	couple	couple	NOUN
dti-3213	19	5	of	of	ADP
dti-3213	19	6	decades	decade	NOUN
dti-3213	19	7	,	,	PUNCT
dti-3213	19	8	the	the	DET
dti-3213	19	9	treatment	treatment	NOUN
dti-3213	19	10	of	of	ADP
dti-3213	19	11	namd	namd	NOUN
dti-3213	19	12	has	have	AUX
dti-3213	19	13	evolved	evolve	VERB
dti-3213	19	14	,	,	PUNCT
dti-3213	19	15	gradually	gradually	ADV
dti-3213	19	16	shifting	shift	VERB
dti-3213	19	17	from	from	ADP
dti-3213	19	18	laser	laser	NOUN
dti-3213	19	19	therapy	therapy	NOUN
dti-3213	19	20	to	to	ADP
dti-3213	19	21	the	the	DET
dti-3213	19	22	use	use	NOUN
dti-3213	19	23	of	of	ADP
dti-3213	19	24	anti	anti	ADJ
dti-3213	19	25	-	-	ADJ
dti-3213	19	26	vegf	vegf	ADJ
dti-3213	19	27	intravitreal	intravitreal	PROPN
dti-3213	19	28	injections	injection	NOUN
dti-3213	19	29	.	.	PUNCT
dti-3213	20	1	antivegf	antivegf	PROPN
dti-3213	20	2	agents	agent	NOUN
dti-3213	20	3	have	have	AUX
dti-3213	20	4	proven	prove	VERB
dti-3213	20	5	to	to	PART
dti-3213	20	6	be	be	AUX
dti-3213	20	7	effective	effective	ADJ
dti-3213	20	8	for	for	ADP
dti-3213	20	9	the	the	DET
dti-3213	20	10	management	management	NOUN
dti-3213	20	11	of	of	ADP
dti-3213	20	12	patients	patient	NOUN
dti-3213	20	13	with	with	ADP
dti-3213	20	14	namd	namd	NOUN
dti-3213	20	15	,	,	PUNCT
dti-3213	20	16	removing	remove	VERB
dti-3213	20	17	exudative	exudative	ADJ
dti-3213	20	18	fluid	fluid	NOUN
dti-3213	20	19	from	from	ADP
dti-3213	20	20	the	the	DET
dti-3213	20	21	retina	retina	NOUN
dti-3213	20	22	,	,	PUNCT
dti-3213	20	23	suppressing	suppress	VERB
dti-3213	20	24	the	the	DET
dti-3213	20	25	formation	formation	NOUN
dti-3213	20	26	of	of	ADP
dti-3213	20	27	leaking	leak	VERB
dti-3213	20	28	new	new	ADJ
dti-3213	20	29	blood	blood	NOUN
dti-3213	20	30	vessels	vessel	NOUN
dti-3213	20	31	,	,	PUNCT
dti-3213	20	32	and	and	CCONJ
dti-3213	20	33	improving	improve	VERB
dti-3213	20	34	or	or	CCONJ
dti-3213	20	35	maintaining	maintain	VERB
dti-3213	20	36	visual	visual	ADJ
dti-3213	20	37	acuity	acuity	NOUN
dti-3213	20	38	(	(	PUNCT
dti-3213	20	39	va	va	NOUN
dti-3213	20	40	)	)	PUNCT
dti-3213	20	41	over	over	ADP
dti-3213	20	42	introduction	introduction	NOUN
dti-3213	20	43	age	age	NOUN
dti-3213	20	44	-	-	PUNCT
dti-3213	20	45	related	relate	VERB
dti-3213	20	46	macular	macular	ADJ
dti-3213	20	47	degeneration	degeneration	NOUN
dti-3213	20	48	(	(	PUNCT
dti-3213	20	49	amd	amd	PROPN
dti-3213	20	50	)	)	PUNCT
dti-3213	20	51	is	be	AUX
dti-3213	20	52	the	the	DET
dti-3213	20	53	leading	lead	VERB
dti-3213	20	54	cause	cause	NOUN
dti-3213	20	55	of	of	ADP
dti-3213	20	56	blindness	blindness	NOUN
dti-3213	20	57	and	and	CCONJ
dti-3213	20	58	visual	visual	ADJ
dti-3213	20	59	impairment	impairment	NOUN
dti-3213	20	60	in	in	ADP
dti-3213	20	61	elderly	elderly	ADJ
dti-3213	20	62	subjects	subject	NOUN
dti-3213	20	63	(	(	PUNCT
dti-3213	20	64	1	1	NUM
dti-3213	20	65	-	-	SYM
dti-3213	20	66	3	3	NUM
dti-3213	20	67	)	)	PUNCT
dti-3213	20	68	.	.	PUNCT
dti-3213	21	1	it	it	PRON
dti-3213	21	2	is	be	AUX
dti-3213	21	3	a	a	DET
dti-3213	21	4	chronic	chronic	NOUN
dti-3213	21	5	,	,	PUNCT
dti-3213	21	6	multifactorial	multifactorial	ADJ
dti-3213	21	7	degenerative	degenerative	ADJ
dti-3213	21	8	pathology	pathology	NOUN
dti-3213	21	9	affecting	affect	VERB
dti-3213	21	10	the	the	DET
dti-3213	21	11	macula	macula	NOUN
dti-3213	21	12	,	,	PUNCT
dti-3213	21	13	typically	typically	ADV
dti-3213	21	14	occurring	occur	VERB
dti-3213	21	15	after	after	ADP
dti-3213	21	16	age	age	NOUN
dti-3213	21	17	55	55	NUM
dti-3213	21	18	(	(	PUNCT
dti-3213	21	19	1	1	NUM
dti-3213	21	20	)	)	PUNCT
dti-3213	21	21	.	.	PUNCT
dti-3213	22	1	https://doi.org/10.33393/dti.2024.3213	https://doi.org/10.33393/dti.2024.3213	NOUN
dti-3213	22	2	https://creativecommons.org/licenses/by-nc/4.0/legalcode	https://creativecommons.org/licenses/by-nc/4.0/legalcode	PROPN
dti-3213	22	3	https://orcid.org/0000-0003-1934-5167	https://orcid.org/0000-0003-1934-5167	ADJ
dti-3213	22	4	https://orcid.org/0000-0002-7824-3091	https://orcid.org/0000-0002-7824-3091	ADJ
dti-3213	22	5	https://orcid.org/0000-0002-2223-7311	https://orcid.org/0000-0002-2223-7311	PROPN
dti-3213	22	6	https://orcid.org/0000-0001-6773-9967	https://orcid.org/0000-0001-6773-9967	ADJ
dti-3213	22	7	https://orcid.org/0009-0002-9010-3005	https://orcid.org/0009-0002-9010-3005	NOUN
dti-3213	22	8	https://orcid.org/0000-0003-3746-141x	https://orcid.org/0000-0003-3746-141x	PROPN
dti-3213	23	1	mailto:carlotta.galeone@unimib.it	mailto:carlotta.galeone@unimib.it	PROPN
dti-3213	23	2	itc	itc	PROPN
dti-3213	23	3	of	of	ADP
dti-3213	23	4	faricimab	faricimab	NOUN
dti-3213	23	5	vs.	vs.	X
dti-3213	23	6	soc	soc	NOUN
dti-3213	23	7	for	for	ADP
dti-3213	23	8	namd	namd	ADJ
dti-3213	23	9	patients	patient	NOUN
dti-3213	23	10	in	in	ADP
dti-3213	23	11	italy106	italy106	PROPN
dti-3213	23	12	©	©	PROPN
dti-3213	23	13	2024	2024	NUM
dti-3213	23	14	the	the	DET
dti-3213	23	15	authors	author	NOUN
dti-3213	23	16	.	.	PUNCT
dti-3213	24	1	drug	drug	NOUN
dti-3213	24	2	target	target	NOUN
dti-3213	24	3	insights	insight	NOUN
dti-3213	24	4	issn	issn	VERB
dti-3213	24	5	1177	1177	NUM
dti-3213	24	6	-	-	SYM
dti-3213	24	7	3928	3928	NUM
dti-3213	24	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-3213	24	9	time	time	NOUN
dti-3213	24	10	(	(	PUNCT
dti-3213	24	11	9	9	NUM
dti-3213	24	12	-	-	SYM
dti-3213	24	13	17	17	NUM
dti-3213	24	14	)	)	PUNCT
dti-3213	24	15	.	.	PUNCT
dti-3213	25	1	in	in	ADP
dti-3213	25	2	italy	italy	PROPN
dti-3213	25	3	,	,	PUNCT
dti-3213	25	4	the	the	DET
dti-3213	25	5	prevalence	prevalence	NOUN
dti-3213	25	6	of	of	ADP
dti-3213	25	7	namd	namd	NOUN
dti-3213	25	8	in	in	ADP
dti-3213	25	9	individuals	individual	NOUN
dti-3213	25	10	aged	age	VERB
dti-3213	25	11	≥55	≥55	PROPN
dti-3213	25	12	was	be	AUX
dti-3213	25	13	estimated	estimate	VERB
dti-3213	25	14	at	at	ADP
dti-3213	25	15	4.6	4.6	NUM
dti-3213	25	16	per	per	ADP
dti-3213	25	17	1,000	1,000	NUM
dti-3213	25	18	inhabitants	inhabitant	NOUN
dti-3213	25	19	(	(	PUNCT
dti-3213	25	20	18	18	NUM
dti-3213	25	21	)	)	PUNCT
dti-3213	25	22	.	.	PUNCT
dti-3213	26	1	currently	currently	ADV
dti-3213	26	2	,	,	PUNCT
dti-3213	26	3	there	there	PRON
dti-3213	26	4	is	be	VERB
dti-3213	26	5	no	no	DET
dti-3213	26	6	single	single	ADJ
dti-3213	26	7	approach	approach	NOUN
dti-3213	26	8	for	for	ADP
dti-3213	26	9	anti	anti	ADJ
dti-3213	26	10	-	-	ADJ
dti-3213	26	11	vegf	vegf	ADJ
dti-3213	26	12	administration	administration	NOUN
dti-3213	26	13	.	.	PUNCT
dti-3213	27	1	the	the	DET
dti-3213	27	2	most	most	ADV
dti-3213	27	3	common	common	ADJ
dti-3213	27	4	approaches	approach	NOUN
dti-3213	27	5	are	be	AUX
dti-3213	27	6	the	the	DET
dti-3213	27	7	reactive	reactive	ADJ
dti-3213	27	8	prore	prore	NOUN
dti-3213	27	9	-	-	PUNCT
dti-3213	27	10	nata	nata	NOUN
dti-3213	27	11	(	(	PUNCT
dti-3213	27	12	prn	prn	NOUN
dti-3213	27	13	)	)	PUNCT
dti-3213	27	14	,	,	PUNCT
dti-3213	27	15	the	the	DET
dti-3213	27	16	proactive	proactive	ADJ
dti-3213	27	17	treat	treat	NOUN
dti-3213	27	18	-	-	PUNCT
dti-3213	27	19	and	and	CCONJ
dti-3213	27	20	-	-	PUNCT
dti-3213	27	21	extend	extend	VERB
dti-3213	27	22	(	(	PUNCT
dti-3213	27	23	t&e	t&e	PROPN
dti-3213	27	24	)	)	PUNCT
dti-3213	27	25	,	,	PUNCT
dti-3213	27	26	and	and	CCONJ
dti-3213	27	27	the	the	DET
dti-3213	27	28	fixed	fix	VERB
dti-3213	27	29	bimonthly	bimonthly	ADJ
dti-3213	27	30	regimen	regiman	NOUN
dti-3213	27	31	.	.	PUNCT
dti-3213	28	1	in	in	ADP
dti-3213	28	2	the	the	DET
dti-3213	28	3	reactive	reactive	ADJ
dti-3213	28	4	prn	prn	NOUN
dti-3213	28	5	approach	approach	NOUN
dti-3213	28	6	,	,	PUNCT
dti-3213	28	7	three	three	NUM
dti-3213	28	8	-	-	PUNCT
dti-3213	28	9	monthly	monthly	ADJ
dti-3213	28	10	loading	loading	NOUN
dti-3213	28	11	doses	dose	NOUN
dti-3213	28	12	are	be	AUX
dti-3213	28	13	followed	follow	VERB
dti-3213	28	14	by	by	ADP
dti-3213	28	15	adaptable	adaptable	ADJ
dti-3213	28	16	dosing	dosing	NOUN
dti-3213	28	17	based	base	VERB
dti-3213	28	18	on	on	ADP
dti-3213	28	19	monthly	monthly	ADJ
dti-3213	28	20	monitoring	monitoring	NOUN
dti-3213	28	21	of	of	ADP
dti-3213	28	22	va	va	PROPN
dti-3213	28	23	and/or	and/or	CCONJ
dti-3213	28	24	macular	macular	ADJ
dti-3213	28	25	morphology	morphology	NOUN
dti-3213	28	26	.	.	PUNCT
dti-3213	29	1	in	in	ADP
dti-3213	29	2	clinical	clinical	ADJ
dti-3213	29	3	practice	practice	NOUN
dti-3213	29	4	,	,	PUNCT
dti-3213	29	5	this	this	DET
dti-3213	29	6	approach	approach	NOUN
dti-3213	29	7	has	have	AUX
dti-3213	29	8	been	be	AUX
dti-3213	29	9	associated	associate	VERB
dti-3213	29	10	with	with	ADP
dti-3213	29	11	suboptimal	suboptimal	ADJ
dti-3213	29	12	outcomes	outcome	NOUN
dti-3213	29	13	and	and	CCONJ
dti-3213	29	14	risk	risk	NOUN
dti-3213	29	15	of	of	ADP
dti-3213	29	16	undertreatment	undertreatment	ADJ
dti-3213	29	17	(	(	PUNCT
dti-3213	29	18	19	19	NUM
dti-3213	29	19	)	)	PUNCT
dti-3213	29	20	.	.	PUNCT
dti-3213	30	1	the	the	DET
dti-3213	30	2	proactive	proactive	ADJ
dti-3213	30	3	fixed	fix	VERB
dti-3213	30	4	bimonthly	bimonthly	ADV
dti-3213	30	5	dosing	dose	VERB
dti-3213	30	6	consists	consist	NOUN
dti-3213	30	7	of	of	ADP
dti-3213	30	8	bimonthly	bimonthly	ADJ
dti-3213	30	9	injections	injection	NOUN
dti-3213	30	10	for	for	ADP
dti-3213	30	11	at	at	ADV
dti-3213	30	12	least	least	ADV
dti-3213	30	13	1	1	NUM
dti-3213	30	14	year	year	NOUN
dti-3213	30	15	(	(	PUNCT
dti-3213	30	16	13,15	13,15	NUM
dti-3213	30	17	)	)	PUNCT
dti-3213	30	18	and	and	CCONJ
dti-3213	30	19	has	have	AUX
dti-3213	30	20	been	be	AUX
dti-3213	30	21	shown	show	VERB
dti-3213	30	22	to	to	PART
dti-3213	30	23	improve	improve	VERB
dti-3213	30	24	outcomes	outcome	NOUN
dti-3213	30	25	compared	compare	VERB
dti-3213	30	26	to	to	ADP
dti-3213	30	27	prn	prn	NOUN
dti-3213	30	28	(	(	PUNCT
dti-3213	30	29	20	20	NUM
dti-3213	30	30	)	)	PUNCT
dti-3213	30	31	,	,	PUNCT
dti-3213	30	32	although	although	SCONJ
dti-3213	30	33	it	it	PRON
dti-3213	30	34	is	be	AUX
dti-3213	30	35	associated	associate	VERB
dti-3213	30	36	with	with	ADP
dti-3213	30	37	a	a	DET
dti-3213	30	38	considerable	considerable	ADJ
dti-3213	30	39	treatment	treatment	NOUN
dti-3213	30	40	burden	burden	NOUN
dti-3213	30	41	(	(	PUNCT
dti-3213	30	42	21	21	NUM
dti-3213	30	43	)	)	PUNCT
dti-3213	30	44	.	.	PUNCT
dti-3213	31	1	in	in	ADP
dti-3213	31	2	the	the	DET
dti-3213	31	3	proactive	proactive	ADJ
dti-3213	31	4	t&e	t&e	ADJ
dti-3213	31	5	regimen	regiman	NOUN
dti-3213	31	6	,	,	PUNCT
dti-3213	31	7	anti	anti	ADJ
dti-3213	31	8	-	-	ADJ
dti-3213	31	9	vegf	vegf	PROPN
dti-3213	31	10	is	be	AUX
dti-3213	31	11	administered	administer	VERB
dti-3213	31	12	at	at	ADP
dti-3213	31	13	every	every	DET
dti-3213	31	14	visit	visit	NOUN
dti-3213	31	15	.	.	PUNCT
dti-3213	32	1	following	follow	VERB
dti-3213	32	2	the	the	DET
dti-3213	32	3	loading	loading	NOUN
dti-3213	32	4	phase	phase	NOUN
dti-3213	32	5	,	,	PUNCT
dti-3213	32	6	the	the	DET
dti-3213	32	7	treatment	treatment	NOUN
dti-3213	32	8	interval	interval	NOUN
dti-3213	32	9	can	can	AUX
dti-3213	32	10	be	be	AUX
dti-3213	32	11	gradually	gradually	ADV
dti-3213	32	12	extended	extend	VERB
dti-3213	32	13	or	or	CCONJ
dti-3213	32	14	reduced	reduce	VERB
dti-3213	32	15	based	base	VERB
dti-3213	32	16	on	on	ADP
dti-3213	32	17	anatomic	anatomic	ADJ
dti-3213	32	18	and	and	CCONJ
dti-3213	32	19	va	va	NOUN
dti-3213	32	20	status	status	NOUN
dti-3213	32	21	.	.	PUNCT
dti-3213	33	1	this	this	DET
dti-3213	33	2	approach	approach	NOUN
dti-3213	33	3	allows	allow	VERB
dti-3213	33	4	the	the	DET
dti-3213	33	5	extension	extension	NOUN
dti-3213	33	6	of	of	ADP
dti-3213	33	7	treatment	treatment	NOUN
dti-3213	33	8	intervals	interval	NOUN
dti-3213	33	9	,	,	PUNCT
dti-3213	33	10	reducing	reduce	VERB
dti-3213	33	11	the	the	DET
dti-3213	33	12	overall	overall	ADJ
dti-3213	33	13	number	number	NOUN
dti-3213	33	14	of	of	ADP
dti-3213	33	15	visits	visit	NOUN
dti-3213	33	16	and	and	CCONJ
dti-3213	33	17	improving	improve	VERB
dti-3213	33	18	va	va	NOUN
dti-3213	33	19	outcomes	outcome	NOUN
dti-3213	33	20	(	(	PUNCT
dti-3213	33	21	20	20	NUM
dti-3213	33	22	-	-	SYM
dti-3213	33	23	26	26	NUM
dti-3213	33	24	)	)	PUNCT
dti-3213	33	25	.	.	PUNCT
dti-3213	34	1	in	in	ADP
dti-3213	34	2	2023	2023	NUM
dti-3213	34	3	,	,	PUNCT
dti-3213	34	4	faricimab	faricimab	NOUN
dti-3213	34	5	,	,	PUNCT
dti-3213	34	6	a	a	DET
dti-3213	34	7	novel	novel	ADJ
dti-3213	34	8	bispecific	bispecific	NOUN
dti-3213	34	9	antibody	antibody	NOUN
dti-3213	34	10	that	that	PRON
dti-3213	34	11	simultaneously	simultaneously	ADV
dti-3213	34	12	binds	bind	VERB
dti-3213	34	13	and	and	CCONJ
dti-3213	34	14	neutralizes	neutralize	VERB
dti-3213	34	15	ang-2	ang-2	ADV
dti-3213	34	16	and	and	CCONJ
dti-3213	34	17	vegf	vegf	PROPN
dti-3213	34	18	-	-	PUNCT
dti-3213	34	19	a	a	NOUN
dti-3213	34	20	,	,	PUNCT
dti-3213	34	21	received	receive	VERB
dti-3213	34	22	approval	approval	NOUN
dti-3213	34	23	by	by	ADP
dti-3213	34	24	the	the	DET
dti-3213	34	25	european	european	PROPN
dti-3213	34	26	medicines	medicines	PROPN
dti-3213	34	27	agency	agency	NOUN
dti-3213	34	28	(	(	PUNCT
dti-3213	34	29	ema	ema	PROPN
dti-3213	34	30	)	)	PUNCT
dti-3213	34	31	and	and	CCONJ
dti-3213	34	32	reimbursement	reimbursement	NOUN
dti-3213	34	33	by	by	ADP
dti-3213	34	34	italian	italian	ADJ
dti-3213	34	35	medicines	medicine	NOUN
dti-3213	34	36	agency	agency	NOUN
dti-3213	34	37	(	(	PUNCT
dti-3213	34	38	agenzia	agenzia	PROPN
dti-3213	34	39	italiana	italiana	PROPN
dti-3213	34	40	del	del	PROPN
dti-3213	34	41	farmaco	farmaco	PROPN
dti-3213	34	42	—	—	PUNCT
dti-3213	34	43	aifa	aifa	PROPN
dti-3213	34	44	)	)	PUNCT
dti-3213	34	45	for	for	ADP
dti-3213	34	46	the	the	DET
dti-3213	34	47	treatment	treatment	NOUN
dti-3213	34	48	of	of	ADP
dti-3213	34	49	adult	adult	NOUN
dti-3213	34	50	patients	patient	NOUN
dti-3213	34	51	with	with	ADP
dti-3213	34	52	namd	namd	NOUN
dti-3213	34	53	(	(	PUNCT
dti-3213	34	54	27	27	NUM
dti-3213	34	55	)	)	PUNCT
dti-3213	34	56	.	.	PUNCT
dti-3213	35	1	in	in	ADP
dti-3213	35	2	italy	italy	PROPN
dti-3213	35	3	,	,	PUNCT
dti-3213	35	4	the	the	DET
dti-3213	35	5	currently	currently	ADV
dti-3213	35	6	available	available	ADJ
dti-3213	35	7	anti	anti	ADJ
dti-3213	35	8	-	-	ADJ
dti-3213	35	9	vegfs	vegfs	ADJ
dti-3213	35	10	include	include	VERB
dti-3213	35	11	aflibercept	aflibercept	ADJ
dti-3213	35	12	,	,	PUNCT
dti-3213	35	13	ranibizumab	ranibizumab	NOUN
dti-3213	35	14	,	,	PUNCT
dti-3213	35	15	bevacizumab	bevacizumab	NOUN
dti-3213	35	16	,	,	PUNCT
dti-3213	35	17	and	and	CCONJ
dti-3213	35	18	brolucizumab	brolucizumab	NOUN
dti-3213	35	19	(	(	PUNCT
dti-3213	35	20	28	28	NUM
dti-3213	35	21	)	)	PUNCT
dti-3213	35	22	.	.	PUNCT
dti-3213	36	1	aflibercept	aflibercept	PROPN
dti-3213	36	2	,	,	PUNCT
dti-3213	36	3	ranibizumab	ranibizumab	NOUN
dti-3213	36	4	,	,	PUNCT
dti-3213	36	5	and	and	CCONJ
dti-3213	36	6	brolucizumab	brolucizumab	NOUN
dti-3213	36	7	have	have	AUX
dti-3213	36	8	received	receive	VERB
dti-3213	36	9	marketing	marketing	NOUN
dti-3213	36	10	authorization	authorization	NOUN
dti-3213	36	11	from	from	ADP
dti-3213	36	12	ema	ema	PROPN
dti-3213	36	13	for	for	ADP
dti-3213	36	14	the	the	DET
dti-3213	36	15	treatment	treatment	NOUN
dti-3213	36	16	of	of	ADP
dti-3213	36	17	namd	namd	NOUN
dti-3213	36	18	,	,	PUNCT
dti-3213	36	19	while	while	SCONJ
dti-3213	36	20	bevacizumab	bevacizumab	NOUN
dti-3213	36	21	can	can	AUX
dti-3213	36	22	be	be	AUX
dti-3213	36	23	administered	administer	VERB
dti-3213	36	24	on	on	ADP
dti-3213	36	25	an	an	DET
dti-3213	36	26	offlabel	offlabel	NOUN
dti-3213	36	27	regimen	regimen	NOUN
dti-3213	36	28	according	accord	VERB
dti-3213	36	29	to	to	ADP
dti-3213	36	30	the	the	DET
dti-3213	36	31	law	law	NOUN
dti-3213	36	32	648/96	648/96	NUM
dti-3213	36	33	(	(	PUNCT
dti-3213	36	34	law	law	NOUN
dti-3213	36	35	648/96	648/96	NUM
dti-3213	36	36	provides	provide	VERB
dti-3213	36	37	for	for	ADP
dti-3213	36	38	the	the	DET
dti-3213	36	39	reimbursement	reimbursement	NOUN
dti-3213	36	40	of	of	ADP
dti-3213	36	41	the	the	DET
dti-3213	36	42	medicinal	medicinal	ADJ
dti-3213	36	43	product	product	NOUN
dti-3213	36	44	by	by	ADP
dti-3213	36	45	the	the	DET
dti-3213	36	46	national	national	PROPN
dti-3213	36	47	health	health	PROPN
dti-3213	36	48	service	service	NOUN
dti-3213	36	49	when	when	SCONJ
dti-3213	36	50	there	there	PRON
dti-3213	36	51	is	be	VERB
dti-3213	36	52	no	no	DET
dti-3213	36	53	valid	valid	ADJ
dti-3213	36	54	therapeutic	therapeutic	ADJ
dti-3213	36	55	alternative	alternative	NOUN
dti-3213	36	56	for	for	ADP
dti-3213	36	57	innovative	innovative	ADJ
dti-3213	36	58	medicines	medicine	NOUN
dti-3213	36	59	authorized	authorize	VERB
dti-3213	36	60	in	in	ADP
dti-3213	36	61	other	other	ADJ
dti-3213	36	62	states	state	NOUN
dti-3213	36	63	but	but	CCONJ
dti-3213	36	64	not	not	PART
dti-3213	36	65	in	in	ADP
dti-3213	36	66	italy	italy	PROPN
dti-3213	36	67	,	,	PUNCT
dti-3213	36	68	for	for	ADP
dti-3213	36	69	medicines	medicine	NOUN
dti-3213	36	70	not	not	PART
dti-3213	36	71	yet	yet	ADV
dti-3213	36	72	authorized	authorize	VERB
dti-3213	36	73	but	but	CCONJ
dti-3213	36	74	undergoing	undergo	VERB
dti-3213	36	75	clinical	clinical	ADJ
dti-3213	36	76	trials	trial	NOUN
dti-3213	36	77	,	,	PUNCT
dti-3213	36	78	and	and	CCONJ
dti-3213	36	79	for	for	ADP
dti-3213	36	80	medicines	medicine	NOUN
dti-3213	36	81	already	already	ADV
dti-3213	36	82	authorized	authorize	VERB
dti-3213	36	83	in	in	ADP
dti-3213	36	84	italy	italy	PROPN
dti-3213	36	85	,	,	PUNCT
dti-3213	36	86	for	for	ADP
dti-3213	36	87	indications	indication	NOUN
dti-3213	36	88	other	other	ADJ
dti-3213	36	89	than	than	SCONJ
dti-3213	36	90	authorized	authorize	VERB
dti-3213	36	91	one	one	NUM
dti-3213	36	92	)	)	PUNCT
dti-3213	36	93	(	(	PUNCT
dti-3213	36	94	29	29	NUM
dti-3213	36	95	)	)	PUNCT
dti-3213	36	96	.	.	PUNCT
dti-3213	37	1	efficacy	efficacy	NOUN
dti-3213	37	2	and	and	CCONJ
dti-3213	37	3	safety	safety	NOUN
dti-3213	37	4	of	of	ADP
dti-3213	37	5	faricimab	faricimab	NOUN
dti-3213	37	6	were	be	AUX
dti-3213	37	7	evaluated	evaluate	VERB
dti-3213	37	8	in	in	ADP
dti-3213	37	9	the	the	DET
dti-3213	37	10	randomized	randomized	ADJ
dti-3213	37	11	,	,	PUNCT
dti-3213	37	12	double	double	ADJ
dti-3213	37	13	-	-	PUNCT
dti-3213	37	14	masked	masked	ADJ
dti-3213	37	15	,	,	PUNCT
dti-3213	37	16	phase	phase	NOUN
dti-3213	37	17	iii	iii	NOUN
dti-3213	37	18	,	,	PUNCT
dti-3213	37	19	non	non	ADJ
dti-3213	37	20	-	-	ADJ
dti-3213	37	21	inferiority	inferiority	ADJ
dti-3213	37	22	trials	trial	NOUN
dti-3213	37	23	tenaya	tenaya	PROPN
dti-3213	37	24	and	and	CCONJ
dti-3213	37	25	lucerne	lucerne	PROPN
dti-3213	37	26	(	(	PUNCT
dti-3213	37	27	30	30	NUM
dti-3213	37	28	)	)	PUNCT
dti-3213	37	29	that	that	PRON
dti-3213	37	30	randomized	randomize	VERB
dti-3213	37	31	patients	patient	NOUN
dti-3213	37	32	to	to	PART
dti-3213	37	33	receive	receive	VERB
dti-3213	37	34	faricimab	faricimab	NOUN
dti-3213	37	35	6.0	6.0	NUM
dti-3213	37	36	mg	mg	NOUN
dti-3213	37	37	up	up	ADP
dti-3213	37	38	to	to	ADP
dti-3213	37	39	every	every	DET
dti-3213	37	40	16	16	NUM
dti-3213	37	41	weeks	week	NOUN
dti-3213	37	42	(	(	PUNCT
dti-3213	37	43	tenaya	tenaya	NOUN
dti-3213	37	44	n	n	NOUN
dti-3213	37	45	=	=	SYM
dti-3213	37	46	334	334	NUM
dti-3213	37	47	,	,	PUNCT
dti-3213	37	48	lucerne	lucerne	NOUN
dti-3213	37	49	n	n	NOUN
dti-3213	37	50	=	=	SYM
dti-3213	37	51	331	331	NUM
dti-3213	37	52	)	)	PUNCT
dti-3213	37	53	or	or	CCONJ
dti-3213	37	54	aflibercept	aflibercept	ADP
dti-3213	37	55	2.0	2.0	NUM
dti-3213	37	56	mg	mg	NOUN
dti-3213	37	57	every	every	DET
dti-3213	37	58	8	8	NUM
dti-3213	37	59	weeks	week	NOUN
dti-3213	37	60	(	(	PUNCT
dti-3213	37	61	tenaya	tenaya	NOUN
dti-3213	37	62	n	n	NOUN
dti-3213	37	63	=	=	SYM
dti-3213	37	64	337	337	NUM
dti-3213	37	65	,	,	PUNCT
dti-3213	37	66	lucerne	lucerne	NOUN
dti-3213	37	67	n	n	NOUN
dti-3213	37	68	=	=	SYM
dti-3213	37	69	327	327	NUM
dti-3213	37	70	)	)	PUNCT
dti-3213	37	71	.	.	PUNCT
dti-3213	38	1	in	in	ADP
dti-3213	38	2	both	both	DET
dti-3213	38	3	studies	study	NOUN
dti-3213	38	4	,	,	PUNCT
dti-3213	38	5	faricimab	faricimab	NOUN
dti-3213	38	6	was	be	AUX
dti-3213	38	7	non	non	ADJ
dti-3213	38	8	-	-	ADJ
dti-3213	38	9	inferior	inferior	ADJ
dti-3213	38	10	to	to	ADP
dti-3213	38	11	aflibercept	aflibercept	NOUN
dti-3213	38	12	in	in	ADP
dti-3213	38	13	terms	term	NOUN
dti-3213	38	14	of	of	ADP
dti-3213	38	15	change	change	NOUN
dti-3213	38	16	in	in	ADP
dti-3213	38	17	best	well	ADV
dti-3213	38	18	corrected	correct	VERB
dti-3213	38	19	va	va	NOUN
dti-3213	38	20	(	(	PUNCT
dti-3213	38	21	bcva	bcva	PROPN
dti-3213	38	22	)	)	PUNCT
dti-3213	38	23	from	from	ADP
dti-3213	38	24	baseline	baseline	PROPN
dti-3213	38	25	averaged	average	VERB
dti-3213	38	26	over	over	ADP
dti-3213	38	27	weeks	week	NOUN
dti-3213	38	28	40	40	NUM
dti-3213	38	29	,	,	PUNCT
dti-3213	38	30	44	44	NUM
dti-3213	38	31	,	,	PUNCT
dti-3213	38	32	and	and	CCONJ
dti-3213	38	33	48	48	NUM
dti-3213	38	34	,	,	PUNCT
dti-3213	38	35	with	with	ADP
dti-3213	38	36	mean	mean	ADJ
dti-3213	38	37	changes	change	NOUN
dti-3213	38	38	of	of	ADP
dti-3213	38	39	5.8	5.8	NUM
dti-3213	38	40	letters	letter	NOUN
dti-3213	38	41	(	(	PUNCT
dti-3213	38	42	95	95	NUM
dti-3213	38	43	%	%	NOUN
dti-3213	38	44	confidence	confidence	NOUN
dti-3213	38	45	interval	interval	NOUN
dti-3213	38	46	,	,	PUNCT
dti-3213	38	47	ci	ci	NOUN
dti-3213	38	48	:	:	PUNCT
dti-3213	38	49	4.6	4.6	NUM
dti-3213	38	50	to	to	ADP
dti-3213	38	51	7.1	7.1	NUM
dti-3213	38	52	)	)	PUNCT
dti-3213	38	53	and	and	CCONJ
dti-3213	38	54	6.6	6.6	NUM
dti-3213	38	55	letters	letter	NOUN
dti-3213	38	56	(	(	PUNCT
dti-3213	38	57	95	95	NUM
dti-3213	38	58	%	%	NOUN
dti-3213	38	59	ci	ci	NOUN
dti-3213	38	60	:	:	PUNCT
dti-3213	38	61	5.23	5.23	NUM
dti-3213	38	62	to	to	PART
dti-3213	38	63	7.8	7.8	NUM
dti-3213	38	64	)	)	PUNCT
dti-3213	38	65	in	in	ADP
dti-3213	38	66	tenaya	tenaya	PROPN
dti-3213	38	67	and	and	CCONJ
dti-3213	38	68	lucerne	lucerne	NOUN
dti-3213	38	69	,	,	PUNCT
dti-3213	38	70	respectively	respectively	ADV
dti-3213	38	71	.	.	PUNCT
dti-3213	39	1	the	the	DET
dti-3213	39	2	treatment	treatment	NOUN
dti-3213	39	3	difference	difference	NOUN
dti-3213	39	4	was	be	AUX
dti-3213	39	5	equal	equal	ADJ
dti-3213	39	6	to	to	ADP
dti-3213	39	7	0.7	0.7	NUM
dti-3213	39	8	letters	letter	NOUN
dti-3213	39	9	(	(	PUNCT
dti-3213	39	10	95	95	NUM
dti-3213	39	11	%	%	NOUN
dti-3213	39	12	ci	ci	NOUN
dti-3213	39	13	:	:	PUNCT
dti-3213	39	14	−1.1	−1.1	NOUN
dti-3213	39	15	to	to	ADP
dti-3213	39	16	2.5	2.5	NUM
dti-3213	39	17	)	)	PUNCT
dti-3213	39	18	in	in	ADP
dti-3213	39	19	tenaya	tenaya	PROPN
dti-3213	39	20	and	and	CCONJ
dti-3213	39	21	0.0	0.0	NUM
dti-3213	39	22	letters	letter	NOUN
dti-3213	39	23	(	(	PUNCT
dti-3213	39	24	95	95	NUM
dti-3213	39	25	%	%	NOUN
dti-3213	39	26	ci	ci	NOUN
dti-3213	39	27	:	:	PUNCT
dti-3213	39	28	−1.7	−1.7	PROPN
dti-3213	39	29	to	to	ADP
dti-3213	39	30	1.8	1.8	NUM
dti-3213	39	31	)	)	PUNCT
dti-3213	39	32	in	in	ADP
dti-3213	39	33	lucerne	lucerne	NOUN
dti-3213	39	34	.	.	PUNCT
dti-3213	40	1	radiance	radiance	NOUN
dti-3213	40	2	is	be	AUX
dti-3213	40	3	an	an	DET
dti-3213	40	4	italian	italian	ADJ
dti-3213	40	5	,	,	PUNCT
dti-3213	40	6	retrospective	retrospective	ADJ
dti-3213	40	7	,	,	PUNCT
dti-3213	40	8	observational	observational	ADJ
dti-3213	40	9	,	,	PUNCT
dti-3213	40	10	multicenter	multicenter	ADJ
dti-3213	40	11	cohort	cohort	NOUN
dti-3213	40	12	study	study	NOUN
dti-3213	40	13	(	(	PUNCT
dti-3213	40	14	31	31	NUM
dti-3213	40	15	)	)	PUNCT
dti-3213	40	16	that	that	PRON
dti-3213	40	17	aimed	aim	VERB
dti-3213	40	18	to	to	PART
dti-3213	40	19	describe	describe	VERB
dti-3213	40	20	the	the	DET
dti-3213	40	21	realworld	realworld	PROPN
dti-3213	40	22	treatment	treatment	NOUN
dti-3213	40	23	patterns	pattern	NOUN
dti-3213	40	24	of	of	ADP
dti-3213	40	25	available	available	ADJ
dti-3213	40	26	intravitreal	intravitreal	NOUN
dti-3213	40	27	anti	anti	NOUN
dti-3213	40	28	-	-	NOUN
dti-3213	40	29	vegf	vegf	NOUN
dti-3213	40	30	in	in	ADP
dti-3213	40	31	italy	italy	PROPN
dti-3213	40	32	and	and	CCONJ
dti-3213	40	33	the	the	DET
dti-3213	40	34	associated	associated	ADJ
dti-3213	40	35	effectiveness	effectiveness	NOUN
dti-3213	40	36	.	.	PUNCT
dti-3213	41	1	the	the	DET
dti-3213	41	2	study	study	NOUN
dti-3213	41	3	enrolled	enrol	VERB
dti-3213	41	4	all	all	DET
dti-3213	41	5	consecutive	consecutive	ADJ
dti-3213	41	6	anti	anti	ADJ
dti-3213	41	7	-	-	ADJ
dti-3213	41	8	vegf	vegf	ADJ
dti-3213	41	9	treatment	treatment	NOUN
dti-3213	41	10	-	-	PUNCT
dti-3213	41	11	naïve	naïve	ADJ
dti-3213	41	12	subjects	subject	NOUN
dti-3213	41	13	with	with	ADP
dti-3213	41	14	a	a	DET
dti-3213	41	15	diagnosis	diagnosis	NOUN
dti-3213	41	16	of	of	ADP
dti-3213	41	17	namd	namd	NOUN
dti-3213	41	18	who	who	PRON
dti-3213	41	19	initiated	initiate	VERB
dti-3213	41	20	therapy	therapy	NOUN
dti-3213	41	21	with	with	ADP
dti-3213	41	22	one	one	NUM
dti-3213	41	23	of	of	ADP
dti-3213	41	24	the	the	DET
dti-3213	41	25	available	available	ADJ
dti-3213	41	26	agents	agent	NOUN
dti-3213	41	27	(	(	PUNCT
dti-3213	41	28	i.e.	i.e.	X
dti-3213	41	29	,	,	PUNCT
dti-3213	41	30	aflibercept	aflibercept	ADJ
dti-3213	41	31	,	,	PUNCT
dti-3213	41	32	bevacizumab	bevacizumab	NOUN
dti-3213	41	33	,	,	PUNCT
dti-3213	41	34	and	and	CCONJ
dti-3213	41	35	ranibizumab	ranibizumab	NOUN
dti-3213	41	36	)	)	PUNCT
dti-3213	41	37	between	between	ADP
dti-3213	41	38	january	january	PROPN
dti-3213	41	39	2017	2017	NUM
dti-3213	41	40	and	and	CCONJ
dti-3213	41	41	november	november	PROPN
dti-3213	41	42	2018	2018	NUM
dti-3213	41	43	.	.	PUNCT
dti-3213	42	1	the	the	DET
dti-3213	42	2	primary	primary	ADJ
dti-3213	42	3	objective	objective	NOUN
dti-3213	42	4	of	of	ADP
dti-3213	42	5	the	the	DET
dti-3213	42	6	study	study	NOUN
dti-3213	42	7	was	be	AUX
dti-3213	42	8	to	to	PART
dti-3213	42	9	evaluate	evaluate	VERB
dti-3213	42	10	the	the	DET
dti-3213	42	11	change	change	NOUN
dti-3213	42	12	in	in	ADP
dti-3213	42	13	va	va	PROPN
dti-3213	42	14	52	52	NUM
dti-3213	42	15	weeks	week	NOUN
dti-3213	42	16	after	after	ADP
dti-3213	42	17	starting	start	VERB
dti-3213	42	18	treatment	treatment	NOUN
dti-3213	42	19	with	with	ADP
dti-3213	42	20	any	any	PRON
dti-3213	42	21	of	of	ADP
dti-3213	42	22	the	the	DET
dti-3213	42	23	three	three	NUM
dti-3213	42	24	agents	agent	NOUN
dti-3213	42	25	.	.	PUNCT
dti-3213	43	1	all	all	DET
dti-3213	43	2	va	va	NOUN
dti-3213	43	3	measurements	measurement	NOUN
dti-3213	43	4	were	be	AUX
dti-3213	43	5	converted	convert	VERB
dti-3213	43	6	to	to	ADP
dti-3213	43	7	the	the	DET
dti-3213	43	8	approximate	approximate	ADJ
dti-3213	43	9	etdrs	etdr	NOUN
dti-3213	43	10	letter	letter	NOUN
dti-3213	43	11	score	score	NOUN
dti-3213	43	12	.	.	PUNCT
dti-3213	44	1	overall	overall	ADJ
dti-3213	44	2	,	,	PUNCT
dti-3213	44	3	after	after	ADP
dti-3213	44	4	52	52	NUM
dti-3213	44	5	weeks	week	NOUN
dti-3213	44	6	of	of	ADP
dti-3213	44	7	treatment	treatment	NOUN
dti-3213	44	8	,	,	PUNCT
dti-3213	44	9	the	the	DET
dti-3213	44	10	patients	patient	NOUN
dti-3213	44	11	showed	show	VERB
dti-3213	44	12	a	a	DET
dti-3213	44	13	median	median	ADJ
dti-3213	44	14	change	change	NOUN
dti-3213	44	15	in	in	ADP
dti-3213	44	16	va	va	PROPN
dti-3213	44	17	of	of	ADP
dti-3213	44	18	1.0	1.0	NUM
dti-3213	44	19	letter	letter	NOUN
dti-3213	44	20	(	(	PUNCT
dti-3213	44	21	25th-75th	25th-75th	NUM
dti-3213	44	22	percentile	percentile	NOUN
dti-3213	44	23	:	:	PUNCT
dti-3213	44	24	−5	−5	ADJ
dti-3213	44	25	;	;	PUNCT
dti-3213	44	26	+1.9	+1.9	NUM
dti-3213	44	27	)	)	PUNCT
dti-3213	44	28	.	.	PUNCT
dti-3213	45	1	by	by	ADP
dti-3213	45	2	stratifying	stratify	VERB
dti-3213	45	3	va	va	NOUN
dti-3213	45	4	changes	change	NOUN
dti-3213	45	5	by	by	ADP
dti-3213	45	6	the	the	DET
dti-3213	45	7	number	number	NOUN
dti-3213	45	8	of	of	ADP
dti-3213	45	9	injections	injection	NOUN
dti-3213	45	10	per	per	ADP
dti-3213	45	11	year	year	NOUN
dti-3213	45	12	,	,	PUNCT
dti-3213	45	13	patients	patient	NOUN
dti-3213	45	14	treated	treat	VERB
dti-3213	45	15	with	with	ADP
dti-3213	45	16	>	>	SYM
dti-3213	45	17	6	6	NUM
dti-3213	45	18	injections	injection	NOUN
dti-3213	45	19	in	in	ADP
dti-3213	45	20	the	the	DET
dti-3213	45	21	first	first	ADJ
dti-3213	45	22	year	year	NOUN
dti-3213	45	23	of	of	ADP
dti-3213	45	24	treatment	treatment	NOUN
dti-3213	45	25	showed	show	VERB
dti-3213	45	26	a	a	DET
dti-3213	45	27	median	median	ADJ
dti-3213	45	28	va	va	NOUN
dti-3213	45	29	improvement	improvement	NOUN
dti-3213	45	30	of	of	ADP
dti-3213	45	31	3	3	NUM
dti-3213	45	32	letters	letter	NOUN
dti-3213	45	33	(	(	PUNCT
dti-3213	45	34	25th-75th	25th-75th	NUM
dti-3213	45	35	percentile	percentile	NOUN
dti-3213	45	36	:	:	PUNCT
dti-3213	45	37	−1	−1	NOUN
dti-3213	45	38	;	;	PUNCT
dti-3213	45	39	11	11	NUM
dti-3213	45	40	)	)	PUNCT
dti-3213	45	41	,	,	PUNCT
dti-3213	45	42	while	while	SCONJ
dti-3213	45	43	no	no	DET
dti-3213	45	44	improvement	improvement	NOUN
dti-3213	45	45	was	be	AUX
dti-3213	45	46	observed	observe	VERB
dti-3213	45	47	in	in	ADP
dti-3213	45	48	patients	patient	NOUN
dti-3213	45	49	treated	treat	VERB
dti-3213	45	50	with	with	ADP
dti-3213	45	51	<	<	X
dti-3213	45	52	2	2	NUM
dti-3213	45	53	(	(	PUNCT
dti-3213	45	54	median	median	NOUN
dti-3213	45	55	0	0	NUM
dti-3213	45	56	letters	letter	NOUN
dti-3213	45	57	,	,	PUNCT
dti-3213	45	58	25th-75th	25th-75th	NUM
dti-3213	45	59	percentile	percentile	NOUN
dti-3213	45	60	:	:	PUNCT
dti-3213	45	61	−2	−2	NOUN
dti-3213	45	62	;	;	PUNCT
dti-3213	45	63	0	0	NUM
dti-3213	45	64	)	)	PUNCT
dti-3213	45	65	and	and	CCONJ
dti-3213	45	66	3	3	NUM
dti-3213	45	67	-	-	SYM
dti-3213	45	68	5	5	NUM
dti-3213	45	69	injections	injection	NOUN
dti-3213	45	70	(	(	PUNCT
dti-3213	45	71	median	median	NOUN
dti-3213	45	72	0	0	NUM
dti-3213	45	73	letters	letter	NOUN
dti-3213	45	74	;	;	PUNCT
dti-3213	45	75	25th-75th	25th-75th	NUM
dti-3213	45	76	percentile	percentile	NOUN
dti-3213	45	77	:	:	PUNCT
dti-3213	45	78	−5.0	−5.0	PROPN
dti-3213	45	79	;	;	PUNCT
dti-3213	45	80	+9.0	+9.0	NUM
dti-3213	45	81	)	)	PUNCT
dti-3213	45	82	.	.	PUNCT
dti-3213	46	1	in	in	ADP
dti-3213	46	2	this	this	DET
dti-3213	46	3	study	study	NOUN
dti-3213	46	4	an	an	DET
dti-3213	46	5	indirect	indirect	ADJ
dti-3213	46	6	treatment	treatment	NOUN
dti-3213	46	7	comparison	comparison	NOUN
dti-3213	46	8	using	use	VERB
dti-3213	46	9	individual	individual	ADJ
dti-3213	46	10	patient	patient	NOUN
dti-3213	46	11	-	-	PUNCT
dti-3213	46	12	level	level	NOUN
dti-3213	46	13	data	datum	NOUN
dti-3213	46	14	(	(	PUNCT
dti-3213	46	15	ipd	ipd	PROPN
dti-3213	46	16	)	)	PUNCT
dti-3213	46	17	was	be	AUX
dti-3213	46	18	performed	perform	VERB
dti-3213	46	19	to	to	PART
dti-3213	46	20	evaluate	evaluate	VERB
dti-3213	46	21	the	the	DET
dti-3213	46	22	potential	potential	ADJ
dti-3213	46	23	benefit	benefit	NOUN
dti-3213	46	24	of	of	ADP
dti-3213	46	25	faricimab	faricimab	NOUN
dti-3213	46	26	vs.	vs.	ADP
dti-3213	46	27	the	the	DET
dti-3213	46	28	real	real	ADJ
dti-3213	46	29	-	-	PUNCT
dti-3213	46	30	life	life	NOUN
dti-3213	46	31	scenario	scenario	NOUN
dti-3213	46	32	of	of	ADP
dti-3213	46	33	intravitreal	intravitreal	ADJ
dti-3213	46	34	anti	anti	ADJ
dti-3213	46	35	-	-	ADJ
dti-3213	46	36	vegf	vegf	ADJ
dti-3213	46	37	monotherapies	monotherapie	NOUN
dti-3213	46	38	available	available	ADJ
dti-3213	46	39	at	at	ADP
dti-3213	46	40	the	the	DET
dti-3213	46	41	time	time	NOUN
dti-3213	46	42	of	of	ADP
dti-3213	46	43	analysis	analysis	NOUN
dti-3213	46	44	(	(	PUNCT
dti-3213	46	45	namely	namely	ADV
dti-3213	46	46	aflibercept	aflibercept	ADJ
dti-3213	46	47	2	2	NUM
dti-3213	46	48	mg	mg	PROPN
dti-3213	46	49	,	,	PUNCT
dti-3213	46	50	bevacizumab	bevacizumab	NOUN
dti-3213	46	51	,	,	PUNCT
dti-3213	46	52	and	and	CCONJ
dti-3213	46	53	ranibizumab	ranibizumab	NOUN
dti-3213	46	54	,	,	PUNCT
dti-3213	46	55	hereby	hereby	ADV
dti-3213	46	56	defined	define	VERB
dti-3213	46	57	standard	standard	NOUN
dti-3213	46	58	of	of	ADP
dti-3213	46	59	care	care	NOUN
dti-3213	46	60	—	—	PUNCT
dti-3213	46	61	soc	soc	NOUN
dti-3213	46	62	)	)	PUNCT
dti-3213	46	63	for	for	ADP
dti-3213	46	64	namd	namd	ADJ
dti-3213	46	65	patients	patient	NOUN
dti-3213	46	66	in	in	ADP
dti-3213	46	67	italy	italy	PROPN
dti-3213	46	68	.	.	PUNCT
dti-3213	47	1	methods	method	VERB
dti-3213	47	2	an	an	DET
dti-3213	47	3	indirect	indirect	ADJ
dti-3213	47	4	comparison	comparison	NOUN
dti-3213	47	5	of	of	ADP
dti-3213	47	6	the	the	DET
dti-3213	47	7	efficacy	efficacy	NOUN
dti-3213	47	8	at	at	ADP
dti-3213	47	9	1	1	NUM
dti-3213	47	10	year	year	NOUN
dti-3213	47	11	of	of	ADP
dti-3213	47	12	faricimab	faricimab	NOUN
dti-3213	47	13	in	in	ADP
dti-3213	47	14	two	two	NUM
dti-3213	47	15	phase	phase	NOUN
dti-3213	47	16	iii	iii	NUM
dti-3213	47	17	clinical	clinical	ADJ
dti-3213	47	18	trials	trial	NOUN
dti-3213	47	19	and	and	CCONJ
dti-3213	47	20	the	the	DET
dti-3213	47	21	corresponding	corresponding	ADJ
dti-3213	47	22	effectiveness	effectiveness	NOUN
dti-3213	47	23	of	of	ADP
dti-3213	47	24	anti	anti	NOUN
dti-3213	47	25	-	-	NOUN
dti-3213	47	26	vegf	vegf	NOUN
dti-3213	47	27	in	in	ADP
dti-3213	47	28	a	a	DET
dti-3213	47	29	real	real	ADJ
dti-3213	47	30	-	-	PUNCT
dti-3213	47	31	world	world	NOUN
dti-3213	47	32	study	study	NOUN
dti-3213	47	33	was	be	AUX
dti-3213	47	34	performed	perform	VERB
dti-3213	47	35	on	on	ADP
dti-3213	47	36	patients	patient	NOUN
dti-3213	47	37	with	with	ADP
dti-3213	47	38	namd	namd	NOUN
dti-3213	47	39	matched	match	VERB
dti-3213	47	40	through	through	ADP
dti-3213	47	41	propensity	propensity	NOUN
dti-3213	47	42	score	score	NOUN
dti-3213	47	43	(	(	PUNCT
dti-3213	47	44	ps	ps	NOUN
dti-3213	47	45	)	)	PUNCT
dti-3213	47	46	weighting	weighting	NOUN
dti-3213	47	47	.	.	PUNCT
dti-3213	48	1	efficacy	efficacy	NOUN
dti-3213	48	2	was	be	AUX
dti-3213	48	3	assessed	assess	VERB
dti-3213	48	4	in	in	ADP
dti-3213	48	5	terms	term	NOUN
dti-3213	48	6	of	of	ADP
dti-3213	48	7	change	change	NOUN
dti-3213	48	8	from	from	ADP
dti-3213	48	9	baseline	baseline	NOUN
dti-3213	48	10	to	to	ADP
dti-3213	48	11	1	1	NUM
dti-3213	48	12	year	year	NOUN
dti-3213	48	13	(	(	PUNCT
dti-3213	48	14	week	week	NOUN
dti-3213	48	15	52	52	NUM
dti-3213	48	16	in	in	ADP
dti-3213	48	17	the	the	DET
dti-3213	48	18	radiance	radiance	NOUN
dti-3213	48	19	and	and	CCONJ
dti-3213	48	20	week	week	NOUN
dti-3213	48	21	48	48	NUM
dti-3213	48	22	in	in	ADP
dti-3213	48	23	the	the	DET
dti-3213	48	24	faricimab	faricimab	NOUN
dti-3213	48	25	cohorts	cohort	NOUN
dti-3213	48	26	)	)	PUNCT
dti-3213	48	27	in	in	ADP
dti-3213	48	28	bcva	bcva	NOUN
dti-3213	48	29	,	,	PUNCT
dti-3213	48	30	as	as	SCONJ
dti-3213	48	31	assessed	assess	VERB
dti-3213	48	32	by	by	ADP
dti-3213	48	33	etdrs	etdr	NOUN
dti-3213	48	34	letter	letter	NOUN
dti-3213	48	35	score	score	NOUN
dti-3213	48	36	,	,	PUNCT
dti-3213	48	37	and	and	CCONJ
dti-3213	48	38	central	central	ADJ
dti-3213	48	39	subfield	subfield	NOUN
dti-3213	48	40	thickness	thickness	NOUN
dti-3213	48	41	(	(	PUNCT
dti-3213	48	42	cst	cst	PROPN
dti-3213	48	43	)	)	PUNCT
dti-3213	48	44	,	,	PUNCT
dti-3213	48	45	as	as	SCONJ
dti-3213	48	46	determined	determine	VERB
dti-3213	48	47	by	by	ADP
dti-3213	48	48	spectral	spectral	ADJ
dti-3213	48	49	domain	domain	NOUN
dti-3213	48	50	-	-	PUNCT
dti-3213	48	51	optical	optical	ADJ
dti-3213	48	52	coherence	coherence	NOUN
dti-3213	48	53	tomography	tomography	NOUN
dti-3213	48	54	.	.	PUNCT
dti-3213	49	1	data	data	PROPN
dti-3213	49	2	sources	sources	PROPN
dti-3213	49	3	ipd	ipd	PROPN
dti-3213	49	4	for	for	ADP
dti-3213	49	5	the	the	DET
dti-3213	49	6	faricimab	faricimab	NOUN
dti-3213	49	7	cohort	cohort	NOUN
dti-3213	49	8	was	be	AUX
dti-3213	49	9	taken	take	VERB
dti-3213	49	10	from	from	ADP
dti-3213	49	11	the	the	DET
dti-3213	49	12	pivotal	pivotal	ADJ
dti-3213	49	13	trials	trial	NOUN
dti-3213	49	14	tenaya	tenaya	PROPN
dti-3213	49	15	(	(	PUNCT
dti-3213	49	16	clinicaltrials.gov	clinicaltrials.gov	X
dti-3213	49	17	identifier	identifier	X
dti-3213	49	18	nct03823287	nct03823287	ADJ
dti-3213	49	19	)	)	PUNCT
dti-3213	49	20	and	and	CCONJ
dti-3213	49	21	lucerne	lucerne	NOUN
dti-3213	49	22	(	(	PUNCT
dti-3213	49	23	clinicaltrials.gov	clinicaltrials.gov	X
dti-3213	49	24	identifier	identifier	NOUN
dti-3213	49	25	nct03823300	nct03823300	NOUN
dti-3213	49	26	)	)	PUNCT
dti-3213	49	27	(	(	PUNCT
dti-3213	49	28	30	30	NUM
dti-3213	49	29	)	)	PUNCT
dti-3213	49	30	.	.	PUNCT
dti-3213	50	1	ipd	ipd	PROPN
dti-3213	50	2	for	for	ADP
dti-3213	50	3	the	the	DET
dti-3213	50	4	radiance	radiance	NOUN
dti-3213	50	5	cohort	cohort	NOUN
dti-3213	50	6	was	be	AUX
dti-3213	50	7	taken	take	VERB
dti-3213	50	8	from	from	ADP
dti-3213	50	9	the	the	DET
dti-3213	50	10	italian	italian	ADJ
dti-3213	50	11	,	,	PUNCT
dti-3213	50	12	real	real	ADJ
dti-3213	50	13	-	-	PUNCT
dti-3213	50	14	world	world	NOUN
dti-3213	50	15	study	study	NOUN
dti-3213	50	16	radiance	radiance	NOUN
dti-3213	50	17	(	(	PUNCT
dti-3213	50	18	31	31	NUM
dti-3213	50	19	)	)	PUNCT
dti-3213	50	20	.	.	PUNCT
dti-3213	51	1	in	in	ADP
dti-3213	51	2	the	the	DET
dti-3213	51	3	tenaya	tenaya	PROPN
dti-3213	51	4	and	and	CCONJ
dti-3213	51	5	lucerne	lucerne	NOUN
dti-3213	51	6	studies	study	NOUN
dti-3213	51	7	bilateral	bilateral	ADJ
dti-3213	51	8	treatment	treatment	NOUN
dti-3213	51	9	was	be	AUX
dti-3213	51	10	not	not	PART
dti-3213	51	11	allowed	allow	VERB
dti-3213	51	12	and	and	CCONJ
dti-3213	51	13	for	for	ADP
dti-3213	51	14	patients	patient	NOUN
dti-3213	51	15	with	with	ADP
dti-3213	51	16	bilateral	bilateral	ADJ
dti-3213	51	17	namd	namd	NOUN
dti-3213	51	18	,	,	PUNCT
dti-3213	51	19	the	the	DET
dti-3213	51	20	eye	eye	NOUN
dti-3213	51	21	with	with	ADP
dti-3213	51	22	the	the	DET
dti-3213	51	23	worst	bad	ADJ
dti-3213	51	24	bcva	bcva	NOUN
dti-3213	51	25	at	at	ADP
dti-3213	51	26	diagnosis	diagnosis	NOUN
dti-3213	51	27	was	be	AUX
dti-3213	51	28	included	include	VERB
dti-3213	51	29	(	(	PUNCT
dti-3213	51	30	study	study	NOUN
dti-3213	51	31	eye	eye	NOUN
dti-3213	51	32	)	)	PUNCT
dti-3213	51	33	.	.	PUNCT
dti-3213	52	1	in	in	ADP
dti-3213	52	2	the	the	DET
dti-3213	52	3	radiance	radiance	NOUN
dti-3213	52	4	study	study	NOUN
dti-3213	52	5	,	,	PUNCT
dti-3213	52	6	in	in	ADP
dti-3213	52	7	case	case	NOUN
dti-3213	52	8	of	of	ADP
dti-3213	52	9	bilateral	bilateral	ADJ
dti-3213	52	10	treatment	treatment	NOUN
dti-3213	52	11	during	during	ADP
dti-3213	52	12	the	the	DET
dti-3213	52	13	index	index	NOUN
dti-3213	52	14	period	period	NOUN
dti-3213	52	15	,	,	PUNCT
dti-3213	52	16	the	the	DET
dti-3213	52	17	eye	eye	NOUN
dti-3213	52	18	with	with	ADP
dti-3213	52	19	the	the	DET
dti-3213	52	20	worst	bad	ADJ
dti-3213	52	21	condition	condition	NOUN
dti-3213	52	22	at	at	ADP
dti-3213	52	23	treatment	treatment	NOUN
dti-3213	52	24	start	start	NOUN
dti-3213	52	25	was	be	AUX
dti-3213	52	26	selected	select	VERB
dti-3213	52	27	as	as	ADP
dti-3213	52	28	the	the	DET
dti-3213	52	29	study	study	NOUN
dti-3213	52	30	eye	eye	NOUN
dti-3213	52	31	.	.	PUNCT
dti-3213	53	1	population	population	NOUN
dti-3213	53	2	this	this	DET
dti-3213	53	3	analysis	analysis	NOUN
dti-3213	53	4	included	include	VERB
dti-3213	53	5	all	all	DET
dti-3213	53	6	the	the	DET
dti-3213	53	7	patients	patient	NOUN
dti-3213	53	8	enrolled	enrol	VERB
dti-3213	53	9	in	in	ADP
dti-3213	53	10	the	the	DET
dti-3213	53	11	radiance	radiance	NOUN
dti-3213	53	12	study	study	NOUN
dti-3213	53	13	(	(	PUNCT
dti-3213	53	14	31	31	NUM
dti-3213	53	15	)	)	PUNCT
dti-3213	53	16	with	with	ADP
dti-3213	53	17	at	at	ADV
dti-3213	53	18	least	least	ADV
dti-3213	53	19	two	two	NUM
dti-3213	53	20	va	va	NOUN
dti-3213	53	21	measurements	measurement	NOUN
dti-3213	53	22	after	after	ADP
dti-3213	53	23	the	the	DET
dti-3213	53	24	one	one	NOUN
dti-3213	53	25	at	at	ADP
dti-3213	53	26	baseline	baseline	NOUN
dti-3213	53	27	,	,	PUNCT
dti-3213	53	28	of	of	ADP
dti-3213	53	29	which	which	PRON
dti-3213	53	30	at	at	ADP
dti-3213	53	31	least	least	ADJ
dti-3213	53	32	one	one	NUM
dti-3213	53	33	was	be	AUX
dti-3213	53	34	at	at	ADP
dti-3213	53	35	week	week	NOUN
dti-3213	53	36	52	52	NUM
dti-3213	53	37	±	±	NUM
dti-3213	53	38	10	10	NUM
dti-3213	53	39	(	(	PUNCT
dti-3213	53	40	radiance	radiance	NOUN
dti-3213	53	41	cohort	cohort	NOUN
dti-3213	53	42	)	)	PUNCT
dti-3213	53	43	.	.	PUNCT
dti-3213	54	1	a	a	DET
dti-3213	54	2	cohort	cohort	NOUN
dti-3213	54	3	of	of	ADP
dti-3213	54	4	patients	patient	NOUN
dti-3213	54	5	treated	treat	VERB
dti-3213	54	6	with	with	ADP
dti-3213	54	7	faricimab	faricimab	NOUN
dti-3213	54	8	was	be	AUX
dti-3213	54	9	created	create	VERB
dti-3213	54	10	by	by	ADP
dti-3213	54	11	combining	combine	VERB
dti-3213	54	12	data	datum	NOUN
dti-3213	54	13	from	from	ADP
dti-3213	54	14	the	the	DET
dti-3213	54	15	active	active	ADJ
dti-3213	54	16	arms	arm	NOUN
dti-3213	54	17	in	in	ADP
dti-3213	54	18	the	the	DET
dti-3213	54	19	lucerne	lucerne	NOUN
dti-3213	54	20	and	and	CCONJ
dti-3213	54	21	tenaya	tenaya	PROPN
dti-3213	54	22	trials	trial	NOUN
dti-3213	54	23	(	(	PUNCT
dti-3213	54	24	faricimab	faricimab	NOUN
dti-3213	54	25	cohort	cohort	NOUN
dti-3213	54	26	)	)	PUNCT
dti-3213	54	27	.	.	PUNCT
dti-3213	55	1	since	since	SCONJ
dti-3213	55	2	the	the	DET
dti-3213	55	3	pivotal	pivotal	ADJ
dti-3213	55	4	trials	trial	NOUN
dti-3213	55	5	(	(	PUNCT
dti-3213	55	6	30	30	NUM
dti-3213	55	7	)	)	PUNCT
dti-3213	55	8	included	include	VERB
dti-3213	55	9	patients	patient	NOUN
dti-3213	55	10	worldwide	worldwide	ADV
dti-3213	55	11	and	and	CCONJ
dti-3213	55	12	the	the	DET
dti-3213	55	13	radiance	radiance	NOUN
dti-3213	55	14	study	study	NOUN
dti-3213	55	15	included	include	VERB
dti-3213	55	16	italian	italian	ADJ
dti-3213	55	17	patients	patient	NOUN
dti-3213	55	18	only	only	ADV
dti-3213	55	19	,	,	PUNCT
dti-3213	55	20	to	to	PART
dti-3213	55	21	ensure	ensure	VERB
dti-3213	55	22	consistency	consistency	NOUN
dti-3213	55	23	across	across	ADP
dti-3213	55	24	the	the	DET
dti-3213	55	25	cohorts	cohort	NOUN
dti-3213	55	26	,	,	PUNCT
dti-3213	55	27	only	only	ADV
dti-3213	55	28	caucasian	caucasian	ADJ
dti-3213	55	29	patients	patient	NOUN
dti-3213	55	30	from	from	ADP
dti-3213	55	31	lucerne	lucerne	NOUN
dti-3213	55	32	and	and	CCONJ
dti-3213	55	33	tenaya	tenaya	PROPN
dti-3213	55	34	were	be	AUX
dti-3213	55	35	considered	consider	VERB
dti-3213	55	36	;	;	PUNCT
dti-3213	55	37	in	in	ADP
dti-3213	55	38	addition	addition	NOUN
dti-3213	55	39	,	,	PUNCT
dti-3213	55	40	patients	patient	NOUN
dti-3213	55	41	with	with	ADP
dti-3213	55	42	no	no	DET
dti-3213	55	43	va	va	NOUN
dti-3213	55	44	and	and	CCONJ
dti-3213	55	45	cst	cst	PROPN
dti-3213	55	46	data	datum	NOUN
dti-3213	55	47	at	at	ADP
dti-3213	55	48	week	week	NOUN
dti-3213	55	49	48	48	NUM
dti-3213	55	50	or	or	CCONJ
dti-3213	55	51	with	with	ADP
dti-3213	55	52	polypoidal	polypoidal	ADJ
dti-3213	55	53	choroidal	choroidal	ADJ
dti-3213	55	54	vasculopathy	vasculopathy	NOUN
dti-3213	55	55	(	(	PUNCT
dti-3213	55	56	pcv	pcv	NOUN
dti-3213	55	57	)	)	PUNCT
dti-3213	55	58	lesions	lesion	NOUN
dti-3213	55	59	were	be	AUX
dti-3213	55	60	excluded	exclude	VERB
dti-3213	55	61	from	from	ADP
dti-3213	55	62	the	the	DET
dti-3213	55	63	faricimab	faricimab	NOUN
dti-3213	55	64	cohort	cohort	NOUN
dti-3213	55	65	.	.	PUNCT
dti-3213	56	1	we	we	PRON
dti-3213	56	2	excluded	exclude	VERB
dti-3213	56	3	pcv	pcv	NOUN
dti-3213	56	4	lesions	lesion	NOUN
dti-3213	56	5	from	from	ADP
dti-3213	56	6	the	the	DET
dti-3213	56	7	faricimab	faricimab	NOUN
dti-3213	56	8	galeone	galeone	NOUN
dti-3213	56	9	et	et	NOUN
dti-3213	56	10	al	al	PROPN
dti-3213	56	11	drug	drug	PROPN
dti-3213	56	12	target	target	NOUN
dti-3213	56	13	insights	insight	NOUN
dti-3213	56	14	2024	2024	NUM
dti-3213	56	15	;	;	PUNCT
dti-3213	56	16	18	18	NUM
dti-3213	56	17	:	:	SYM
dti-3213	56	18	107	107	NUM
dti-3213	56	19	©	©	PROPN
dti-3213	56	20	2024	2024	NUM
dti-3213	56	21	the	the	DET
dti-3213	56	22	authors	author	NOUN
dti-3213	56	23	.	.	PUNCT
dti-3213	57	1	published	publish	VERB
dti-3213	57	2	by	by	ADP
dti-3213	57	3	aboutscience	aboutscience	NOUN
dti-3213	57	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3213	57	5	cohort	cohort	NOUN
dti-3213	57	6	because	because	SCONJ
dti-3213	57	7	there	there	PRON
dti-3213	57	8	were	be	VERB
dti-3213	57	9	no	no	DET
dti-3213	57	10	patients	patient	NOUN
dti-3213	57	11	with	with	ADP
dti-3213	57	12	pcv	pcv	NOUN
dti-3213	57	13	in	in	ADP
dti-3213	57	14	the	the	DET
dti-3213	57	15	radiance	radiance	NOUN
dti-3213	57	16	cohort	cohort	NOUN
dti-3213	57	17	.	.	PUNCT
dti-3213	58	1	statistical	statistical	ADJ
dti-3213	58	2	analyses	analysis	NOUN
dti-3213	58	3	ps	ps	NOUN
dti-3213	58	4	-	-	PUNCT
dti-3213	58	5	based	base	VERB
dti-3213	58	6	inverse	inverse	NOUN
dti-3213	58	7	probability	probability	NOUN
dti-3213	58	8	of	of	ADP
dti-3213	58	9	treatment	treatment	NOUN
dti-3213	58	10	weighting	weighting	NOUN
dti-3213	58	11	(	(	PUNCT
dti-3213	58	12	iptw	iptw	NOUN
dti-3213	58	13	)	)	PUNCT
dti-3213	58	14	was	be	AUX
dti-3213	58	15	utilized	utilize	VERB
dti-3213	58	16	to	to	PART
dti-3213	58	17	balance	balance	VERB
dti-3213	58	18	the	the	DET
dti-3213	58	19	two	two	NUM
dti-3213	58	20	cohorts	cohort	NOUN
dti-3213	58	21	and	and	CCONJ
dti-3213	58	22	mitigate	mitigate	VERB
dti-3213	58	23	bias	bias	NOUN
dti-3213	58	24	due	due	ADP
dti-3213	58	25	to	to	ADP
dti-3213	58	26	potential	potential	ADJ
dti-3213	58	27	confounding	confounding	NOUN
dti-3213	58	28	.	.	PUNCT
dti-3213	59	1	in	in	ADP
dti-3213	59	2	iptw	iptw	NOUN
dti-3213	59	3	,	,	PUNCT
dti-3213	59	4	weights	weight	NOUN
dti-3213	59	5	are	be	AUX
dti-3213	59	6	calculated	calculate	VERB
dti-3213	59	7	for	for	ADP
dti-3213	59	8	each	each	DET
dti-3213	59	9	individual	individual	NOUN
dti-3213	59	10	as	as	ADP
dti-3213	59	11	1	1	NUM
dti-3213	59	12	/	/	SYM
dti-3213	59	13	ps	ps	NOUN
dti-3213	59	14	for	for	ADP
dti-3213	59	15	the	the	DET
dti-3213	59	16	treated	treat	VERB
dti-3213	59	17	group	group	NOUN
dti-3213	59	18	and	and	CCONJ
dti-3213	59	19	1/(1	1/(1	NUM
dti-3213	59	20	−	−	PROPN
dti-3213	59	21	ps	ps	PROPN
dti-3213	59	22	)	)	PUNCT
dti-3213	59	23	for	for	ADP
dti-3213	59	24	the	the	DET
dti-3213	59	25	control	control	NOUN
dti-3213	59	26	group	group	NOUN
dti-3213	59	27	,	,	PUNCT
dti-3213	59	28	where	where	SCONJ
dti-3213	59	29	the	the	DET
dti-3213	59	30	ps	ps	NOUN
dti-3213	59	31	is	be	AUX
dti-3213	59	32	defined	define	VERB
dti-3213	59	33	as	as	ADP
dti-3213	59	34	the	the	DET
dti-3213	59	35	inverse	inverse	ADJ
dti-3213	59	36	probability	probability	NOUN
dti-3213	59	37	of	of	ADP
dti-3213	59	38	receiving	receive	VERB
dti-3213	59	39	the	the	DET
dti-3213	59	40	treatment	treatment	NOUN
dti-3213	59	41	based	base	VERB
dti-3213	59	42	on	on	ADP
dti-3213	59	43	the	the	DET
dti-3213	59	44	baseline	baseline	PROPN
dti-3213	59	45	characteristics	characteristic	NOUN
dti-3213	59	46	.	.	PUNCT
dti-3213	60	1	this	this	PRON
dti-3213	60	2	creates	create	VERB
dti-3213	60	3	pseudo	pseudo	NOUN
dti-3213	60	4	-	-	NOUN
dti-3213	60	5	populations	population	NOUN
dti-3213	60	6	to	to	PART
dti-3213	60	7	achieve	achieve	VERB
dti-3213	60	8	a	a	DET
dti-3213	60	9	balanced	balanced	ADJ
dti-3213	60	10	distribution	distribution	NOUN
dti-3213	60	11	of	of	ADP
dti-3213	60	12	baseline	baseline	NOUN
dti-3213	60	13	covariates	covariate	NOUN
dti-3213	60	14	between	between	ADP
dti-3213	60	15	groups	group	NOUN
dti-3213	60	16	(	(	PUNCT
dti-3213	60	17	32	32	NUM
dti-3213	60	18	)	)	PUNCT
dti-3213	60	19	.	.	PUNCT
dti-3213	61	1	in	in	ADP
dti-3213	61	2	this	this	DET
dti-3213	61	3	analysis	analysis	NOUN
dti-3213	61	4	,	,	PUNCT
dti-3213	61	5	the	the	DET
dti-3213	61	6	ps	ps	NOUN
dti-3213	61	7	was	be	AUX
dti-3213	61	8	estimated	estimate	VERB
dti-3213	61	9	by	by	ADP
dti-3213	61	10	logistic	logistic	ADJ
dti-3213	61	11	regression	regression	NOUN
dti-3213	61	12	including	include	VERB
dti-3213	61	13	the	the	DET
dti-3213	61	14	following	follow	VERB
dti-3213	61	15	baseline	baseline	NOUN
dti-3213	61	16	covariates	covariate	NOUN
dti-3213	61	17	,	,	PUNCT
dti-3213	61	18	selected	select	VERB
dti-3213	61	19	according	accord	VERB
dti-3213	61	20	to	to	ADP
dti-3213	61	21	both	both	DET
dti-3213	61	22	expert	expert	ADJ
dti-3213	61	23	opinion	opinion	NOUN
dti-3213	61	24	and	and	CCONJ
dti-3213	61	25	evaluation	evaluation	NOUN
dti-3213	61	26	of	of	ADP
dti-3213	61	27	covariates	covariate	NOUN
dti-3213	61	28	’	'	PUNCT
dti-3213	61	29	imbalance	imbalance	NOUN
dti-3213	61	30	between	between	ADP
dti-3213	61	31	cohorts	cohort	NOUN
dti-3213	61	32	:	:	PUNCT
dti-3213	61	33	•	•	NUM
dti-3213	61	34	va	va	NOUN
dti-3213	61	35	or	or	CCONJ
dti-3213	61	36	cst	cst	PROPN
dti-3213	61	37	at	at	ADP
dti-3213	61	38	baseline	baseline	PROPN
dti-3213	61	39	,	,	PUNCT
dti-3213	61	40	respectively	respectively	ADV
dti-3213	61	41	,	,	PUNCT
dti-3213	61	42	when	when	SCONJ
dti-3213	61	43	analyzing	analyze	VERB
dti-3213	61	44	bcva	bcva	PROPN
dti-3213	61	45	and	and	CCONJ
dti-3213	61	46	cst	cst	PROPN
dti-3213	61	47	change	change	NOUN
dti-3213	61	48	;	;	PUNCT
dti-3213	61	49	•	•	X
dti-3213	61	50	age	age	NOUN
dti-3213	61	51	;	;	PUNCT
dti-3213	61	52	•	•	NUM
dti-3213	61	53	sex	sex	NOUN
dti-3213	61	54	;	;	PUNCT
dti-3213	61	55	•	•	NUM
dti-3213	61	56	type	type	NOUN
dti-3213	61	57	of	of	ADP
dti-3213	61	58	lesion	lesion	NOUN
dti-3213	61	59	(	(	PUNCT
dti-3213	61	60	type	type	NOUN
dti-3213	61	61	1	1	NUM
dti-3213	61	62	,	,	PUNCT
dti-3213	61	63	2	2	NUM
dti-3213	61	64	,	,	PUNCT
dti-3213	61	65	and	and	CCONJ
dti-3213	61	66	3	3	NUM
dti-3213	61	67	)	)	PUNCT
dti-3213	61	68	;	;	PUNCT
dti-3213	61	69	•	•	NUM
dti-3213	61	70	presence	presence	NOUN
dti-3213	61	71	of	of	ADP
dti-3213	61	72	intraretinal	intraretinal	ADJ
dti-3213	61	73	fluid	fluid	NOUN
dti-3213	61	74	(	(	PUNCT
dti-3213	61	75	irf	irf	PROPN
dti-3213	61	76	)	)	PUNCT
dti-3213	61	77	at	at	ADP
dti-3213	61	78	baseline	baseline	NOUN
dti-3213	61	79	;	;	PUNCT
dti-3213	62	1	•	•	NUM
dti-3213	62	2	presence	presence	NOUN
dti-3213	62	3	of	of	ADP
dti-3213	62	4	subretinal	subretinal	ADJ
dti-3213	62	5	fluid	fluid	NOUN
dti-3213	62	6	(	(	PUNCT
dti-3213	62	7	srf	srf	NOUN
dti-3213	62	8	)	)	PUNCT
dti-3213	62	9	at	at	ADP
dti-3213	62	10	baseline	baseline	NOUN
dti-3213	62	11	.	.	PUNCT
dti-3213	63	1	missing	miss	VERB
dti-3213	63	2	values	value	NOUN
dti-3213	63	3	in	in	ADP
dti-3213	63	4	type	type	NOUN
dti-3213	63	5	of	of	ADP
dti-3213	63	6	lesion	lesion	NOUN
dti-3213	63	7	,	,	PUNCT
dti-3213	63	8	and	and	CCONJ
dti-3213	63	9	baseline	baseline	PROPN
dti-3213	63	10	irf	irf	PROPN
dti-3213	63	11	and	and	CCONJ
dti-3213	63	12	srf	srf	PROPN
dti-3213	63	13	were	be	AUX
dti-3213	63	14	handled	handle	VERB
dti-3213	63	15	by	by	ADP
dti-3213	63	16	inclusion	inclusion	NOUN
dti-3213	63	17	of	of	ADP
dti-3213	63	18	categories	category	NOUN
dti-3213	63	19	for	for	ADP
dti-3213	63	20	missing	miss	VERB
dti-3213	63	21	values	value	NOUN
dti-3213	63	22	in	in	ADP
dti-3213	63	23	the	the	DET
dti-3213	63	24	ps	ps	NOUN
dti-3213	63	25	models	model	NOUN
dti-3213	63	26	.	.	PUNCT
dti-3213	64	1	standardized	standardized	ADJ
dti-3213	64	2	mean	mean	ADJ
dti-3213	64	3	differences	difference	NOUN
dti-3213	64	4	(	(	PUNCT
dti-3213	64	5	smds	smds	NOUN
dti-3213	64	6	)	)	PUNCT
dti-3213	64	7	and	and	CCONJ
dti-3213	64	8	appropriate	appropriate	ADJ
dti-3213	64	9	statistical	statistical	ADJ
dti-3213	64	10	tests	test	NOUN
dti-3213	64	11	(	(	PUNCT
dti-3213	64	12	i.e.	i.e.	X
dti-3213	64	13	,	,	PUNCT
dti-3213	64	14	chi	chi	ADJ
dti-3213	64	15	-	-	PUNCT
dti-3213	64	16	square	square	ADJ
dti-3213	64	17	tests	test	NOUN
dti-3213	64	18	for	for	ADP
dti-3213	64	19	categorical	categorical	ADJ
dti-3213	64	20	variables	variable	NOUN
dti-3213	64	21	,	,	PUNCT
dti-3213	64	22	and	and	CCONJ
dti-3213	64	23	t	t	NOUN
dti-3213	64	24	-	-	PUNCT
dti-3213	64	25	tests	test	NOUN
dti-3213	64	26	or	or	CCONJ
dti-3213	64	27	non	non	ADJ
dti-3213	64	28	-	-	ADJ
dti-3213	64	29	parametric	parametric	ADJ
dti-3213	64	30	mann	mann	PROPN
dti-3213	64	31	-	-	PUNCT
dti-3213	64	32	whitney	whitney	PROPN
dti-3213	64	33	tests	test	NOUN
dti-3213	64	34	,	,	PUNCT
dti-3213	64	35	respectively	respectively	ADV
dti-3213	64	36	,	,	PUNCT
dti-3213	64	37	for	for	ADP
dti-3213	64	38	normally	normally	ADV
dti-3213	64	39	and	and	CCONJ
dti-3213	64	40	not	not	PART
dti-3213	64	41	normally	normally	ADV
dti-3213	64	42	distributed	distribute	VERB
dti-3213	64	43	continuous	continuous	ADJ
dti-3213	64	44	variables	variable	NOUN
dti-3213	64	45	)	)	PUNCT
dti-3213	64	46	were	be	AUX
dti-3213	64	47	used	use	VERB
dti-3213	64	48	to	to	PART
dti-3213	64	49	compare	compare	VERB
dti-3213	64	50	the	the	DET
dti-3213	64	51	distribution	distribution	NOUN
dti-3213	64	52	of	of	ADP
dti-3213	64	53	baseline	baseline	NOUN
dti-3213	64	54	covariates	covariate	NOUN
dti-3213	64	55	between	between	ADP
dti-3213	64	56	the	the	DET
dti-3213	64	57	radiance	radiance	NOUN
dti-3213	64	58	and	and	CCONJ
dti-3213	64	59	faricimab	faricimab	NOUN
dti-3213	64	60	cohorts	cohort	NOUN
dti-3213	64	61	before	before	ADP
dti-3213	64	62	and	and	CCONJ
dti-3213	64	63	after	after	ADP
dti-3213	64	64	iptw	iptw	NOUN
dti-3213	64	65	.	.	PUNCT
dti-3213	65	1	a	a	DET
dti-3213	65	2	weighted	weighted	ADJ
dti-3213	65	3	one	one	NUM
dti-3213	65	4	-	-	PUNCT
dti-3213	65	5	way	way	NOUN
dti-3213	65	6	analysis	analysis	NOUN
dti-3213	65	7	of	of	ADP
dti-3213	65	8	variance	variance	NOUN
dti-3213	65	9	(	(	PUNCT
dti-3213	65	10	anova	anova	PROPN
dti-3213	65	11	)	)	PUNCT
dti-3213	65	12	was	be	AUX
dti-3213	65	13	applied	apply	VERB
dti-3213	65	14	to	to	PART
dti-3213	65	15	compare	compare	VERB
dti-3213	65	16	mean	mean	ADJ
dti-3213	65	17	changes	change	NOUN
dti-3213	65	18	in	in	ADP
dti-3213	65	19	bcva	bcva	PROPN
dti-3213	65	20	and	and	CCONJ
dti-3213	65	21	cst	cst	PROPN
dti-3213	65	22	between	between	ADP
dti-3213	65	23	the	the	DET
dti-3213	65	24	two	two	NUM
dti-3213	65	25	cohorts	cohort	NOUN
dti-3213	65	26	.	.	PUNCT
dti-3213	66	1	the	the	DET
dti-3213	66	2	frequency	frequency	NOUN
dti-3213	66	3	of	of	ADP
dti-3213	66	4	injections	injection	NOUN
dti-3213	66	5	may	may	AUX
dti-3213	66	6	differ	differ	VERB
dti-3213	66	7	in	in	ADP
dti-3213	66	8	randomized	randomized	ADJ
dti-3213	66	9	controlled	control	VERB
dti-3213	66	10	trial	trial	NOUN
dti-3213	66	11	(	(	PUNCT
dti-3213	66	12	rct	rct	PROPN
dti-3213	66	13	)	)	PUNCT
dti-3213	66	14	and	and	CCONJ
dti-3213	66	15	clinical	clinical	ADJ
dti-3213	66	16	practice	practice	NOUN
dti-3213	66	17	and	and	CCONJ
dti-3213	66	18	,	,	PUNCT
dti-3213	66	19	as	as	SCONJ
dti-3213	66	20	already	already	ADV
dti-3213	66	21	reported	report	VERB
dti-3213	66	22	in	in	ADP
dti-3213	66	23	the	the	DET
dti-3213	66	24	radiance	radiance	NOUN
dti-3213	66	25	study	study	NOUN
dti-3213	66	26	,	,	PUNCT
dti-3213	66	27	patients	patient	NOUN
dti-3213	66	28	with	with	ADP
dti-3213	66	29	a	a	DET
dti-3213	66	30	higher	high	ADJ
dti-3213	66	31	number	number	NOUN
dti-3213	66	32	of	of	ADP
dti-3213	66	33	injections	injection	NOUN
dti-3213	66	34	showed	show	VERB
dti-3213	66	35	more	more	ADV
dti-3213	66	36	favorable	favorable	ADJ
dti-3213	66	37	clinical	clinical	ADJ
dti-3213	66	38	outcomes	outcome	NOUN
dti-3213	66	39	(	(	PUNCT
dti-3213	66	40	31	31	NUM
dti-3213	66	41	)	)	PUNCT
dti-3213	66	42	.	.	PUNCT
dti-3213	67	1	to	to	PART
dti-3213	67	2	account	account	VERB
dti-3213	67	3	for	for	ADP
dti-3213	67	4	the	the	DET
dti-3213	67	5	difference	difference	NOUN
dti-3213	67	6	in	in	ADP
dti-3213	67	7	treatment	treatment	NOUN
dti-3213	67	8	regime	regime	NOUN
dti-3213	67	9	and	and	CCONJ
dti-3213	67	10	protocol	protocol	NOUN
dti-3213	67	11	between	between	ADP
dti-3213	67	12	the	the	DET
dti-3213	67	13	pivotal	pivotal	ADJ
dti-3213	67	14	and	and	CCONJ
dti-3213	67	15	real	real	ADJ
dti-3213	67	16	-	-	PUNCT
dti-3213	67	17	world	world	NOUN
dti-3213	67	18	studies	study	NOUN
dti-3213	67	19	,	,	PUNCT
dti-3213	67	20	in	in	ADP
dti-3213	67	21	a	a	DET
dti-3213	67	22	sensitivity	sensitivity	NOUN
dti-3213	67	23	analysis	analysis	NOUN
dti-3213	67	24	an	an	DET
dti-3213	67	25	analysis	analysis	NOUN
dti-3213	67	26	of	of	ADP
dti-3213	67	27	covariance	covariance	NOUN
dti-3213	67	28	(	(	PUNCT
dti-3213	67	29	ancova	ancova	NOUN
dti-3213	67	30	)	)	PUNCT
dti-3213	67	31	model	model	NOUN
dti-3213	67	32	incorporating	incorporate	VERB
dti-3213	67	33	the	the	DET
dti-3213	67	34	number	number	NOUN
dti-3213	67	35	of	of	ADP
dti-3213	67	36	injections	injection	NOUN
dti-3213	67	37	as	as	ADV
dti-3213	67	38	covariate	covariate	ADJ
dti-3213	67	39	and	and	CCONJ
dti-3213	67	40	weighting	weight	VERB
dti-3213	67	41	for	for	ADP
dti-3213	67	42	iptw	iptw	NOUN
dti-3213	67	43	was	be	AUX
dti-3213	67	44	used	use	VERB
dti-3213	67	45	to	to	PART
dti-3213	67	46	obtain	obtain	VERB
dti-3213	67	47	adjusted	adjust	VERB
dti-3213	67	48	mean	mean	ADJ
dti-3213	67	49	treatment	treatment	NOUN
dti-3213	67	50	differences	difference	NOUN
dti-3213	67	51	.	.	PUNCT
dti-3213	68	1	all	all	DET
dti-3213	68	2	tests	test	NOUN
dti-3213	68	3	were	be	AUX
dti-3213	68	4	two	two	NUM
dti-3213	68	5	-	-	PUNCT
dti-3213	68	6	sided	sided	ADJ
dti-3213	68	7	,	,	PUNCT
dti-3213	68	8	and	and	CCONJ
dti-3213	68	9	a	a	DET
dti-3213	68	10	p	p	NOUN
dti-3213	68	11	value	value	NOUN
dti-3213	68	12	<	<	NOUN
dti-3213	68	13	0.05	0.05	NUM
dti-3213	68	14	was	be	AUX
dti-3213	68	15	considered	consider	VERB
dti-3213	68	16	statistically	statistically	ADV
dti-3213	68	17	significant	significant	ADJ
dti-3213	68	18	.	.	PUNCT
dti-3213	69	1	statistical	statistical	ADJ
dti-3213	69	2	analyses	analysis	NOUN
dti-3213	69	3	were	be	AUX
dti-3213	69	4	performed	perform	VERB
dti-3213	69	5	with	with	ADP
dti-3213	69	6	sas	sas	PROPN
dti-3213	69	7	version	version	PROPN
dti-3213	69	8	9.4	9.4	NUM
dti-3213	69	9	(	(	PUNCT
dti-3213	69	10	sas	sas	PROPN
dti-3213	69	11	institute	institute	PROPN
dti-3213	69	12	,	,	PUNCT
dti-3213	69	13	cary	cary	PROPN
dti-3213	69	14	,	,	PUNCT
dti-3213	69	15	nc	nc	PROPN
dti-3213	69	16	)	)	PUNCT
dti-3213	69	17	.	.	PUNCT
dti-3213	70	1	results	result	VERB
dti-3213	70	2	patients	patient	NOUN
dti-3213	70	3	and	and	CCONJ
dti-3213	70	4	baseline	baseline	VERB
dti-3213	70	5	characteristics	characteristic	NOUN
dti-3213	70	6	the	the	DET
dti-3213	70	7	radiance	radiance	NOUN
dti-3213	70	8	study	study	NOUN
dti-3213	70	9	enrolled	enrol	VERB
dti-3213	70	10	405	405	NUM
dti-3213	70	11	patients	patient	NOUN
dti-3213	70	12	.	.	PUNCT
dti-3213	71	1	of	of	ADP
dti-3213	71	2	those	those	PRON
dti-3213	71	3	,	,	PUNCT
dti-3213	71	4	17	17	NUM
dti-3213	71	5	were	be	AUX
dti-3213	71	6	excluded	exclude	VERB
dti-3213	71	7	because	because	SCONJ
dti-3213	71	8	they	they	PRON
dti-3213	71	9	did	do	AUX
dti-3213	71	10	not	not	PART
dti-3213	71	11	satisfy	satisfy	VERB
dti-3213	71	12	the	the	DET
dti-3213	71	13	inclusion	inclusion	NOUN
dti-3213	71	14	criteria	criterion	NOUN
dti-3213	71	15	(	(	PUNCT
dti-3213	71	16	i.e.	i.e.	X
dti-3213	71	17	,	,	PUNCT
dti-3213	71	18	patients	patient	NOUN
dti-3213	71	19	with	with	ADP
dti-3213	71	20	diagnosis	diagnosis	NOUN
dti-3213	71	21	of	of	ADP
dti-3213	71	22	namd	namd	NOUN
dti-3213	71	23	,	,	PUNCT
dti-3213	71	24	naïve	naïve	ADJ
dti-3213	71	25	to	to	ADP
dti-3213	71	26	any	any	DET
dti-3213	71	27	intraocular	intraocular	ADJ
dti-3213	71	28	anti	anti	ADJ
dti-3213	71	29	-	-	ADJ
dti-3213	71	30	vegf	vegf	ADJ
dti-3213	71	31	treatment	treatment	NOUN
dti-3213	71	32	,	,	PUNCT
dti-3213	71	33	with	with	ADP
dti-3213	71	34	age	age	NOUN
dti-3213	71	35	≥50	≥50	NUM
dti-3213	71	36	years	year	NOUN
dti-3213	71	37	on	on	ADP
dti-3213	71	38	the	the	DET
dti-3213	71	39	date	date	NOUN
dti-3213	71	40	of	of	ADP
dti-3213	71	41	the	the	DET
dti-3213	71	42	first	first	ADJ
dti-3213	71	43	anti	anti	ADJ
dti-3213	71	44	-	-	ADJ
dti-3213	71	45	vegf	vegf	ADJ
dti-3213	71	46	injection	injection	NOUN
dti-3213	71	47	)	)	PUNCT
dti-3213	71	48	,	,	PUNCT
dti-3213	71	49	1	1	NUM
dti-3213	71	50	because	because	SCONJ
dti-3213	71	51	of	of	ADP
dti-3213	71	52	the	the	DET
dti-3213	71	53	lack	lack	NOUN
dti-3213	71	54	of	of	ADP
dti-3213	71	55	hospital	hospital	NOUN
dti-3213	71	56	charts	chart	NOUN
dti-3213	71	57	/	/	SYM
dti-3213	71	58	clinical	clinical	ADJ
dti-3213	71	59	records	record	NOUN
dti-3213	71	60	at	at	ADP
dti-3213	71	61	anti	anti	ADJ
dti-3213	71	62	-	-	ADJ
dti-3213	71	63	vegf	vegf	ADJ
dti-3213	71	64	treatment	treatment	NOUN
dti-3213	71	65	start	start	NOUN
dti-3213	71	66	,	,	PUNCT
dti-3213	71	67	43	43	NUM
dti-3213	71	68	because	because	SCONJ
dti-3213	71	69	of	of	ADP
dti-3213	71	70	the	the	DET
dti-3213	71	71	lack	lack	NOUN
dti-3213	71	72	of	of	ADP
dti-3213	71	73	at	at	ADV
dti-3213	71	74	least	least	ADV
dti-3213	71	75	two	two	NUM
dti-3213	71	76	va	va	NOUN
dti-3213	71	77	measurements	measurement	NOUN
dti-3213	71	78	after	after	ADP
dti-3213	71	79	the	the	DET
dti-3213	71	80	baseline	baseline	NOUN
dti-3213	71	81	,	,	PUNCT
dti-3213	71	82	and	and	CCONJ
dti-3213	71	83	81	81	NUM
dti-3213	71	84	because	because	SCONJ
dti-3213	71	85	of	of	ADP
dti-3213	71	86	the	the	DET
dti-3213	71	87	lack	lack	NOUN
dti-3213	71	88	of	of	ADP
dti-3213	71	89	a	a	DET
dti-3213	71	90	va	va	NOUN
dti-3213	71	91	measurement	measurement	NOUN
dti-3213	71	92	at	at	ADP
dti-3213	71	93	week	week	NOUN
dti-3213	71	94	52	52	NUM
dti-3213	71	95	±	±	NUM
dti-3213	71	96	10	10	NUM
dti-3213	71	97	.	.	PUNCT
dti-3213	72	1	the	the	DET
dti-3213	72	2	tenaya	tenaya	PROPN
dti-3213	72	3	and	and	CCONJ
dti-3213	72	4	lucerne	lucerne	NOUN
dti-3213	72	5	studies	study	NOUN
dti-3213	72	6	included	include	VERB
dti-3213	72	7	a	a	DET
dti-3213	72	8	total	total	NOUN
dti-3213	72	9	of	of	ADP
dti-3213	72	10	665	665	NUM
dti-3213	72	11	patients	patient	NOUN
dti-3213	72	12	treated	treat	VERB
dti-3213	72	13	with	with	ADP
dti-3213	72	14	faricimab	faricimab	NOUN
dti-3213	72	15	;	;	PUNCT
dti-3213	72	16	of	of	ADP
dti-3213	72	17	those	those	PRON
dti-3213	72	18	,	,	PUNCT
dti-3213	72	19	152	152	NUM
dti-3213	72	20	patients	patient	NOUN
dti-3213	72	21	were	be	AUX
dti-3213	72	22	not	not	PART
dti-3213	72	23	eligible	eligible	ADJ
dti-3213	72	24	for	for	ADP
dti-3213	72	25	this	this	DET
dti-3213	72	26	analysis	analysis	NOUN
dti-3213	72	27	(	(	PUNCT
dti-3213	72	28	85	85	NUM
dti-3213	72	29	were	be	AUX
dti-3213	72	30	noncaucasian	noncaucasian	ADJ
dti-3213	72	31	,	,	PUNCT
dti-3213	72	32	65	65	NUM
dti-3213	72	33	had	have	AUX
dti-3213	72	34	missing	miss	VERB
dti-3213	72	35	bcva	bcva	NOUN
dti-3213	72	36	and	and	CCONJ
dti-3213	72	37	cst	cst	PROPN
dti-3213	72	38	data	datum	NOUN
dti-3213	72	39	at	at	ADP
dti-3213	72	40	week	week	NOUN
dti-3213	72	41	48	48	NUM
dti-3213	72	42	,	,	PUNCT
dti-3213	72	43	and	and	CCONJ
dti-3213	72	44	,	,	PUNCT
dti-3213	72	45	among	among	ADP
dti-3213	72	46	the	the	DET
dti-3213	72	47	remaining	remain	VERB
dti-3213	72	48	,	,	PUNCT
dti-3213	72	49	2	2	NUM
dti-3213	72	50	were	be	AUX
dti-3213	72	51	diagnosed	diagnose	VERB
dti-3213	72	52	as	as	ADP
dti-3213	72	53	having	have	VERB
dti-3213	72	54	pcv	pcv	NOUN
dti-3213	72	55	at	at	ADP
dti-3213	72	56	baseline	baseline	NOUN
dti-3213	72	57	by	by	ADP
dti-3213	72	58	the	the	DET
dti-3213	72	59	centralized	centralized	ADJ
dti-3213	72	60	reading	reading	NOUN
dti-3213	72	61	center	center	NOUN
dti-3213	72	62	)	)	PUNCT
dti-3213	72	63	.	.	PUNCT
dti-3213	73	1	thus	thus	ADV
dti-3213	73	2	,	,	PUNCT
dti-3213	73	3	finally	finally	ADV
dti-3213	73	4	,	,	PUNCT
dti-3213	73	5	a	a	DET
dti-3213	73	6	total	total	NOUN
dti-3213	73	7	of	of	ADP
dti-3213	73	8	513	513	NUM
dti-3213	73	9	patients	patient	NOUN
dti-3213	73	10	treated	treat	VERB
dti-3213	73	11	with	with	ADP
dti-3213	73	12	faricimab	faricimab	NOUN
dti-3213	73	13	from	from	ADP
dti-3213	73	14	tenaya	tenaya	PROPN
dti-3213	73	15	and	and	CCONJ
dti-3213	73	16	lucerne	lucerne	NOUN
dti-3213	73	17	trials	trial	NOUN
dti-3213	73	18	and	and	CCONJ
dti-3213	73	19	263	263	NUM
dti-3213	73	20	patients	patient	NOUN
dti-3213	73	21	treated	treat	VERB
dti-3213	73	22	with	with	ADP
dti-3213	73	23	aflibercept	aflibercept	NOUN
dti-3213	73	24	(	(	PUNCT
dti-3213	73	25	n	n	NOUN
dti-3213	73	26	=	=	SYM
dti-3213	73	27	101	101	NUM
dti-3213	73	28	)	)	PUNCT
dti-3213	73	29	,	,	PUNCT
dti-3213	73	30	bevacizumab	bevacizumab	X
dti-3213	73	31	(	(	PUNCT
dti-3213	73	32	n	n	NOUN
dti-3213	73	33	=	=	SYM
dti-3213	73	34	53	53	NUM
dti-3213	73	35	)	)	PUNCT
dti-3213	73	36	,	,	PUNCT
dti-3213	73	37	or	or	CCONJ
dti-3213	73	38	ranibizumab	ranibizumab	NOUN
dti-3213	73	39	(	(	PUNCT
dti-3213	73	40	n	n	NOUN
dti-3213	73	41	=	=	SYM
dti-3213	73	42	109	109	NUM
dti-3213	73	43	)	)	PUNCT
dti-3213	73	44	from	from	ADP
dti-3213	73	45	the	the	DET
dti-3213	73	46	radiance	radiance	NOUN
dti-3213	73	47	study	study	NOUN
dti-3213	73	48	were	be	AUX
dti-3213	73	49	included	include	VERB
dti-3213	73	50	for	for	ADP
dti-3213	73	51	comparison	comparison	NOUN
dti-3213	73	52	.	.	PUNCT
dti-3213	74	1	all	all	DET
dti-3213	74	2	patients	patient	NOUN
dti-3213	74	3	from	from	ADP
dti-3213	74	4	both	both	CCONJ
dti-3213	74	5	the	the	DET
dti-3213	74	6	faricimab	faricimab	NOUN
dti-3213	74	7	and	and	CCONJ
dti-3213	74	8	the	the	DET
dti-3213	74	9	radiance	radiance	NOUN
dti-3213	74	10	cohorts	cohort	NOUN
dti-3213	74	11	had	have	VERB
dti-3213	74	12	bcva	bcva	NOUN
dti-3213	74	13	data	datum	NOUN
dti-3213	74	14	at	at	ADP
dti-3213	74	15	1	1	NUM
dti-3213	74	16	year	year	NOUN
dti-3213	74	17	(	(	PUNCT
dti-3213	74	18	i.e.	i.e.	X
dti-3213	74	19	,	,	PUNCT
dti-3213	74	20	week	week	NOUN
dti-3213	74	21	48	48	NUM
dti-3213	74	22	and	and	CCONJ
dti-3213	74	23	52	52	NUM
dti-3213	74	24	,	,	PUNCT
dti-3213	74	25	respectively	respectively	ADV
dti-3213	74	26	)	)	PUNCT
dti-3213	74	27	and	and	CCONJ
dti-3213	74	28	were	be	AUX
dti-3213	74	29	therefore	therefore	ADV
dti-3213	74	30	included	include	VERB
dti-3213	74	31	in	in	ADP
dti-3213	74	32	the	the	DET
dti-3213	74	33	analysis	analysis	NOUN
dti-3213	74	34	of	of	ADP
dti-3213	74	35	bcva	bcva	NOUN
dti-3213	74	36	change	change	NOUN
dti-3213	74	37	from	from	ADP
dti-3213	74	38	baseline	baseline	NOUN
dti-3213	74	39	.	.	PUNCT
dti-3213	75	1	cst	cst	PROPN
dti-3213	75	2	data	data	PROPN
dti-3213	75	3	at	at	ADP
dti-3213	75	4	week	week	NOUN
dti-3213	75	5	48	48	NUM
dti-3213	75	6	-	-	SYM
dti-3213	75	7	52	52	NUM
dti-3213	75	8	were	be	AUX
dti-3213	75	9	missing	miss	VERB
dti-3213	75	10	in	in	ADP
dti-3213	75	11	97	97	NUM
dti-3213	75	12	patients	patient	NOUN
dti-3213	75	13	from	from	ADP
dti-3213	75	14	the	the	DET
dti-3213	75	15	radiance	radiance	NOUN
dti-3213	75	16	cohort	cohort	NOUN
dti-3213	75	17	and	and	CCONJ
dti-3213	75	18	4	4	NUM
dti-3213	75	19	patients	patient	NOUN
dti-3213	75	20	from	from	ADP
dti-3213	75	21	the	the	DET
dti-3213	75	22	faricimab	faricimab	NOUN
dti-3213	75	23	cohort	cohort	NOUN
dti-3213	75	24	;	;	PUNCT
dti-3213	75	25	therefore	therefore	ADV
dti-3213	75	26	,	,	PUNCT
dti-3213	75	27	the	the	DET
dti-3213	75	28	analysis	analysis	NOUN
dti-3213	75	29	of	of	ADP
dti-3213	75	30	cst	cst	PROPN
dti-3213	75	31	changes	change	NOUN
dti-3213	75	32	from	from	ADP
dti-3213	75	33	baseline	baseline	NOUN
dti-3213	75	34	at	at	ADP
dti-3213	75	35	1	1	NUM
dti-3213	75	36	year	year	NOUN
dti-3213	75	37	was	be	AUX
dti-3213	75	38	based	base	VERB
dti-3213	75	39	on	on	ADP
dti-3213	75	40	509	509	NUM
dti-3213	75	41	patients	patient	NOUN
dti-3213	75	42	treated	treat	VERB
dti-3213	75	43	with	with	ADP
dti-3213	75	44	faricimab	faricimab	NOUN
dti-3213	75	45	and	and	CCONJ
dti-3213	75	46	166	166	NUM
dti-3213	75	47	patients	patient	NOUN
dti-3213	75	48	treated	treat	VERB
dti-3213	75	49	with	with	ADP
dti-3213	75	50	the	the	DET
dti-3213	75	51	anti	anti	ADJ
dti-3213	75	52	-	-	ADJ
dti-3213	75	53	vegf	vegf	ADJ
dti-3213	75	54	soc	soc	NOUN
dti-3213	75	55	.	.	PUNCT
dti-3213	76	1	before	before	ADP
dti-3213	76	2	iptw	iptw	NOUN
dti-3213	76	3	,	,	PUNCT
dti-3213	76	4	significant	significant	ADJ
dti-3213	76	5	differences	difference	NOUN
dti-3213	76	6	in	in	ADP
dti-3213	76	7	baseline	baseline	ADJ
dti-3213	76	8	patients	patient	NOUN
dti-3213	76	9	’	'	PUNCT
dti-3213	76	10	characteristics	characteristic	NOUN
dti-3213	76	11	between	between	ADP
dti-3213	76	12	the	the	DET
dti-3213	76	13	two	two	NUM
dti-3213	76	14	groups	group	NOUN
dti-3213	76	15	were	be	AUX
dti-3213	76	16	observed	observe	VERB
dti-3213	76	17	.	.	PUNCT
dti-3213	77	1	specifically	specifically	ADV
dti-3213	77	2	,	,	PUNCT
dti-3213	77	3	in	in	ADP
dti-3213	77	4	the	the	DET
dti-3213	77	5	radiance	radiance	NOUN
dti-3213	77	6	cohort	cohort	NOUN
dti-3213	77	7	,	,	PUNCT
dti-3213	77	8	compared	compare	VERB
dti-3213	77	9	to	to	ADP
dti-3213	77	10	the	the	DET
dti-3213	77	11	faricimab	faricimab	NOUN
dti-3213	77	12	cohort	cohort	NOUN
dti-3213	77	13	,	,	PUNCT
dti-3213	77	14	patients	patient	NOUN
dti-3213	77	15	were	be	AUX
dti-3213	77	16	older	old	ADJ
dti-3213	77	17	,	,	PUNCT
dti-3213	77	18	had	have	VERB
dti-3213	77	19	lower	low	ADJ
dti-3213	77	20	bcva	bcva	NOUN
dti-3213	77	21	and	and	CCONJ
dti-3213	77	22	higher	high	ADJ
dti-3213	77	23	cst	cst	PROPN
dti-3213	77	24	,	,	PUNCT
dti-3213	77	25	and	and	CCONJ
dti-3213	77	26	there	there	PRON
dti-3213	77	27	was	be	VERB
dti-3213	77	28	a	a	DET
dti-3213	77	29	higher	high	ADJ
dti-3213	77	30	proportion	proportion	NOUN
dti-3213	77	31	of	of	ADP
dti-3213	77	32	patients	patient	NOUN
dti-3213	77	33	with	with	ADP
dti-3213	77	34	irf	irf	PROPN
dti-3213	77	35	.	.	PUNCT
dti-3213	78	1	after	after	ADP
dti-3213	78	2	iptw	iptw	NOUN
dti-3213	78	3	,	,	PUNCT
dti-3213	78	4	the	the	DET
dti-3213	78	5	cohorts	cohort	NOUN
dti-3213	78	6	were	be	AUX
dti-3213	78	7	well	well	ADV
dti-3213	78	8	-	-	PUNCT
dti-3213	78	9	balanced	balanced	ADJ
dti-3213	78	10	(	(	PUNCT
dti-3213	78	11	tabs	tab	NOUN
dti-3213	78	12	.	.	PUNCT
dti-3213	78	13	1	1	NUM
dti-3213	78	14	and	and	CCONJ
dti-3213	78	15	2	2	NUM
dti-3213	78	16	)	)	PUNCT
dti-3213	78	17	.	.	PUNCT
dti-3213	79	1	table	table	NOUN
dti-3213	79	2	1	1	NUM
dti-3213	79	3	baseline	baseline	VERB
dti-3213	79	4	demographic	demographic	ADJ
dti-3213	79	5	and	and	CCONJ
dti-3213	79	6	clinical	clinical	ADJ
dti-3213	79	7	characteristics	characteristic	NOUN
dti-3213	79	8	in	in	ADP
dti-3213	79	9	the	the	DET
dti-3213	79	10	faricimab	faricimab	NOUN
dti-3213	79	11	and	and	CCONJ
dti-3213	79	12	radiance	radiance	NOUN
dti-3213	79	13	cohorts	cohort	NOUN
dti-3213	79	14	before	before	ADP
dti-3213	79	15	and	and	CCONJ
dti-3213	79	16	after	after	ADP
dti-3213	79	17	the	the	DET
dti-3213	79	18	iptw	iptw	NOUN
dti-3213	79	19	in	in	ADP
dti-3213	79	20	the	the	DET
dti-3213	79	21	analysis	analysis	NOUN
dti-3213	79	22	of	of	ADP
dti-3213	79	23	the	the	DET
dti-3213	79	24	va	va	PROPN
dti-3213	79	25	change	change	NOUN
dti-3213	79	26	before	before	ADP
dti-3213	79	27	iptw	iptw	NOUN
dti-3213	79	28	after	after	ADP
dti-3213	79	29	iptw	iptw	NOUN
dti-3213	79	30	tenaya+lucerne	tenaya+lucerne	PROPN
dti-3213	79	31	(	(	PUNCT
dti-3213	79	32	faricimab	faricimab	NOUN
dti-3213	79	33	)	)	PUNCT
dti-3213	79	34	radiance	radiance	NOUN
dti-3213	79	35	(	(	PUNCT
dti-3213	79	36	soc	soc	NOUN
dti-3213	79	37	)	)	PUNCT
dti-3213	79	38	smd	smd	NOUN
dti-3213	79	39	p	p	NOUN
dti-3213	79	40	value	value	NOUN
dti-3213	79	41	for	for	ADP
dti-3213	79	42	comparison	comparison	NOUN
dti-3213	79	43	*	*	PUNCT
dti-3213	79	44	tenaya+lucerne	tenaya+lucerne	PROPN
dti-3213	79	45	(	(	PUNCT
dti-3213	79	46	faricimab	faricimab	NOUN
dti-3213	79	47	)	)	PUNCT
dti-3213	79	48	radiance	radiance	NOUN
dti-3213	79	49	(	(	PUNCT
dti-3213	79	50	soc	soc	NOUN
dti-3213	79	51	)	)	PUNCT
dti-3213	79	52	smd	smd	NOUN
dti-3213	79	53	p	p	NOUN
dti-3213	79	54	value	value	NOUN
dti-3213	79	55	for	for	ADP
dti-3213	79	56	comparison	comparison	NOUN
dti-3213	79	57	*	*	PUNCT
dti-3213	79	58	n	n	PROPN
dti-3213	79	59	513	513	NUM
dti-3213	79	60	263	263	NUM
dti-3213	79	61	772.4	772.4	NUM
dti-3213	79	62	297.2	297.2	NUM
dti-3213	79	63	age	age	NOUN
dti-3213	79	64	,	,	PUNCT
dti-3213	79	65	median	median	NOUN
dti-3213	79	66	(	(	PUNCT
dti-3213	79	67	iqr	iqr	NOUN
dti-3213	79	68	)	)	PUNCT
dti-3213	79	69	76	76	NUM
dti-3213	79	70	(	(	PUNCT
dti-3213	79	71	70	70	NUM
dti-3213	79	72	-	-	SYM
dti-3213	79	73	81	81	NUM
dti-3213	79	74	)	)	PUNCT
dti-3213	79	75	78	78	NUM
dti-3213	79	76	(	(	PUNCT
dti-3213	79	77	73	73	NUM
dti-3213	79	78	-	-	SYM
dti-3213	79	79	82	82	NUM
dti-3213	79	80	)	)	PUNCT
dti-3213	79	81	−0.254	−0.254	PROPN
dti-3213	79	82	0.0007	0.0007	NUM
dti-3213	79	83	77	77	NUM
dti-3213	79	84	(	(	PUNCT
dti-3213	79	85	71	71	NUM
dti-3213	79	86	-	-	SYM
dti-3213	79	87	82	82	NUM
dti-3213	79	88	)	)	PUNCT
dti-3213	79	89	76	76	NUM
dti-3213	79	90	(	(	PUNCT
dti-3213	79	91	71	71	NUM
dti-3213	79	92	-	-	SYM
dti-3213	79	93	81	81	NUM
dti-3213	79	94	)	)	PUNCT
dti-3213	79	95	0.040	0.040	NUM
dti-3213	79	96	0.601	0.601	NUM
dti-3213	79	97	sex	sex	NOUN
dti-3213	79	98	,	,	PUNCT
dti-3213	79	99	n	n	CCONJ
dti-3213	79	100	(	(	PUNCT
dti-3213	79	101	%	%	INTJ
dti-3213	79	102	)	)	PUNCT
dti-3213	79	103	 	 	SPACE
dti-3213	79	104	men	man	NOUN
dti-3213	79	105	187	187	NUM
dti-3213	79	106	(	(	PUNCT
dti-3213	79	107	36.5	36.5	NUM
dti-3213	79	108	)	)	PUNCT
dti-3213	79	109	115	115	NUM
dti-3213	79	110	(	(	PUNCT
dti-3213	79	111	43.7	43.7	NUM
dti-3213	79	112	)	)	PUNCT
dti-3213	79	113	−0.149	−0.149	VERB
dti-3213	79	114	0.049	0.049	NUM
dti-3213	79	115	315.2	315.2	NUM
dti-3213	79	116	(	(	PUNCT
dti-3213	79	117	40.8	40.8	NUM
dti-3213	79	118	)	)	PUNCT
dti-3213	79	119	319.7	319.7	NUM
dti-3213	79	120	(	(	PUNCT
dti-3213	79	121	40.1	40.1	NUM
dti-3213	79	122	)	)	PUNCT
dti-3213	79	123	0.014	0.014	NUM
dti-3213	79	124	0.778	0.778	NUM
dti-3213	79	125	 	 	SPACE
dti-3213	79	126	women	woman	NOUN
dti-3213	79	127	326	326	NUM
dti-3213	79	128	(	(	PUNCT
dti-3213	79	129	63.6	63.6	NUM
dti-3213	79	130	)	)	SYM
dti-3213	79	131	148	148	NUM
dti-3213	79	132	(	(	PUNCT
dti-3213	79	133	56.3	56.3	NUM
dti-3213	79	134	)	)	PUNCT
dti-3213	79	135	457.2	457.2	NUM
dti-3213	79	136	(	(	PUNCT
dti-3213	79	137	59.2	59.2	NUM
dti-3213	79	138	)	)	PUNCT
dti-3213	79	139	477.6	477.6	NUM
dti-3213	79	140	(	(	PUNCT
dti-3213	79	141	59.9	59.9	NUM
dti-3213	79	142	)	)	PUNCT
dti-3213	79	143	(	(	PUNCT
dti-3213	79	144	continued	continue	VERB
dti-3213	79	145	)	)	PUNCT
dti-3213	79	146	itc	itc	NOUN
dti-3213	79	147	of	of	ADP
dti-3213	79	148	faricimab	faricimab	NOUN
dti-3213	79	149	vs.	vs.	X
dti-3213	79	150	soc	soc	NOUN
dti-3213	79	151	for	for	ADP
dti-3213	79	152	namd	namd	ADJ
dti-3213	79	153	patients	patient	NOUN
dti-3213	79	154	in	in	ADP
dti-3213	79	155	italy108	italy108	PROPN
dti-3213	79	156	©	©	PROPN
dti-3213	79	157	2024	2024	NUM
dti-3213	79	158	the	the	DET
dti-3213	79	159	authors	author	NOUN
dti-3213	79	160	.	.	PUNCT
dti-3213	80	1	drug	drug	NOUN
dti-3213	80	2	target	target	NOUN
dti-3213	80	3	insights	insight	NOUN
dti-3213	80	4	issn	issn	VERB
dti-3213	80	5	1177	1177	NUM
dti-3213	80	6	-	-	SYM
dti-3213	80	7	3928	3928	NUM
dti-3213	80	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-3213	80	9	before	before	ADP
dti-3213	80	10	iptw	iptw	NOUN
dti-3213	80	11	after	after	ADP
dti-3213	80	12	iptw	iptw	NOUN
dti-3213	80	13	tenaya+lucerne	tenaya+lucerne	PROPN
dti-3213	80	14	(	(	PUNCT
dti-3213	80	15	faricimab	faricimab	NOUN
dti-3213	80	16	)	)	PUNCT
dti-3213	80	17	radiance	radiance	NOUN
dti-3213	80	18	(	(	PUNCT
dti-3213	80	19	soc	soc	NOUN
dti-3213	80	20	)	)	PUNCT
dti-3213	80	21	smd	smd	NOUN
dti-3213	80	22	p	p	NOUN
dti-3213	80	23	value	value	NOUN
dti-3213	80	24	for	for	ADP
dti-3213	80	25	comparison	comparison	NOUN
dti-3213	80	26	*	*	PUNCT
dti-3213	80	27	tenaya+lucerne	tenaya+lucerne	PROPN
dti-3213	80	28	(	(	PUNCT
dti-3213	80	29	faricimab	faricimab	NOUN
dti-3213	80	30	)	)	PUNCT
dti-3213	80	31	radiance	radiance	NOUN
dti-3213	80	32	(	(	PUNCT
dti-3213	80	33	soc	soc	NOUN
dti-3213	80	34	)	)	PUNCT
dti-3213	80	35	smd	smd	NOUN
dti-3213	80	36	p	p	NOUN
dti-3213	80	37	value	value	NOUN
dti-3213	80	38	for	for	ADP
dti-3213	80	39	comparison	comparison	NOUN
dti-3213	80	40	*	*	PUNCT
dti-3213	80	41	lesion	lesion	NOUN
dti-3213	80	42	type	type	NOUN
dti-3213	80	43	,	,	PUNCT
dti-3213	80	44	n	n	CCONJ
dti-3213	80	45	(	(	PUNCT
dti-3213	80	46	%	%	INTJ
dti-3213	80	47	)	)	PUNCT
dti-3213	80	48	 	 	SPACE
dti-3213	80	49	occult	occult	NOUN
dti-3213	80	50	(	(	PUNCT
dti-3213	80	51	type	type	NOUN
dti-3213	80	52	1	1	NUM
dti-3213	80	53	)	)	PUNCT
dti-3213	80	54	275	275	NUM
dti-3213	80	55	(	(	PUNCT
dti-3213	80	56	54.6	54.6	NUM
dti-3213	80	57	)	)	PUNCT
dti-3213	80	58	103	103	NUM
dti-3213	80	59	(	(	PUNCT
dti-3213	80	60	40.9	40.9	NUM
dti-3213	80	61	)	)	PUNCT
dti-3213	80	62	0.292	0.292	NUM
dti-3213	80	63	<	<	NOUN
dti-3213	80	64	0.001	0.001	NUM
dti-3213	80	65	395.7	395.7	NUM
dti-3213	80	66	(	(	PUNCT
dti-3213	80	67	52.3	52.3	NUM
dti-3213	80	68	)	)	PUNCT
dti-3213	80	69	406.4	406.4	NUM
dti-3213	80	70	(	(	PUNCT
dti-3213	80	71	52.1	52.1	NUM
dti-3213	80	72	)	)	PUNCT
dti-3213	81	1	0.005	0.005	NUM
dti-3213	81	2	0.951	0.951	NUM
dti-3213	81	3	 	 	SPACE
dti-3213	81	4	classic	classic	ADJ
dti-3213	81	5	(	(	PUNCT
dti-3213	81	6	type	type	NOUN
dti-3213	81	7	2)†	2)†	NUM
dti-3213	81	8	210	210	NUM
dti-3213	81	9	(	(	PUNCT
dti-3213	81	10	41.7	41.7	NUM
dti-3213	81	11	)	)	SYM
dti-3213	81	12	121	121	NUM
dti-3213	81	13	(	(	PUNCT
dti-3213	81	14	48.0	48.0	NUM
dti-3213	81	15	)	)	PUNCT
dti-3213	81	16	−0.102	−0.102	NOUN
dti-3213	81	17	316.6	316.6	NUM
dti-3213	81	18	(	(	PUNCT
dti-3213	81	19	41.8	41.8	NUM
dti-3213	81	20	)	)	PUNCT
dti-3213	81	21	323.6	323.6	NUM
dti-3213	81	22	(	(	PUNCT
dti-3213	81	23	41.5	41.5	NUM
dti-3213	81	24	)	)	PUNCT
dti-3213	81	25	0.008	0.008	NUM
dti-3213	81	26	 	 	SPACE
dti-3213	81	27	type	type	NOUN
dti-3213	81	28	3	3	NUM
dti-3213	81	29	19	19	NUM
dti-3213	81	30	(	(	PUNCT
dti-3213	81	31	3.8	3.8	NUM
dti-3213	81	32	)	)	PUNCT
dti-3213	81	33	28	28	NUM
dti-3213	81	34	(	(	PUNCT
dti-3213	81	35	11.1	11.1	NUM
dti-3213	81	36	)	)	PUNCT
dti-3213	81	37	−0.271	−0.271	NOUN
dti-3213	81	38	45.1	45.1	NUM
dti-3213	81	39	(	(	PUNCT
dti-3213	81	40	6.0	6.0	NUM
dti-3213	81	41	)	)	PUNCT
dti-3213	81	42	49.4	49.4	NUM
dti-3213	81	43	(	(	PUNCT
dti-3213	81	44	6.3	6.3	NUM
dti-3213	81	45	)	)	PUNCT
dti-3213	81	46	−0.014	−0.014	PROPN
dti-3213	81	47	 	 	SPACE
dti-3213	81	48	missing	miss	VERB
dti-3213	81	49	9	9	NUM
dti-3213	81	50	11	11	NUM
dti-3213	81	51	14.9	14.9	NUM
dti-3213	81	52	17.8	17.8	NUM
dti-3213	81	53	irf	irf	NOUN
dti-3213	81	54	at	at	ADP
dti-3213	81	55	baseline	baseline	NOUN
dti-3213	81	56	,	,	PUNCT
dti-3213	81	57	n	n	CCONJ
dti-3213	81	58	(	(	PUNCT
dti-3213	81	59	%	%	INTJ
dti-3213	81	60	)	)	PUNCT
dti-3213	81	61	 	 	SPACE
dti-3213	81	62	no	no	DET
dti-3213	81	63	276	276	NUM
dti-3213	81	64	(	(	PUNCT
dti-3213	81	65	54.9	54.9	NUM
dti-3213	81	66	)	)	PUNCT
dti-3213	81	67	84	84	NUM
dti-3213	81	68	(	(	PUNCT
dti-3213	81	69	42.6	42.6	NUM
dti-3213	81	70	)	)	PUNCT
dti-3213	81	71	0.026	0.026	NUM
dti-3213	81	72	0.004	0.004	NUM
dti-3213	81	73	359.2	359.2	NUM
dti-3213	81	74	(	(	PUNCT
dti-3213	81	75	51.5	51.5	NUM
dti-3213	81	76	)	)	PUNCT
dti-3213	81	77	371.8	371.8	NUM
dti-3213	81	78	(	(	PUNCT
dti-3213	81	79	51.5	51.5	NUM
dti-3213	81	80	)	)	PUNCT
dti-3213	81	81	−0.003	−0.003	NOUN
dti-3213	81	82	0.998	0.998	NUM
dti-3213	81	83	 	 	SPACE
dti-3213	82	1	yes	yes	INTJ
dti-3213	82	2	227	227	NUM
dti-3213	82	3	(	(	PUNCT
dti-3213	82	4	45.1	45.1	NUM
dti-3213	82	5	)	)	SYM
dti-3213	82	6	113	113	NUM
dti-3213	82	7	(	(	PUNCT
dti-3213	82	8	57.4	57.4	NUM
dti-3213	82	9	)	)	PUNCT
dti-3213	82	10	337.9	337.9	NUM
dti-3213	82	11	(	(	PUNCT
dti-3213	82	12	48.5	48.5	NUM
dti-3213	82	13	)	)	PUNCT
dti-3213	82	14	349.9	349.9	NUM
dti-3213	82	15	(	(	PUNCT
dti-3213	82	16	48.5	48.5	NUM
dti-3213	82	17	)	)	PUNCT
dti-3213	82	18	 	 	SPACE
dti-3213	83	1	missing	miss	VERB
dti-3213	83	2	10	10	NUM
dti-3213	83	3	66	66	NUM
dti-3213	83	4	75.3	75.3	NUM
dti-3213	83	5	75.4	75.4	NUM
dti-3213	83	6	srf	srf	NOUN
dti-3213	83	7	at	at	ADP
dti-3213	83	8	baseline	baseline	NOUN
dti-3213	83	9	,	,	PUNCT
dti-3213	83	10	n	n	PROPN
dti-3213	83	11	(	(	PUNCT
dti-3213	83	12	%	%	INTJ
dti-3213	83	13	)	)	PUNCT
dti-3213	83	14	 	 	SPACE
dti-3213	83	15	no	no	DET
dti-3213	83	16	172	172	NUM
dti-3213	83	17	(	(	PUNCT
dti-3213	83	18	34.0	34.0	NUM
dti-3213	83	19	)	)	PUNCT
dti-3213	83	20	58	58	NUM
dti-3213	83	21	(	(	PUNCT
dti-3213	83	22	29.2	29.2	NUM
dti-3213	83	23	)	)	PUNCT
dti-3213	83	24	0.236	0.236	NUM
dti-3213	83	25	0.217	0.217	NUM
dti-3213	83	26	233.4	233.4	NUM
dti-3213	83	27	(	(	PUNCT
dti-3213	83	28	33.3	33.3	NUM
dti-3213	83	29	)	)	PUNCT
dti-3213	83	30	264.5	264.5	NUM
dti-3213	83	31	(	(	PUNCT
dti-3213	83	32	36.4	36.4	NUM
dti-3213	83	33	)	)	PUNCT
dti-3213	83	34	0.055	0.055	NUM
dti-3213	83	35	0.211	0.211	NUM
dti-3213	83	36	 	 	SPACE
dti-3213	84	1	yes	yes	INTJ
dti-3213	84	2	334	334	NUM
dti-3213	84	3	(	(	PUNCT
dti-3213	84	4	66.0	66.0	NUM
dti-3213	84	5	)	)	SYM
dti-3213	84	6	141	141	NUM
dti-3213	84	7	(	(	PUNCT
dti-3213	84	8	70.8	70.8	NUM
dti-3213	84	9	)	)	PUNCT
dti-3213	84	10	468.2	468.2	NUM
dti-3213	84	11	(	(	PUNCT
dti-3213	84	12	66.7	66.7	NUM
dti-3213	84	13	)	)	PUNCT
dti-3213	84	14	461.7	461.7	NUM
dti-3213	84	15	(	(	PUNCT
dti-3213	84	16	63.6	63.6	NUM
dti-3213	84	17	)	)	PUNCT
dti-3213	84	18	 	 	SPACE
dti-3213	84	19	missing	miss	VERB
dti-3213	84	20	7	7	NUM
dti-3213	84	21	64	64	NUM
dti-3213	84	22	70.8	70.8	NUM
dti-3213	84	23	71.0	71.0	NUM
dti-3213	84	24	va	va	NOUN
dti-3213	84	25	(	(	PUNCT
dti-3213	84	26	etdrs	etdr	NOUN
dti-3213	84	27	letter	letter	NOUN
dti-3213	84	28	)	)	PUNCT
dti-3213	84	29	at	at	ADP
dti-3213	84	30	baseline	baseline	NOUN
dti-3213	84	31	,	,	PUNCT
dti-3213	84	32	mean	mean	VERB
dti-3213	84	33	±	±	NUM
dti-3213	84	34	sd	sd	ADP
dti-3213	84	35	60.5	60.5	NUM
dti-3213	84	36	±	±	NUM
dti-3213	84	37	13.1	13.1	NUM
dti-3213	84	38	57.1	57.1	NUM
dti-3213	84	39	±	±	NUM
dti-3213	84	40	21.1	21.1	NUM
dti-3213	84	41	0.219	0.219	NUM
dti-3213	84	42	0.004	0.004	NUM
dti-3213	84	43	59.6	59.6	NUM
dti-3213	84	44	±	±	NUM
dti-3213	84	45	16.5	16.5	NUM
dti-3213	84	46	61.1	61.1	NUM
dti-3213	84	47	±	±	NUM
dti-3213	84	48	34.3	34.3	NUM
dti-3213	84	49	−0.088	−0.088	NOUN
dti-3213	84	50	0.244	0.244	NOUN
dti-3213	84	51	*	*	PUNCT
dti-3213	84	52	p	p	NOUN
dti-3213	84	53	values	value	NOUN
dti-3213	84	54	were	be	AUX
dti-3213	84	55	nominal	nominal	ADJ
dti-3213	84	56	.	.	PUNCT
dti-3213	85	1	†including	†include	VERB
dti-3213	85	2	“	"	PUNCT
dti-3213	85	3	minimally	minimally	ADV
dti-3213	85	4	”	"	PUNCT
dti-3213	85	5	and	and	CCONJ
dti-3213	85	6	“	"	PUNCT
dti-3213	85	7	predominantly	predominantly	ADV
dti-3213	85	8	”	"	PUNCT
dti-3213	85	9	classic	classic	ADJ
dti-3213	85	10	lesions	lesion	NOUN
dti-3213	85	11	.	.	PUNCT
dti-3213	86	1	iptw	iptw	NOUN
dti-3213	86	2	=	=	PUNCT
dti-3213	86	3	inverse	inverse	NOUN
dti-3213	86	4	probability	probability	NOUN
dti-3213	86	5	of	of	ADP
dti-3213	86	6	treatment	treatment	NOUN
dti-3213	86	7	weighting	weighting	NOUN
dti-3213	86	8	;	;	PUNCT
dti-3213	86	9	iqr	iqr	PROPN
dti-3213	86	10	=	=	NOUN
dti-3213	86	11	interquartile	interquartile	NOUN
dti-3213	86	12	range	range	NOUN
dti-3213	86	13	;	;	PUNCT
dti-3213	86	14	irf	irf	PROPN
dti-3213	86	15	=	=	PROPN
dti-3213	86	16	intraretinal	intraretinal	ADJ
dti-3213	86	17	fluid	fluid	NOUN
dti-3213	86	18	;	;	PUNCT
dti-3213	86	19	sd	sd	NOUN
dti-3213	86	20	=	=	SYM
dti-3213	86	21	standard	standard	ADJ
dti-3213	86	22	deviation	deviation	NOUN
dti-3213	86	23	;	;	PUNCT
dti-3213	86	24	smd	smd	NOUN
dti-3213	86	25	=	=	SYM
dti-3213	86	26	standardized	standardized	ADJ
dti-3213	86	27	mean	mean	NOUN
dti-3213	86	28	difference	difference	NOUN
dti-3213	86	29	;	;	PUNCT
dti-3213	86	30	soc	soc	NOUN
dti-3213	86	31	=	=	SYM
dti-3213	86	32	standard	standard	NOUN
dti-3213	86	33	of	of	ADP
dti-3213	86	34	care	care	NOUN
dti-3213	86	35	(	(	PUNCT
dti-3213	86	36	aflibercept	aflibercept	ADJ
dti-3213	86	37	,	,	PUNCT
dti-3213	86	38	ranibizumab	ranibizumab	NOUN
dti-3213	86	39	,	,	PUNCT
dti-3213	86	40	and	and	CCONJ
dti-3213	86	41	bevacizumab	bevacizumab	PROPN
dti-3213	86	42	)	)	PUNCT
dti-3213	86	43	;	;	PUNCT
dti-3213	86	44	srf	srf	ADJ
dti-3213	86	45	=	=	ADJ
dti-3213	86	46	subretinal	subretinal	ADJ
dti-3213	86	47	fluid	fluid	NOUN
dti-3213	86	48	;	;	PUNCT
dti-3213	86	49	va	va	X
dti-3213	86	50	=	=	PROPN
dti-3213	86	51	visual	visual	ADJ
dti-3213	86	52	acuity	acuity	NOUN
dti-3213	86	53	.	.	PUNCT
dti-3213	87	1	table	table	NOUN
dti-3213	87	2	2	2	NUM
dti-3213	87	3	baseline	baseline	NOUN
dti-3213	87	4	demographic	demographic	ADJ
dti-3213	87	5	and	and	CCONJ
dti-3213	87	6	clinical	clinical	ADJ
dti-3213	87	7	characteristics	characteristic	NOUN
dti-3213	87	8	in	in	ADP
dti-3213	87	9	the	the	DET
dti-3213	87	10	faricimab	faricimab	NOUN
dti-3213	87	11	and	and	CCONJ
dti-3213	87	12	radiance	radiance	NOUN
dti-3213	87	13	cohorts	cohort	NOUN
dti-3213	87	14	before	before	ADP
dti-3213	87	15	and	and	CCONJ
dti-3213	87	16	after	after	ADP
dti-3213	87	17	the	the	DET
dti-3213	87	18	iptw	iptw	NOUN
dti-3213	87	19	in	in	ADP
dti-3213	87	20	the	the	DET
dti-3213	87	21	analysis	analysis	NOUN
dti-3213	87	22	of	of	ADP
dti-3213	87	23	the	the	DET
dti-3213	87	24	cst	cst	PROPN
dti-3213	87	25	change	change	NOUN
dti-3213	87	26	before	before	ADP
dti-3213	87	27	iptw	iptw	NOUN
dti-3213	87	28	after	after	ADP
dti-3213	87	29	iptw	iptw	NOUN
dti-3213	87	30	tenaya+lucerne	tenaya+lucerne	PROPN
dti-3213	87	31	(	(	PUNCT
dti-3213	87	32	faricimab	faricimab	NOUN
dti-3213	87	33	)	)	PUNCT
dti-3213	87	34	radiance	radiance	NOUN
dti-3213	87	35	(	(	PUNCT
dti-3213	87	36	soc	soc	NOUN
dti-3213	87	37	)	)	PUNCT
dti-3213	87	38	smd	smd	NOUN
dti-3213	87	39	p	p	NOUN
dti-3213	87	40	value	value	NOUN
dti-3213	87	41	for	for	ADP
dti-3213	87	42	comparison	comparison	NOUN
dti-3213	87	43	*	*	PUNCT
dti-3213	87	44	tenaya+lucerne	tenaya+lucerne	PROPN
dti-3213	87	45	(	(	PUNCT
dti-3213	87	46	faricimab	faricimab	NOUN
dti-3213	87	47	)	)	PUNCT
dti-3213	87	48	radiance	radiance	NOUN
dti-3213	87	49	(	(	PUNCT
dti-3213	87	50	soc	soc	NOUN
dti-3213	87	51	)	)	PUNCT
dti-3213	87	52	smd	smd	NOUN
dti-3213	87	53	p	p	NOUN
dti-3213	87	54	value	value	NOUN
dti-3213	87	55	for	for	ADP
dti-3213	87	56	comparison	comparison	NOUN
dti-3213	87	57	*	*	PUNCT
dti-3213	87	58	n	n	PROPN
dti-3213	87	59	509	509	NUM
dti-3213	87	60	166	166	NUM
dti-3213	87	61	673.3	673.3	NUM
dti-3213	87	62	683.3	683.3	NUM
dti-3213	87	63	age	age	NOUN
dti-3213	87	64	,	,	PUNCT
dti-3213	87	65	median	median	NOUN
dti-3213	87	66	(	(	PUNCT
dti-3213	87	67	iqr	iqr	NOUN
dti-3213	87	68	)	)	PUNCT
dti-3213	87	69	76	76	NUM
dti-3213	88	1	(	(	PUNCT
dti-3213	88	2	70	70	NUM
dti-3213	88	3	-	-	SYM
dti-3213	88	4	81	81	NUM
dti-3213	88	5	)	)	PUNCT
dti-3213	88	6	77	77	NUM
dti-3213	88	7	(	(	PUNCT
dti-3213	88	8	72	72	NUM
dti-3213	88	9	-	-	SYM
dti-3213	88	10	82	82	NUM
dti-3213	88	11	)	)	PUNCT
dti-3213	88	12	−0.155	−0.155	PROPN
dti-3213	88	13	0.077	0.077	NUM
dti-3213	88	14	76	76	NUM
dti-3213	88	15	(	(	PUNCT
dti-3213	88	16	70	70	NUM
dti-3213	88	17	-	-	SYM
dti-3213	88	18	81	81	NUM
dti-3213	88	19	)	)	PUNCT
dti-3213	88	20	76	76	NUM
dti-3213	88	21	(	(	PUNCT
dti-3213	88	22	70	70	NUM
dti-3213	88	23	-	-	SYM
dti-3213	88	24	80	80	NUM
dti-3213	88	25	)	)	PUNCT
dti-3213	88	26	0.030	0.030	NUM
dti-3213	88	27	0.739	0.739	NUM
dti-3213	88	28	sex	sex	NOUN
dti-3213	88	29	,	,	PUNCT
dti-3213	88	30	n	n	CCONJ
dti-3213	88	31	(	(	PUNCT
dti-3213	88	32	%	%	INTJ
dti-3213	88	33	)	)	PUNCT
dti-3213	88	34	 	 	SPACE
dti-3213	88	35	men	man	NOUN
dti-3213	88	36	184	184	NUM
dti-3213	88	37	(	(	PUNCT
dti-3213	88	38	36.2	36.2	NUM
dti-3213	88	39	)	)	SYM
dti-3213	88	40	80	80	NUM
dti-3213	88	41	(	(	PUNCT
dti-3213	88	42	48.2	48.2	NUM
dti-3213	88	43	)	)	PUNCT
dti-3213	88	44	−0.246	−0.246	PROPN
dti-3213	88	45	0.006	0.006	NUM
dti-3213	88	46	365.4	365.4	NUM
dti-3213	88	47	(	(	PUNCT
dti-3213	88	48	39.4	39.4	NUM
dti-3213	88	49	)	)	PUNCT
dti-3213	88	50	275.7	275.7	NUM
dti-3213	88	51	(	(	PUNCT
dti-3213	88	52	40.4	40.4	NUM
dti-3213	88	53	)	)	PUNCT
dti-3213	89	1	−0.019	−0.019	VERB
dti-3213	89	2	0.727	0.727	NUM
dti-3213	89	3	 	 	SPACE
dti-3213	89	4	women	woman	NOUN
dti-3213	89	5	325	325	NUM
dti-3213	89	6	(	(	PUNCT
dti-3213	89	7	63.8	63.8	NUM
dti-3213	89	8	)	)	PUNCT
dti-3213	89	9	86	86	NUM
dti-3213	89	10	(	(	PUNCT
dti-3213	89	11	51.8	51.8	NUM
dti-3213	89	12	)	)	PUNCT
dti-3213	89	13	407.8	407.8	NUM
dti-3213	89	14	(	(	PUNCT
dti-3213	89	15	60.6	60.6	NUM
dti-3213	89	16	)	)	PUNCT
dti-3213	89	17	407.6	407.6	NUM
dti-3213	89	18	(	(	PUNCT
dti-3213	89	19	59.7	59.7	NUM
dti-3213	89	20	)	)	PUNCT
dti-3213	89	21	lesion	lesion	NOUN
dti-3213	89	22	type	type	NOUN
dti-3213	89	23	,	,	PUNCT
dti-3213	89	24	n	n	CCONJ
dti-3213	89	25	(	(	PUNCT
dti-3213	89	26	%	%	INTJ
dti-3213	89	27	)	)	PUNCT
dti-3213	89	28	 	 	SPACE
dti-3213	89	29	occult	occult	NOUN
dti-3213	89	30	(	(	PUNCT
dti-3213	89	31	type	type	NOUN
dti-3213	89	32	1	1	NUM
dti-3213	89	33	)	)	PUNCT
dti-3213	89	34	274	274	NUM
dti-3213	89	35	(	(	PUNCT
dti-3213	89	36	54.8	54.8	NUM
dti-3213	89	37	)	)	PUNCT
dti-3213	89	38	76	76	NUM
dti-3213	89	39	(	(	PUNCT
dti-3213	89	40	47.2	47.2	NUM
dti-3213	89	41	)	)	PUNCT
dti-3213	89	42	0.161	0.161	NUM
dti-3213	89	43	<	<	X
dti-3213	89	44	0.001	0.001	NUM
dti-3213	89	45	350.5	350.5	NUM
dti-3213	89	46	(	(	PUNCT
dti-3213	89	47	53.1	53.1	NUM
dti-3213	89	48	)	)	PUNCT
dti-3213	89	49	363.1	363.1	NUM
dti-3213	89	50	(	(	PUNCT
dti-3213	89	51	54.2	54.2	NUM
dti-3213	89	52	)	)	PUNCT
dti-3213	89	53	−0.022	−0.022	NOUN
dti-3213	89	54	0.916	0.916	NUM
dti-3213	89	55	 	 	SPACE
dti-3213	89	56	classic	classic	ADJ
dti-3213	89	57	(	(	PUNCT
dti-3213	89	58	type	type	NOUN
dti-3213	89	59	2)†	2)†	NUM
dti-3213	89	60	207	207	NUM
dti-3213	89	61	(	(	PUNCT
dti-3213	89	62	41.4	41.4	NUM
dti-3213	89	63	)	)	PUNCT
dti-3213	89	64	63	63	NUM
dti-3213	89	65	(	(	PUNCT
dti-3213	89	66	39.1	39.1	NUM
dti-3213	89	67	)	)	PUNCT
dti-3213	89	68	0.056	0.056	NUM
dti-3213	89	69	268.4	268.4	NUM
dti-3213	89	70	(	(	PUNCT
dti-3213	89	71	40.7	40.7	NUM
dti-3213	89	72	)	)	PUNCT
dti-3213	89	73	265.4	265.4	NUM
dti-3213	89	74	(	(	PUNCT
dti-3213	89	75	39.6	39.6	NUM
dti-3213	89	76	)	)	PUNCT
dti-3213	89	77	0.022	0.022	NUM
dti-3213	89	78	 	 	SPACE
dti-3213	89	79	type	type	NOUN
dti-3213	89	80	3	3	NUM
dti-3213	89	81	19	19	NUM
dti-3213	89	82	(	(	PUNCT
dti-3213	89	83	3.8	3.8	NUM
dti-3213	89	84	)	)	PUNCT
dti-3213	89	85	22	22	NUM
dti-3213	89	86	(	(	PUNCT
dti-3213	89	87	13.7	13.7	NUM
dti-3213	89	88	)	)	PUNCT
dti-3213	89	89	−0.346	−0.346	VERB
dti-3213	89	90	40.8	40.8	NUM
dti-3213	89	91	(	(	PUNCT
dti-3213	89	92	6.2	6.2	NUM
dti-3213	89	93	)	)	PUNCT
dti-3213	89	94	41.9	41.9	NUM
dti-3213	89	95	(	(	PUNCT
dti-3213	89	96	6.5	6.5	NUM
dti-3213	89	97	)	)	PUNCT
dti-3213	89	98	−0.002	−0.002	NOUN
dti-3213	89	99	 	 	SPACE
dti-3213	89	100	missing	miss	VERB
dti-3213	89	101	9	9	NUM
dti-3213	89	102	5	5	NUM
dti-3213	89	103	13.3	13.3	NUM
dti-3213	89	104	12.8	12.8	NUM
dti-3213	89	105	irf	irf	NOUN
dti-3213	89	106	at	at	ADP
dti-3213	89	107	baseline	baseline	NOUN
dti-3213	89	108	,	,	PUNCT
dti-3213	89	109	n	n	CCONJ
dti-3213	89	110	(	(	PUNCT
dti-3213	89	111	%	%	INTJ
dti-3213	89	112	)	)	PUNCT
dti-3213	89	113	 	 	SPACE
dti-3213	89	114	no	no	DET
dti-3213	89	115	276	276	NUM
dti-3213	89	116	(	(	PUNCT
dti-3213	89	117	55.2	55.2	NUM
dti-3213	89	118	)	)	PUNCT
dti-3213	89	119	68	68	NUM
dti-3213	89	120	(	(	PUNCT
dti-3213	89	121	43.9	43.9	NUM
dti-3213	89	122	)	)	PUNCT
dti-3213	90	1	−0.168	−0.168	VERB
dti-3213	90	2	0.004	0.004	NUM
dti-3213	90	3	343.4	343.4	NUM
dti-3213	90	4	(	(	PUNCT
dti-3213	90	5	52.4	52.4	NUM
dti-3213	90	6	)	)	PUNCT
dti-3213	90	7	342.6	342.6	NUM
dti-3213	90	8	(	(	PUNCT
dti-3213	90	9	51.6	51.6	NUM
dti-3213	90	10	)	)	PUNCT
dti-3213	90	11	−0.016	−0.016	NOUN
dti-3213	90	12	0.755	0.755	NUM
dti-3213	90	13	 	 	SPACE
dti-3213	90	14	yes	yes	INTJ
dti-3213	90	15	224	224	NUM
dti-3213	90	16	(	(	PUNCT
dti-3213	90	17	44.8	44.8	NUM
dti-3213	90	18	)	)	PUNCT
dti-3213	90	19	87	87	NUM
dti-3213	90	20	(	(	PUNCT
dti-3213	90	21	56.1	56.1	NUM
dti-3213	90	22	)	)	PUNCT
dti-3213	90	23	311.8	311.8	NUM
dti-3213	90	24	(	(	PUNCT
dti-3213	90	25	47.6	47.6	NUM
dti-3213	90	26	)	)	PUNCT
dti-3213	90	27	321.8	321.8	NUM
dti-3213	90	28	(	(	PUNCT
dti-3213	90	29	48.4	48.4	NUM
dti-3213	90	30	)	)	PUNCT
dti-3213	90	31	 	 	SPACE
dti-3213	90	32	missing	miss	VERB
dti-3213	90	33	9	9	NUM
dti-3213	90	34	11	11	NUM
dti-3213	90	35	18.0	18.0	NUM
dti-3213	90	36	18.8	18.8	NUM
dti-3213	90	37	srf	srf	NOUN
dti-3213	90	38	at	at	ADP
dti-3213	90	39	baseline	baseline	NOUN
dti-3213	90	40	,	,	PUNCT
dti-3213	90	41	n	n	PROPN
dti-3213	90	42	(	(	PUNCT
dti-3213	90	43	%	%	INTJ
dti-3213	90	44	)	)	PUNCT
dti-3213	90	45	 	 	SPACE
dti-3213	90	46	no	no	DET
dti-3213	90	47	170	170	NUM
dti-3213	90	48	(	(	PUNCT
dti-3213	90	49	33.9	33.9	NUM
dti-3213	90	50	)	)	PUNCT
dti-3213	90	51	46	46	NUM
dti-3213	90	52	(	(	PUNCT
dti-3213	90	53	29.5	29.5	NUM
dti-3213	90	54	)	)	PUNCT
dti-3213	91	1	−0.022	−0.022	PROPN
dti-3213	91	2	0.309	0.309	NUM
dti-3213	91	3	219.3	219.3	NUM
dti-3213	91	4	(	(	PUNCT
dti-3213	91	5	33.3	33.3	NUM
dti-3213	91	6	)	)	PUNCT
dti-3213	91	7	242.6	242.6	NUM
dti-3213	91	8	(	(	PUNCT
dti-3213	91	9	36.4	36.4	NUM
dti-3213	91	10	)	)	PUNCT
dti-3213	92	1	0.065	0.065	NUM
dti-3213	92	2	0.244	0.244	NUM
dti-3213	92	3	 	 	SPACE
dti-3213	93	1	yes	yes	INTJ
dti-3213	93	2	332	332	NUM
dti-3213	93	3	(	(	PUNCT
dti-3213	93	4	66.1	66.1	NUM
dti-3213	93	5	)	)	PUNCT
dti-3213	93	6	110	110	NUM
dti-3213	93	7	(	(	PUNCT
dti-3213	93	8	70.5	70.5	NUM
dti-3213	93	9	)	)	PUNCT
dti-3213	93	10	438.8	438.8	NUM
dti-3213	93	11	(	(	PUNCT
dti-3213	93	12	66.7	66.7	NUM
dti-3213	93	13	)	)	PUNCT
dti-3213	93	14	424.4	424.4	NUM
dti-3213	93	15	(	(	PUNCT
dti-3213	93	16	63.6	63.6	NUM
dti-3213	93	17	)	)	PUNCT
dti-3213	93	18	 	 	SPACE
dti-3213	93	19	missing	miss	VERB
dti-3213	93	20	7	7	NUM
dti-3213	93	21	10	10	NUM
dti-3213	93	22	15.1	15.1	NUM
dti-3213	93	23	16.2	16.2	NUM
dti-3213	93	24	cst	cst	PROPN
dti-3213	93	25	(	(	PUNCT
dti-3213	93	26	μm	μm	NOUN
dti-3213	93	27	)	)	PUNCT
dti-3213	93	28	at	at	ADP
dti-3213	93	29	baseline	baseline	NOUN
dti-3213	93	30	,	,	PUNCT
dti-3213	93	31	mean	mean	VERB
dti-3213	93	32	±	±	NUM
dti-3213	93	33	sd	sd	ADP
dti-3213	93	34	359.8	359.8	NUM
dti-3213	93	35	±	±	NUM
dti-3213	93	36	121.3	121.3	NUM
dti-3213	93	37	392.0	392.0	NUM
dti-3213	93	38	±	±	NUM
dti-3213	93	39	163.6	163.6	NUM
dti-3213	93	40	−0.223	−0.223	NOUN
dti-3213	93	41	0.021	0.021	NUM
dti-3213	93	42	366.3	366.3	NUM
dti-3213	93	43	±	±	NUM
dti-3213	93	44	144.3	144.3	NUM
dti-3213	93	45	362.0	362.0	NUM
dti-3213	93	46	±	±	NUM
dti-3213	93	47	287.6	287.6	NUM
dti-3213	93	48	0.030	0.030	NUM
dti-3213	93	49	0.725	0.725	NUM
dti-3213	93	50	*	*	PUNCT
dti-3213	93	51	p	p	NOUN
dti-3213	93	52	values	value	NOUN
dti-3213	93	53	were	be	AUX
dti-3213	93	54	nominal	nominal	ADJ
dti-3213	93	55	.	.	PUNCT
dti-3213	94	1	†including	†include	VERB
dti-3213	94	2	“	"	PUNCT
dti-3213	94	3	minimally	minimally	ADV
dti-3213	94	4	”	"	PUNCT
dti-3213	94	5	and	and	CCONJ
dti-3213	94	6	“	"	PUNCT
dti-3213	94	7	predominantly	predominantly	ADV
dti-3213	94	8	”	"	PUNCT
dti-3213	94	9	classic	classic	ADJ
dti-3213	94	10	lesions	lesion	NOUN
dti-3213	94	11	.	.	PUNCT
dti-3213	95	1	cst	cst	PROPN
dti-3213	95	2	=	=	PROPN
dti-3213	95	3	central	central	ADJ
dti-3213	95	4	subfield	subfield	NOUN
dti-3213	95	5	thickness	thickness	NOUN
dti-3213	95	6	;	;	PUNCT
dti-3213	95	7	iptw	iptw	NOUN
dti-3213	95	8	=	=	SYM
dti-3213	95	9	inverse	inverse	NOUN
dti-3213	95	10	probability	probability	NOUN
dti-3213	95	11	of	of	ADP
dti-3213	95	12	treatment	treatment	NOUN
dti-3213	95	13	weighting	weighting	NOUN
dti-3213	95	14	;	;	PUNCT
dti-3213	95	15	iqr	iqr	PROPN
dti-3213	95	16	=	=	NOUN
dti-3213	95	17	interquartile	interquartile	NOUN
dti-3213	95	18	range	range	NOUN
dti-3213	95	19	;	;	PUNCT
dti-3213	95	20	irf	irf	PROPN
dti-3213	95	21	=	=	PROPN
dti-3213	95	22	intraretinal	intraretinal	ADJ
dti-3213	95	23	fluid	fluid	NOUN
dti-3213	95	24	;	;	PUNCT
dti-3213	95	25	sd	sd	NOUN
dti-3213	95	26	=	=	SYM
dti-3213	95	27	standard	standard	ADJ
dti-3213	95	28	deviation	deviation	NOUN
dti-3213	95	29	;	;	PUNCT
dti-3213	95	30	smd	smd	NOUN
dti-3213	95	31	=	=	SYM
dti-3213	95	32	standardized	standardized	ADJ
dti-3213	95	33	mean	mean	NOUN
dti-3213	95	34	difference	difference	NOUN
dti-3213	95	35	;	;	PUNCT
dti-3213	95	36	soc	soc	NOUN
dti-3213	95	37	=	=	SYM
dti-3213	95	38	standard	standard	NOUN
dti-3213	95	39	of	of	ADP
dti-3213	95	40	care	care	NOUN
dti-3213	95	41	(	(	PUNCT
dti-3213	95	42	aflibercept	aflibercept	ADJ
dti-3213	95	43	,	,	PUNCT
dti-3213	95	44	ranibizumab	ranibizumab	NOUN
dti-3213	95	45	,	,	PUNCT
dti-3213	95	46	and	and	CCONJ
dti-3213	95	47	bevacizumab	bevacizumab	PROPN
dti-3213	95	48	)	)	PUNCT
dti-3213	95	49	;	;	PUNCT
dti-3213	95	50	srf	srf	ADJ
dti-3213	95	51	=	=	ADJ
dti-3213	95	52	subretinal	subretinal	ADJ
dti-3213	95	53	fluid	fluid	NOUN
dti-3213	95	54	.	.	PUNCT
dti-3213	96	1	table	table	NOUN
dti-3213	96	2	1	1	NUM
dti-3213	96	3	(	(	PUNCT
dti-3213	96	4	continued	continue	VERB
dti-3213	96	5	)	)	PUNCT
dti-3213	96	6	galeone	galeone	NOUN
dti-3213	96	7	et	et	NOUN
dti-3213	96	8	al	al	PROPN
dti-3213	96	9	drug	drug	PROPN
dti-3213	96	10	target	target	NOUN
dti-3213	96	11	insights	insight	NOUN
dti-3213	96	12	2024	2024	NUM
dti-3213	96	13	;	;	PUNCT
dti-3213	96	14	18	18	NUM
dti-3213	96	15	:	:	SYM
dti-3213	96	16	109	109	NUM
dti-3213	96	17	©	©	PROPN
dti-3213	96	18	2024	2024	NUM
dti-3213	96	19	the	the	DET
dti-3213	96	20	authors	author	NOUN
dti-3213	96	21	.	.	PUNCT
dti-3213	97	1	published	publish	VERB
dti-3213	97	2	by	by	ADP
dti-3213	97	3	aboutscience	aboutscience	NOUN
dti-3213	97	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-3213	97	5	change	change	NOUN
dti-3213	97	6	from	from	ADP
dti-3213	97	7	baseline	baseline	NOUN
dti-3213	97	8	in	in	ADP
dti-3213	97	9	bcva	bcva	NOUN
dti-3213	97	10	after	after	ADP
dti-3213	97	11	iptw	iptw	NOUN
dti-3213	97	12	,	,	PUNCT
dti-3213	97	13	mean	mean	VERB
dti-3213	97	14	vision	vision	NOUN
dti-3213	97	15	gains	gain	NOUN
dti-3213	97	16	in	in	ADP
dti-3213	97	17	bcva	bcva	NOUN
dti-3213	97	18	after	after	ADP
dti-3213	97	19	1	1	NUM
dti-3213	97	20	year	year	NOUN
dti-3213	97	21	of	of	ADP
dti-3213	97	22	treatment	treatment	NOUN
dti-3213	97	23	were	be	AUX
dti-3213	97	24	6.4	6.4	NUM
dti-3213	97	25	letters	letter	NOUN
dti-3213	97	26	(	(	PUNCT
dti-3213	97	27	95	95	NUM
dti-3213	97	28	%	%	NOUN
dti-3213	97	29	ci	ci	NOUN
dti-3213	97	30	:	:	PUNCT
dti-3213	97	31	5.0	5.0	NUM
dti-3213	97	32	to	to	PART
dti-3213	97	33	7.9	7.9	NUM
dti-3213	97	34	)	)	PUNCT
dti-3213	97	35	in	in	ADP
dti-3213	97	36	the	the	DET
dti-3213	97	37	faricimab	faricimab	NOUN
dti-3213	97	38	cohort	cohort	NOUN
dti-3213	97	39	and	and	CCONJ
dti-3213	97	40	1.0	1.0	NUM
dti-3213	97	41	letter	letter	NOUN
dti-3213	97	42	(	(	PUNCT
dti-3213	97	43	95	95	NUM
dti-3213	97	44	%	%	NOUN
dti-3213	97	45	ci	ci	NOUN
dti-3213	97	46	:	:	PUNCT
dti-3213	97	47	−0.4	−0.4	NUM
dti-3213	97	48	to	to	ADP
dti-3213	97	49	2.5	2.5	NUM
dti-3213	97	50	)	)	PUNCT
dti-3213	97	51	in	in	ADP
dti-3213	97	52	the	the	DET
dti-3213	97	53	radiance	radiance	NOUN
dti-3213	97	54	cohort	cohort	NOUN
dti-3213	97	55	,	,	PUNCT
dti-3213	97	56	with	with	ADP
dti-3213	97	57	a	a	DET
dti-3213	97	58	corresponding	corresponding	ADJ
dti-3213	97	59	treatment	treatment	NOUN
dti-3213	97	60	difference	difference	NOUN
dti-3213	97	61	of	of	ADP
dti-3213	97	62	5.4	5.4	NUM
dti-3213	97	63	letters	letter	NOUN
dti-3213	97	64	(	(	PUNCT
dti-3213	97	65	95	95	NUM
dti-3213	97	66	%	%	NOUN
dti-3213	97	67	ci	ci	NOUN
dti-3213	97	68	:	:	PUNCT
dti-3213	97	69	3.4	3.4	NUM
dti-3213	97	70	to	to	PART
dti-3213	97	71	7.5	7.5	NUM
dti-3213	97	72	,	,	PUNCT
dti-3213	97	73	p<0.001	p<0.001	PUNCT
dti-3213	97	74	)	)	PUNCT
dti-3213	97	75	in	in	ADP
dti-3213	97	76	favor	favor	NOUN
dti-3213	97	77	of	of	ADP
dti-3213	97	78	faricimab	faricimab	NOUN
dti-3213	97	79	(	(	PUNCT
dti-3213	97	80	fig	fig	NOUN
dti-3213	97	81	.	.	PUNCT
dti-3213	97	82	1	1	NUM
dti-3213	97	83	)	)	PUNCT
dti-3213	97	84	.	.	PUNCT
dti-3213	98	1	favors	favor	VERB
dti-3213	98	2	soc	soc	NOUN
dti-3213	98	3	86420	86420	NUM
dti-3213	98	4	-	-	SYM
dti-3213	98	5	2	2	NUM
dti-3213	98	6	-	-	PUNCT
dti-3213	98	7	4	4	NUM
dti-3213	98	8	-	-	PUNCT
dti-3213	98	9	6	6	NUM
dti-3213	98	10	-	-	PUNCT
dti-3213	98	11	8	8	NUM
dti-3213	98	12	-	-	SYM
dti-3213	98	13	10	10	NUM
dti-3213	98	14	10	10	NUM
dti-3213	98	15	favors	favor	VERB
dti-3213	98	16	faricimab	faricimab	NOUN
dti-3213	98	17	4.0	4.0	NUM
dti-3213	98	18	(	(	PUNCT
dti-3213	98	19	95	95	NUM
dti-3213	98	20	%	%	NOUN
dti-3213	98	21	ci	ci	NOUN
dti-3213	98	22	:	:	PUNCT
dti-3213	98	23	1.7	1.7	NUM
dti-3213	98	24	to	to	PART
dti-3213	98	25	6.2	6.2	NUM
dti-3213	98	26	)	)	PUNCT
dti-3213	98	27	sensitivity	sensitivity	NOUN
dti-3213	98	28	analysis	analysis	NOUN
dti-3213	98	29	:	:	PUNCT
dti-3213	98	30	adjusted	adjust	VERB
dti-3213	98	31	for	for	ADP
dti-3213	98	32	n.	n.	NOUN
dti-3213	98	33	of	of	ADP
dti-3213	98	34	injections	injection	NOUN
dti-3213	98	35	5.4	5.4	NUM
dti-3213	98	36	(	(	PUNCT
dti-3213	98	37	95	95	NUM
dti-3213	98	38	%	%	NOUN
dti-3213	98	39	ci	ci	NOUN
dti-3213	98	40	:	:	PUNCT
dti-3213	98	41	3.4	3.4	NUM
dti-3213	98	42	to	to	PART
dti-3213	98	43	7.5	7.5	NUM
dti-3213	98	44	)	)	PUNCT
dti-3213	98	45	primary	primary	ADJ
dti-3213	98	46	analysis	analysis	NOUN
dti-3213	98	47	figure	figure	NOUN
dti-3213	98	48	1	1	NUM
dti-3213	98	49	difference	difference	NOUN
dti-3213	98	50	in	in	ADP
dti-3213	98	51	bcva	bcva	NOUN
dti-3213	98	52	mean	mean	VERB
dti-3213	99	1	change	change	NOUN
dti-3213	99	2	(	(	PUNCT
dti-3213	99	3	95	95	NUM
dti-3213	99	4	%	%	NOUN
dti-3213	99	5	ci	ci	NOUN
dti-3213	99	6	)	)	PUNCT
dti-3213	99	7	from	from	ADP
dti-3213	99	8	baseline	baseline	NOUN
dti-3213	99	9	to	to	ADP
dti-3213	99	10	1	1	NUM
dti-3213	99	11	year	year	NOUN
dti-3213	99	12	after	after	ADP
dti-3213	99	13	iptw	iptw	NOUN
dti-3213	99	14	.	.	PUNCT
dti-3213	100	1	bcva	bcva	NOUN
dti-3213	100	2	=	=	SYM
dti-3213	100	3	best	well	ADV
dti-3213	100	4	corrected	correct	VERB
dti-3213	100	5	visual	visual	ADJ
dti-3213	100	6	acuity	acuity	NOUN
dti-3213	100	7	;	;	PUNCT
dti-3213	100	8	ci	ci	NOUN
dti-3213	100	9	=	=	SYM
dti-3213	100	10	confidential	confidential	ADJ
dti-3213	100	11	interval	interval	NOUN
dti-3213	100	12	;	;	PUNCT
dti-3213	100	13	iptw	iptw	NOUN
dti-3213	100	14	=	=	SYM
dti-3213	100	15	inverse	inverse	NOUN
dti-3213	100	16	probability	probability	NOUN
dti-3213	100	17	of	of	ADP
dti-3213	100	18	treatment	treatment	NOUN
dti-3213	100	19	weighting	weighting	NOUN
dti-3213	100	20	;	;	PUNCT
dti-3213	100	21	soc	soc	NOUN
dti-3213	100	22	=	=	SYM
dti-3213	100	23	standard	standard	NOUN
dti-3213	100	24	of	of	ADP
dti-3213	100	25	care	care	NOUN
dti-3213	100	26	(	(	PUNCT
dti-3213	100	27	aflibercept	aflibercept	ADJ
dti-3213	100	28	,	,	PUNCT
dti-3213	100	29	ranibizumab	ranibizumab	NOUN
dti-3213	100	30	,	,	PUNCT
dti-3213	100	31	and	and	CCONJ
dti-3213	100	32	bevacizumab	bevacizumab	NOUN
dti-3213	100	33	)	)	PUNCT
dti-3213	100	34	.	.	PUNCT
dti-3213	101	1	change	change	NOUN
dti-3213	101	2	from	from	ADP
dti-3213	101	3	baseline	baseline	NOUN
dti-3213	101	4	in	in	ADP
dti-3213	101	5	cst	cst	PROPN
dti-3213	101	6	after	after	ADP
dti-3213	101	7	iptw	iptw	NOUN
dti-3213	101	8	,	,	PUNCT
dti-3213	101	9	the	the	DET
dti-3213	101	10	mean	mean	PROPN
dti-3213	101	11	cst	cst	PROPN
dti-3213	101	12	change	change	NOUN
dti-3213	101	13	from	from	ADP
dti-3213	101	14	baseline	baseline	PROPN
dti-3213	101	15	was	be	AUX
dti-3213	101	16	−143.2	−143.2	NOUN
dti-3213	101	17	μm	μm	NUM
dti-3213	101	18	(	(	PUNCT
dti-3213	101	19	95	95	NUM
dti-3213	101	20	%	%	NOUN
dti-3213	101	21	ci	ci	NOUN
dti-3213	101	22	:	:	PUNCT
dti-3213	101	23	−156.2	−156.2	NOUN
dti-3213	101	24	to	to	PART
dti-3213	101	25	−130.1	−130.1	VERB
dti-3213	101	26	)	)	PUNCT
dti-3213	101	27	in	in	ADP
dti-3213	101	28	the	the	DET
dti-3213	101	29	faricimab	faricimab	NOUN
dti-3213	101	30	cohort	cohort	NOUN
dti-3213	101	31	and	and	CCONJ
dti-3213	101	32	−71.4	−71.4	DET
dti-3213	101	33	μm	μm	NOUN
dti-3213	101	34	(	(	PUNCT
dti-3213	101	35	95	95	NUM
dti-3213	101	36	%	%	NOUN
dti-3213	101	37	ci	ci	NOUN
dti-3213	101	38	:	:	PUNCT
dti-3213	101	39	−84.3	−84.3	VERB
dti-3213	101	40	to	to	ADP
dti-3213	101	41	−58.4	−58.4	NUM
dti-3213	101	42	)	)	PUNCT
dti-3213	101	43	in	in	ADP
dti-3213	101	44	the	the	DET
dti-3213	101	45	radiance	radiance	NOUN
dti-3213	101	46	cohort	cohort	NOUN
dti-3213	101	47	,	,	PUNCT
dti-3213	101	48	with	with	ADP
dti-3213	101	49	a	a	DET
dti-3213	101	50	corresponding	corresponding	ADJ
dti-3213	101	51	treatment	treatment	NOUN
dti-3213	101	52	difference	difference	NOUN
dti-3213	101	53	of	of	ADP
dti-3213	101	54	−71.8	−71.8	INTJ
dti-3213	101	55	μm	μm	INTJ
dti-3213	101	56	(	(	PUNCT
dti-3213	101	57	95	95	NUM
dti-3213	101	58	%	%	NOUN
dti-3213	101	59	ci	ci	NOUN
dti-3213	101	60	:	:	PUNCT
dti-3213	101	61	−90.2	−90.2	NOUN
dti-3213	101	62	to	to	ADP
dti-3213	101	63	−53.4	−53.4	NOUN
dti-3213	101	64	,	,	PUNCT
dti-3213	101	65	p<0.001	p<0.001	PROPN
dti-3213	101	66	)	)	PUNCT
dti-3213	101	67	in	in	ADP
dti-3213	101	68	favor	favor	NOUN
dti-3213	101	69	of	of	ADP
dti-3213	101	70	faricimab	faricimab	NOUN
dti-3213	101	71	(	(	PUNCT
dti-3213	101	72	fig	fig	NOUN
dti-3213	101	73	.	.	PUNCT
dti-3213	102	1	2	2	NUM
dti-3213	102	2	)	)	PUNCT
dti-3213	102	3	.	.	PUNCT
dti-3213	103	1	favors	favor	VERB
dti-3213	103	2	faricimab	faricimab	NOUN
dti-3213	103	3	200	200	NUM
dti-3213	103	4	-	-	SYM
dti-3213	103	5	20	20	NUM
dti-3213	103	6	-	-	PUNCT
dti-3213	103	7	40	40	NUM
dti-3213	103	8	-	-	PUNCT
dti-3213	103	9	60	60	NUM
dti-3213	103	10	-	-	PUNCT
dti-3213	103	11	80	80	NUM
dti-3213	103	12	-	-	SYM
dti-3213	103	13	100	100	NUM
dti-3213	103	14	40	40	NUM
dti-3213	103	15	favors	favor	VERB
dti-3213	103	16	soc	soc	NOUN
dti-3213	103	17	−71.4	−71.4	PRON
dti-3213	103	18	μm	μm	INTJ
dti-3213	103	19	(	(	PUNCT
dti-3213	103	20	95	95	NUM
dti-3213	103	21	%	%	NOUN
dti-3213	103	22	ci	ci	NOUN
dti-3213	103	23	:	:	PUNCT
dti-3213	103	24	−84.3	−84.3	VERB
dti-3213	103	25	to	to	ADP
dti-3213	103	26	−58.4	−58.4	NUM
dti-3213	103	27	)	)	PUNCT
dti-3213	103	28	sensitivity	sensitivity	NOUN
dti-3213	103	29	analysis	analysis	NOUN
dti-3213	103	30	:	:	PUNCT
dti-3213	103	31	adjusted	adjust	VERB
dti-3213	103	32	for	for	ADP
dti-3213	103	33	n.	n.	NOUN
dti-3213	103	34	of	of	ADP
dti-3213	103	35	injections	injection	NOUN
dti-3213	103	36	−71.8	−71.8	INTJ
dti-3213	103	37	μm	μm	INTJ
dti-3213	103	38	(	(	PUNCT
dti-3213	103	39	95	95	NUM
dti-3213	103	40	%	%	NOUN
dti-3213	103	41	ci	ci	NOUN
dti-3213	103	42	:	:	PUNCT
dti-3213	103	43	−90.2	−90.2	NOUN
dti-3213	103	44	to	to	ADP
dti-3213	103	45	−53.4	−53.4	NOUN
dti-3213	103	46	)	)	PUNCT
dti-3213	103	47	primary	primary	ADJ
dti-3213	103	48	analysis	analysis	NOUN
dti-3213	103	49	figure	figure	NOUN
dti-3213	103	50	2	2	NUM
dti-3213	103	51	difference	difference	NOUN
dti-3213	103	52	in	in	ADP
dti-3213	103	53	cst	cst	PROPN
dti-3213	103	54	mean	mean	PROPN
dti-3213	103	55	change	change	NOUN
dti-3213	103	56	(	(	PUNCT
dti-3213	103	57	95	95	NUM
dti-3213	103	58	%	%	NOUN
dti-3213	103	59	ci	ci	NOUN
dti-3213	103	60	)	)	PUNCT
dti-3213	103	61	from	from	ADP
dti-3213	103	62	baseline	baseline	NOUN
dti-3213	103	63	to	to	ADP
dti-3213	103	64	1	1	NUM
dti-3213	103	65	year	year	NOUN
dti-3213	103	66	after	after	ADP
dti-3213	103	67	iptw	iptw	NOUN
dti-3213	103	68	.	.	PUNCT
dti-3213	104	1	ci	ci	NOUN
dti-3213	104	2	=	=	PUNCT
dti-3213	104	3	confidential	confidential	ADJ
dti-3213	104	4	interval	interval	NOUN
dti-3213	104	5	;	;	PUNCT
dti-3213	104	6	cst	cst	PROPN
dti-3213	104	7	=	=	PROPN
dti-3213	104	8	central	central	ADJ
dti-3213	104	9	subfield	subfield	NOUN
dti-3213	104	10	thickness	thickness	NOUN
dti-3213	104	11	;	;	PUNCT
dti-3213	104	12	iptw	iptw	NOUN
dti-3213	104	13	=	=	SYM
dti-3213	104	14	inverse	inverse	NOUN
dti-3213	104	15	probability	probability	NOUN
dti-3213	104	16	of	of	ADP
dti-3213	104	17	treatment	treatment	NOUN
dti-3213	104	18	weighting	weighting	NOUN
dti-3213	104	19	;	;	PUNCT
dti-3213	104	20	soc	soc	NOUN
dti-3213	104	21	=	=	SYM
dti-3213	104	22	standard	standard	NOUN
dti-3213	104	23	of	of	ADP
dti-3213	104	24	care	care	NOUN
dti-3213	104	25	(	(	PUNCT
dti-3213	104	26	aflibercept	aflibercept	ADJ
dti-3213	104	27	,	,	PUNCT
dti-3213	104	28	ranibizumab	ranibizumab	NOUN
dti-3213	104	29	,	,	PUNCT
dti-3213	104	30	and	and	CCONJ
dti-3213	104	31	bevacizumab	bevacizumab	PROPN
dti-3213	104	32	)	)	PUNCT
dti-3213	104	33	.	.	PUNCT
dti-3213	105	1	sensitivity	sensitivity	NOUN
dti-3213	105	2	analysis	analysis	NOUN
dti-3213	105	3	after	after	ADP
dti-3213	105	4	adjusting	adjust	VERB
dti-3213	105	5	for	for	ADP
dti-3213	105	6	the	the	DET
dti-3213	105	7	number	number	NOUN
dti-3213	105	8	of	of	ADP
dti-3213	105	9	injections	injection	NOUN
dti-3213	105	10	,	,	PUNCT
dti-3213	105	11	results	result	NOUN
dti-3213	105	12	were	be	AUX
dti-3213	105	13	consistent	consistent	ADJ
dti-3213	105	14	with	with	ADP
dti-3213	105	15	the	the	DET
dti-3213	105	16	main	main	ADJ
dti-3213	105	17	scenarios	scenario	NOUN
dti-3213	105	18	.	.	PUNCT
dti-3213	106	1	there	there	PRON
dti-3213	106	2	was	be	VERB
dti-3213	106	3	a	a	DET
dti-3213	106	4	slight	slight	ADJ
dti-3213	106	5	reduction	reduction	NOUN
dti-3213	106	6	in	in	ADP
dti-3213	106	7	the	the	DET
dti-3213	106	8	weighted	weighted	ADJ
dti-3213	106	9	bcva	bcva	NOUN
dti-3213	106	10	change	change	NOUN
dti-3213	106	11	from	from	ADP
dti-3213	106	12	baseline	baseline	NOUN
dti-3213	106	13	in	in	ADP
dti-3213	106	14	the	the	DET
dti-3213	106	15	faricimab	faricimab	NOUN
dti-3213	106	16	cohort	cohort	NOUN
dti-3213	106	17	(	(	PUNCT
dti-3213	106	18	+5.9	+5.9	NOUN
dti-3213	106	19	letters	letter	NOUN
dti-3213	106	20	[	[	X
dti-3213	106	21	95	95	NUM
dti-3213	106	22	%	%	NOUN
dti-3213	106	23	ci	ci	NOUN
dti-3213	106	24	:	:	PUNCT
dti-3213	106	25	4.4	4.4	NUM
dti-3213	106	26	to	to	ADP
dti-3213	106	27	7.4	7.4	NUM
dti-3213	106	28	]	]	PUNCT
dti-3213	106	29	)	)	PUNCT
dti-3213	106	30	and	and	CCONJ
dti-3213	106	31	a	a	DET
dti-3213	106	32	slight	slight	ADJ
dti-3213	106	33	increase	increase	NOUN
dti-3213	106	34	in	in	ADP
dti-3213	106	35	the	the	DET
dti-3213	106	36	radiance	radiance	NOUN
dti-3213	106	37	cohort	cohort	NOUN
dti-3213	106	38	(	(	PUNCT
dti-3213	106	39	+1.9	+1.9	NUM
dti-3213	106	40	letters	letter	NOUN
dti-3213	106	41	[	[	X
dti-3213	106	42	95	95	NUM
dti-3213	106	43	%	%	NOUN
dti-3213	106	44	ci	ci	NOUN
dti-3213	106	45	:	:	PUNCT
dti-3213	106	46	0.4	0.4	NUM
dti-3213	106	47	to	to	ADP
dti-3213	106	48	3.5	3.5	NUM
dti-3213	106	49	]	]	PUNCT
dti-3213	106	50	)	)	PUNCT
dti-3213	106	51	.	.	PUNCT
dti-3213	107	1	the	the	DET
dti-3213	107	2	weighted	weight	VERB
dti-3213	107	3	treatment	treatment	NOUN
dti-3213	107	4	difference	difference	NOUN
dti-3213	107	5	remained	remain	VERB
dti-3213	107	6	statistically	statistically	ADV
dti-3213	107	7	significant	significant	ADJ
dti-3213	107	8	and	and	CCONJ
dti-3213	107	9	was	be	AUX
dti-3213	107	10	consistent	consistent	ADJ
dti-3213	107	11	with	with	ADP
dti-3213	107	12	that	that	PRON
dti-3213	107	13	observed	observe	VERB
dti-3213	107	14	in	in	ADP
dti-3213	107	15	the	the	DET
dti-3213	107	16	main	main	ADJ
dti-3213	107	17	scenario	scenario	NOUN
dti-3213	107	18	(	(	PUNCT
dti-3213	107	19	+4.0	+4.0	X
dti-3213	107	20	letters	letter	NOUN
dti-3213	107	21	in	in	ADP
dti-3213	107	22	favor	favor	NOUN
dti-3213	107	23	of	of	ADP
dti-3213	107	24	faricimab	faricimab	NOUN
dti-3213	107	25	[	[	X
dti-3213	107	26	95	95	NUM
dti-3213	107	27	%	%	NOUN
dti-3213	107	28	ci	ci	NOUN
dti-3213	107	29	:	:	PUNCT
dti-3213	107	30	1.7	1.7	NUM
dti-3213	107	31	to	to	ADP
dti-3213	107	32	6.2	6.2	NUM
dti-3213	107	33	;	;	PUNCT
dti-3213	107	34	p	p	X
dti-3213	107	35	=	=	NOUN
dti-3213	107	36	0.0005	0.0005	NUM
dti-3213	107	37	]	]	PUNCT
dti-3213	107	38	)	)	PUNCT
dti-3213	107	39	.	.	PUNCT
dti-3213	108	1	similarly	similarly	ADV
dti-3213	108	2	,	,	PUNCT
dti-3213	108	3	after	after	ADP
dti-3213	108	4	adjusting	adjust	VERB
dti-3213	108	5	for	for	ADP
dti-3213	108	6	the	the	DET
dti-3213	108	7	number	number	NOUN
dti-3213	108	8	of	of	ADP
dti-3213	108	9	injections	injection	NOUN
dti-3213	108	10	,	,	PUNCT
dti-3213	108	11	the	the	DET
dti-3213	108	12	estimated	estimate	VERB
dti-3213	108	13	treatment	treatment	NOUN
dti-3213	108	14	difference	difference	NOUN
dti-3213	108	15	in	in	ADP
dti-3213	108	16	cst	cst	PROPN
dti-3213	108	17	change	change	NOUN
dti-3213	108	18	from	from	ADP
dti-3213	108	19	baseline	baseline	PROPN
dti-3213	108	20	remained	remain	VERB
dti-3213	108	21	in	in	ADP
dti-3213	108	22	favor	favor	NOUN
dti-3213	108	23	of	of	ADP
dti-3213	108	24	faricimab	faricimab	NOUN
dti-3213	108	25	(	(	PUNCT
dti-3213	108	26	−71.5	−71.5	NOUN
dti-3213	108	27	μm	μm	NOUN
dti-3213	109	1	[	[	X
dti-3213	109	2	95	95	NUM
dti-3213	109	3	%	%	NOUN
dti-3213	109	4	ci	ci	NOUN
dti-3213	109	5	:	:	PUNCT
dti-3213	109	6	−91	−91	NOUN
dti-3213	109	7	to	to	ADP
dti-3213	109	8	−52	−52	NOUN
dti-3213	109	9	;	;	PUNCT
dti-3213	109	10	p<0.001	p<0.001	X
dti-3213	109	11	]	]	X
dti-3213	109	12	)	)	PUNCT
dti-3213	109	13	(	(	PUNCT
dti-3213	109	14	figs	fig	NOUN
dti-3213	109	15	.	.	X
dti-3213	109	16	1	1	NUM
dti-3213	109	17	and	and	CCONJ
dti-3213	109	18	2	2	NUM
dti-3213	109	19	)	)	PUNCT
dti-3213	109	20	.	.	PUNCT
dti-3213	110	1	discussion	discussion	NOUN
dti-3213	110	2	this	this	DET
dti-3213	110	3	indirect	indirect	ADJ
dti-3213	110	4	treatment	treatment	NOUN
dti-3213	110	5	comparison	comparison	NOUN
dti-3213	110	6	was	be	AUX
dti-3213	110	7	conducted	conduct	VERB
dti-3213	110	8	to	to	PART
dti-3213	110	9	evaluate	evaluate	VERB
dti-3213	110	10	the	the	DET
dti-3213	110	11	effectiveness	effectiveness	NOUN
dti-3213	110	12	of	of	ADP
dti-3213	110	13	the	the	DET
dti-3213	110	14	novel	novel	ADJ
dti-3213	110	15	anti	anti	ADJ
dti-3213	110	16	-	-	ADJ
dti-3213	110	17	vegf	vegf	ADJ
dti-3213	110	18	/	/	SYM
dti-3213	110	19	ang2	ang2	PROPN
dti-3213	110	20	inhibitor	inhibitor	NOUN
dti-3213	110	21	faricimab	faricimab	NOUN
dti-3213	110	22	compared	compare	VERB
dti-3213	110	23	to	to	ADP
dti-3213	110	24	commonly	commonly	ADV
dti-3213	110	25	used	use	VERB
dti-3213	110	26	anti	anti	ADJ
dti-3213	110	27	-	-	ADJ
dti-3213	110	28	vegf	vegf	ADJ
dti-3213	110	29	agents	agent	NOUN
dti-3213	110	30	in	in	ADP
dti-3213	110	31	italy	italy	PROPN
dti-3213	110	32	.	.	PUNCT
dti-3213	111	1	the	the	DET
dti-3213	111	2	analysis	analysis	NOUN
dti-3213	111	3	was	be	AUX
dti-3213	111	4	performed	perform	VERB
dti-3213	111	5	using	use	VERB
dti-3213	111	6	ipd	ipd	PROPN
dti-3213	111	7	from	from	ADP
dti-3213	111	8	the	the	DET
dti-3213	111	9	real	real	ADJ
dti-3213	111	10	-	-	PUNCT
dti-3213	111	11	world	world	NOUN
dti-3213	111	12	study	study	NOUN
dti-3213	111	13	radiance	radiance	NOUN
dti-3213	111	14	(	(	PUNCT
dti-3213	111	15	31	31	NUM
dti-3213	111	16	)	)	PUNCT
dti-3213	111	17	and	and	CCONJ
dti-3213	111	18	a	a	DET
dti-3213	111	19	subset	subset	NOUN
dti-3213	111	20	of	of	ADP
dti-3213	111	21	faricimab	faricimab	NOUN
dti-3213	111	22	-	-	PUNCT
dti-3213	111	23	treated	treat	VERB
dti-3213	111	24	patients	patient	NOUN
dti-3213	111	25	from	from	ADP
dti-3213	111	26	the	the	DET
dti-3213	111	27	randomized	randomized	ADJ
dti-3213	111	28	clinical	clinical	ADJ
dti-3213	111	29	trials	trial	NOUN
dti-3213	111	30	tenaya	tenaya	PROPN
dti-3213	111	31	and	and	CCONJ
dti-3213	111	32	lucerne	lucerne	PROPN
dti-3213	111	33	(	(	PUNCT
dti-3213	111	34	30	30	NUM
dti-3213	111	35	)	)	PUNCT
dti-3213	111	36	.	.	PUNCT
dti-3213	112	1	despite	despite	SCONJ
dti-3213	112	2	the	the	DET
dti-3213	112	3	initial	initial	ADJ
dti-3213	112	4	significant	significant	ADJ
dti-3213	112	5	differences	difference	NOUN
dti-3213	112	6	of	of	ADP
dti-3213	112	7	baseline	baseline	ADJ
dti-3213	112	8	characteristics	characteristic	NOUN
dti-3213	112	9	between	between	ADP
dti-3213	112	10	the	the	DET
dti-3213	112	11	two	two	NUM
dti-3213	112	12	cohorts	cohort	NOUN
dti-3213	112	13	,	,	PUNCT
dti-3213	112	14	the	the	DET
dti-3213	112	15	iptw	iptw	NOUN
dti-3213	112	16	allowed	allow	VERB
dti-3213	112	17	to	to	PART
dti-3213	112	18	balance	balance	VERB
dti-3213	112	19	the	the	DET
dti-3213	112	20	cohorts	cohort	NOUN
dti-3213	112	21	and	and	CCONJ
dti-3213	112	22	mitigate	mitigate	VERB
dti-3213	112	23	the	the	DET
dti-3213	112	24	effect	effect	NOUN
dti-3213	112	25	of	of	ADP
dti-3213	112	26	potential	potential	ADJ
dti-3213	112	27	confounding	confound	VERB
dti-3213	112	28	variables	variable	NOUN
dti-3213	112	29	(	(	PUNCT
dti-3213	112	30	i.e.	i.e.	X
dti-3213	112	31	,	,	PUNCT
dti-3213	112	32	age	age	NOUN
dti-3213	112	33	,	,	PUNCT
dti-3213	112	34	sex	sex	NOUN
dti-3213	112	35	,	,	PUNCT
dti-3213	112	36	type	type	NOUN
dti-3213	112	37	of	of	ADP
dti-3213	112	38	lesion	lesion	NOUN
dti-3213	112	39	,	,	PUNCT
dti-3213	112	40	irf	irf	PROPN
dti-3213	112	41	,	,	PUNCT
dti-3213	112	42	srf	srf	PROPN
dti-3213	112	43	,	,	PUNCT
dti-3213	112	44	and	and	CCONJ
dti-3213	112	45	baseline	baseline	PROPN
dti-3213	112	46	va	va	PROPN
dti-3213	112	47	)	)	PUNCT
dti-3213	112	48	.	.	PUNCT
dti-3213	113	1	the	the	DET
dti-3213	113	2	base	base	NOUN
dti-3213	113	3	case	case	NOUN
dti-3213	113	4	analyses	analysis	NOUN
dti-3213	113	5	showed	show	VERB
dti-3213	113	6	a	a	DET
dti-3213	113	7	favorable	favorable	ADJ
dti-3213	113	8	effect	effect	NOUN
dti-3213	113	9	for	for	ADP
dti-3213	113	10	faricimab	faricimab	NOUN
dti-3213	113	11	with	with	ADP
dti-3213	113	12	a	a	DET
dti-3213	113	13	treatment	treatment	NOUN
dti-3213	113	14	difference	difference	NOUN
dti-3213	113	15	compared	compare	VERB
dti-3213	113	16	with	with	ADP
dti-3213	113	17	soc	soc	NOUN
dti-3213	113	18	equal	equal	ADJ
dti-3213	113	19	to	to	ADP
dti-3213	113	20	a	a	DET
dti-3213	113	21	bcva	bcva	NOUN
dti-3213	113	22	gain	gain	NOUN
dti-3213	113	23	of	of	ADP
dti-3213	113	24	5.4	5.4	NUM
dti-3213	113	25	letters	letter	NOUN
dti-3213	113	26	(	(	PUNCT
dti-3213	113	27	95	95	NUM
dti-3213	113	28	%	%	NOUN
dti-3213	113	29	ci	ci	NOUN
dti-3213	113	30	:	:	PUNCT
dti-3213	113	31	3.4	3.4	NUM
dti-3213	113	32	to	to	PART
dti-3213	113	33	7.5	7.5	NUM
dti-3213	113	34	,	,	PUNCT
dti-3213	113	35	p<0.001	p<0.001	PROPN
dti-3213	113	36	)	)	PUNCT
dti-3213	113	37	and	and	CCONJ
dti-3213	113	38	a	a	DET
dti-3213	113	39	cst	cst	PROPN
dti-3213	113	40	reduction	reduction	NOUN
dti-3213	113	41	of	of	ADP
dti-3213	113	42	−71.8	−71.8	INTJ
dti-3213	113	43	μm	μm	INTJ
dti-3213	113	44	(	(	PUNCT
dti-3213	113	45	95	95	NUM
dti-3213	113	46	%	%	NOUN
dti-3213	113	47	ci	ci	NOUN
dti-3213	113	48	:	:	PUNCT
dti-3213	113	49	−90.2	−90.2	NOUN
dti-3213	113	50	to	to	ADP
dti-3213	113	51	−53.4	−53.4	NOUN
dti-3213	113	52	,	,	PUNCT
dti-3213	113	53	p<0.001	p<0.001	PROPN
dti-3213	113	54	)	)	PUNCT
dti-3213	113	55	.	.	PUNCT
dti-3213	114	1	the	the	DET
dti-3213	114	2	weighted	weight	VERB
dti-3213	114	3	bcva	bcva	NOUN
dti-3213	114	4	change	change	NOUN
dti-3213	114	5	from	from	ADP
dti-3213	114	6	baseline	baseline	NOUN
dti-3213	114	7	in	in	ADP
dti-3213	114	8	the	the	DET
dti-3213	114	9	faricimab	faricimab	NOUN
dti-3213	114	10	cohort	cohort	NOUN
dti-3213	114	11	(	(	PUNCT
dti-3213	114	12	+6.5	+6.5	X
dti-3213	114	13	letters	letter	NOUN
dti-3213	114	14	[	[	X
dti-3213	114	15	95	95	NUM
dti-3213	114	16	%	%	NOUN
dti-3213	114	17	ci	ci	NOUN
dti-3213	114	18	:	:	PUNCT
dti-3213	114	19	5.0	5.0	NUM
dti-3213	114	20	to	to	PART
dti-3213	114	21	7.9	7.9	NUM
dti-3213	114	22	]	]	PUNCT
dti-3213	114	23	)	)	PUNCT
dti-3213	114	24	was	be	AUX
dti-3213	114	25	in	in	ADP
dti-3213	114	26	line	line	NOUN
dti-3213	114	27	with	with	ADP
dti-3213	114	28	the	the	DET
dti-3213	114	29	results	result	NOUN
dti-3213	114	30	of	of	ADP
dti-3213	114	31	the	the	DET
dti-3213	114	32	tenaya	tenaya	PROPN
dti-3213	114	33	and	and	CCONJ
dti-3213	114	34	lucerne	lucerne	NOUN
dti-3213	114	35	trials	trial	NOUN
dti-3213	114	36	(	(	PUNCT
dti-3213	114	37	+6.2	+6.2	PROPN
dti-3213	114	38	letters	letter	NOUN
dti-3213	114	39	,	,	PUNCT
dti-3213	114	40	average	average	NOUN
dti-3213	114	41	of	of	ADP
dti-3213	114	42	weeks	week	NOUN
dti-3213	114	43	40	40	NUM
dti-3213	114	44	-	-	SYM
dti-3213	114	45	48	48	NUM
dti-3213	114	46	)	)	PUNCT
dti-3213	114	47	(	(	PUNCT
dti-3213	114	48	30	30	NUM
dti-3213	114	49	)	)	PUNCT
dti-3213	114	50	,	,	PUNCT
dti-3213	114	51	and	and	CCONJ
dti-3213	114	52	the	the	DET
dti-3213	114	53	weighted	weighted	ADJ
dti-3213	114	54	bcva	bcva	NOUN
dti-3213	114	55	change	change	NOUN
dti-3213	114	56	from	from	ADP
dti-3213	114	57	baseline	baseline	NOUN
dti-3213	114	58	in	in	ADP
dti-3213	114	59	the	the	DET
dti-3213	114	60	radiance	radiance	NOUN
dti-3213	114	61	cohort	cohort	NOUN
dti-3213	114	62	(	(	PUNCT
dti-3213	114	63	+1.0	+1.0	PROPN
dti-3213	114	64	letter	letter	NOUN
dti-3213	114	65	[	[	X
dti-3213	114	66	95	95	NUM
dti-3213	114	67	%	%	NOUN
dti-3213	114	68	ci	ci	NOUN
dti-3213	114	69	:	:	PUNCT
dti-3213	114	70	−0.4	−0.4	NUM
dti-3213	114	71	to	to	ADP
dti-3213	114	72	2.5	2.5	NUM
dti-3213	114	73	]	]	PUNCT
dti-3213	114	74	)	)	PUNCT
dti-3213	114	75	was	be	AUX
dti-3213	114	76	in	in	ADP
dti-3213	114	77	line	line	NOUN
dti-3213	114	78	with	with	ADP
dti-3213	114	79	that	that	PRON
dti-3213	114	80	observed	observe	VERB
dti-3213	114	81	in	in	ADP
dti-3213	114	82	the	the	DET
dti-3213	114	83	radiance	radiance	NOUN
dti-3213	114	84	study	study	NOUN
dti-3213	114	85	(	(	PUNCT
dti-3213	114	86	+1.0	+1.0	PROPN
dti-3213	114	87	letter	letter	NOUN
dti-3213	115	1	[	[	X
dti-3213	115	2	sd	sd	ADP
dti-3213	115	3	19.3	19.3	NUM
dti-3213	115	4	]	]	PUNCT
dti-3213	115	5	)	)	PUNCT
dti-3213	115	6	(	(	PUNCT
dti-3213	115	7	31	31	NUM
dti-3213	115	8	)	)	PUNCT
dti-3213	115	9	.	.	PUNCT
dti-3213	116	1	similarly	similarly	ADV
dti-3213	116	2	,	,	PUNCT
dti-3213	116	3	the	the	DET
dti-3213	116	4	weighted	weighted	ADJ
dti-3213	116	5	cst	cst	PROPN
dti-3213	116	6	changes	change	NOUN
dti-3213	116	7	observed	observe	VERB
dti-3213	116	8	in	in	ADP
dti-3213	116	9	this	this	DET
dti-3213	116	10	analysis	analysis	NOUN
dti-3213	116	11	(	(	PUNCT
dti-3213	116	12	−143	−143	NOUN
dti-3213	116	13	μm	μm	NOUN
dti-3213	116	14	[	[	X
dti-3213	116	15	95	95	NUM
dti-3213	116	16	%	%	NOUN
dti-3213	116	17	ci	ci	NOUN
dti-3213	116	18	:	:	PUNCT
dti-3213	116	19	−156	−156	NOUN
dti-3213	116	20	to	to	ADP
dti-3213	116	21	−130	−130	ADJ
dti-3213	116	22	]	]	PUNCT
dti-3213	116	23	for	for	ADP
dti-3213	116	24	faricimab	faricimab	NOUN
dti-3213	116	25	and	and	CCONJ
dti-3213	116	26	−71	−71	NOUN
dti-3213	116	27	μm	μm	NOUN
dti-3213	117	1	[	[	X
dti-3213	117	2	95	95	NUM
dti-3213	117	3	%	%	NOUN
dti-3213	117	4	ci	ci	NOUN
dti-3213	117	5	:	:	PUNCT
dti-3213	117	6	−84	−84	NOUN
dti-3213	117	7	to	to	ADP
dti-3213	117	8	58	58	NUM
dti-3213	117	9	]	]	PUNCT
dti-3213	117	10	)	)	PUNCT
dti-3213	117	11	for	for	ADP
dti-3213	117	12	soc	soc	NOUN
dti-3213	117	13	)	)	PUNCT
dti-3213	117	14	were	be	AUX
dti-3213	117	15	comparable	comparable	ADJ
dti-3213	117	16	to	to	ADP
dti-3213	117	17	those	those	PRON
dti-3213	117	18	observed	observe	VERB
dti-3213	117	19	in	in	ADP
dti-3213	117	20	the	the	DET
dti-3213	117	21	tenaya	tenaya	PROPN
dti-3213	117	22	and	and	CCONJ
dti-3213	117	23	lucerne	lucerne	NOUN
dti-3213	117	24	trials	trial	NOUN
dti-3213	117	25	(	(	PUNCT
dti-3213	117	26	−137	−137	NOUN
dti-3213	117	27	μm	μm	NOUN
dti-3213	117	28	,	,	PUNCT
dti-3213	117	29	average	average	NOUN
dti-3213	117	30	of	of	ADP
dti-3213	117	31	weeks	week	NOUN
dti-3213	117	32	40	40	NUM
dti-3213	117	33	-	-	SYM
dti-3213	117	34	48	48	NUM
dti-3213	117	35	)	)	PUNCT
dti-3213	117	36	and	and	CCONJ
dti-3213	117	37	in	in	ADP
dti-3213	117	38	the	the	DET
dti-3213	117	39	radiance	radiance	NOUN
dti-3213	117	40	study	study	NOUN
dti-3213	117	41	(	(	PUNCT
dti-3213	117	42	−58	−58	NOUN
dti-3213	117	43	μm	μm	X
dti-3213	118	1	[	[	X
dti-3213	118	2	95	95	NUM
dti-3213	118	3	%	%	NOUN
dti-3213	118	4	ci	ci	NOUN
dti-3213	118	5	:	:	PUNCT
dti-3213	118	6	−161	−161	VERB
dti-3213	118	7	to	to	ADP
dti-3213	118	8	15	15	NUM
dti-3213	118	9	]	]	PUNCT
dti-3213	118	10	)	)	PUNCT
dti-3213	118	11	,	,	PUNCT
dti-3213	118	12	respectively	respectively	ADV
dti-3213	118	13	.	.	PUNCT
dti-3213	119	1	in	in	ADP
dti-3213	119	2	the	the	DET
dti-3213	119	3	radiance	radiance	NOUN
dti-3213	119	4	study	study	NOUN
dti-3213	119	5	,	,	PUNCT
dti-3213	119	6	after	after	ADP
dti-3213	119	7	stratification	stratification	NOUN
dti-3213	119	8	by	by	ADP
dti-3213	119	9	the	the	DET
dti-3213	119	10	number	number	NOUN
dti-3213	119	11	of	of	ADP
dti-3213	119	12	anti	anti	ADJ
dti-3213	119	13	-	-	ADJ
dti-3213	119	14	vegf	vegf	ADJ
dti-3213	119	15	injections	injection	NOUN
dti-3213	119	16	per	per	ADP
dti-3213	119	17	year	year	NOUN
dti-3213	119	18	,	,	PUNCT
dti-3213	119	19	the	the	DET
dti-3213	119	20	median	median	PROPN
dti-3213	119	21	va	va	PROPN
dti-3213	119	22	improvement	improvement	NOUN
dti-3213	119	23	was	be	AUX
dti-3213	119	24	better	well	ADJ
dti-3213	119	25	in	in	ADP
dti-3213	119	26	patients	patient	NOUN
dti-3213	119	27	treated	treat	VERB
dti-3213	119	28	with	with	ADP
dti-3213	119	29	>	>	SYM
dti-3213	119	30	6	6	NUM
dti-3213	119	31	injections	injection	NOUN
dti-3213	119	32	,	,	PUNCT
dti-3213	119	33	whereas	whereas	SCONJ
dti-3213	119	34	no	no	DET
dti-3213	119	35	improvement	improvement	NOUN
dti-3213	119	36	was	be	AUX
dti-3213	119	37	observed	observe	VERB
dti-3213	119	38	in	in	ADP
dti-3213	119	39	patients	patient	NOUN
dti-3213	119	40	treated	treat	VERB
dti-3213	119	41	with	with	ADP
dti-3213	119	42	fewer	few	ADJ
dti-3213	119	43	injections	injection	NOUN
dti-3213	119	44	(	(	PUNCT
dti-3213	119	45	31	31	NUM
dti-3213	119	46	)	)	PUNCT
dti-3213	119	47	.	.	PUNCT
dti-3213	120	1	the	the	DET
dti-3213	120	2	association	association	NOUN
dti-3213	120	3	observed	observe	VERB
dti-3213	120	4	in	in	ADP
dti-3213	120	5	the	the	DET
dti-3213	120	6	radiance	radiance	NOUN
dti-3213	120	7	study	study	NOUN
dti-3213	120	8	between	between	ADP
dti-3213	120	9	the	the	DET
dti-3213	120	10	higher	high	ADJ
dti-3213	120	11	number	number	NOUN
dti-3213	120	12	of	of	ADP
dti-3213	120	13	anti	anti	ADJ
dti-3213	120	14	-	-	ADJ
dti-3213	120	15	vegf	vegf	ADJ
dti-3213	120	16	injections	injection	NOUN
dti-3213	120	17	and	and	CCONJ
dti-3213	120	18	better	well	ADJ
dti-3213	120	19	outcomes	outcome	NOUN
dti-3213	120	20	was	be	AUX
dti-3213	120	21	in	in	ADP
dti-3213	120	22	line	line	NOUN
dti-3213	120	23	with	with	ADP
dti-3213	120	24	what	what	PRON
dti-3213	120	25	has	have	AUX
dti-3213	120	26	been	be	AUX
dti-3213	120	27	reported	report	VERB
dti-3213	120	28	by	by	ADP
dti-3213	120	29	other	other	ADJ
dti-3213	120	30	real	real	ADJ
dti-3213	120	31	-	-	PUNCT
dti-3213	120	32	world	world	NOUN
dti-3213	120	33	studies	study	NOUN
dti-3213	120	34	(	(	PUNCT
dti-3213	120	35	11,14,16,33	11,14,16,33	NUM
dti-3213	120	36	)	)	PUNCT
dti-3213	120	37	.	.	PUNCT
dti-3213	121	1	since	since	SCONJ
dti-3213	121	2	the	the	DET
dti-3213	121	3	injection	injection	NOUN
dti-3213	121	4	frequency	frequency	NOUN
dti-3213	121	5	in	in	ADP
dti-3213	121	6	the	the	DET
dti-3213	121	7	controlled	control	VERB
dti-3213	121	8	setting	setting	NOUN
dti-3213	121	9	of	of	ADP
dti-3213	121	10	a	a	DET
dti-3213	121	11	clinical	clinical	ADJ
dti-3213	121	12	trial	trial	NOUN
dti-3213	121	13	is	be	AUX
dti-3213	121	14	often	often	ADV
dti-3213	121	15	different	different	ADJ
dti-3213	121	16	to	to	ADP
dti-3213	121	17	that	that	PRON
dti-3213	121	18	observed	observe	VERB
dti-3213	121	19	in	in	ADP
dti-3213	121	20	the	the	DET
dti-3213	121	21	real	real	ADJ
dti-3213	121	22	world	world	NOUN
dti-3213	121	23	(	(	PUNCT
dti-3213	121	24	9,10,13,15,17,34,35	9,10,13,15,17,34,35	NOUN
dti-3213	121	25	)	)	PUNCT
dti-3213	121	26	,	,	PUNCT
dti-3213	121	27	a	a	DET
dti-3213	121	28	sensitivity	sensitivity	NOUN
dti-3213	121	29	analysis	analysis	NOUN
dti-3213	121	30	was	be	AUX
dti-3213	121	31	undertaken	undertake	VERB
dti-3213	121	32	to	to	PART
dti-3213	121	33	adjust	adjust	VERB
dti-3213	121	34	for	for	ADP
dti-3213	121	35	the	the	DET
dti-3213	121	36	number	number	NOUN
dti-3213	121	37	of	of	ADP
dti-3213	121	38	injections	injection	NOUN
dti-3213	121	39	between	between	ADP
dti-3213	121	40	the	the	DET
dti-3213	121	41	radiance	radiance	NOUN
dti-3213	121	42	and	and	CCONJ
dti-3213	121	43	faricimab	faricimab	NOUN
dti-3213	121	44	cohorts	cohort	NOUN
dti-3213	121	45	.	.	PUNCT
dti-3213	122	1	the	the	DET
dti-3213	122	2	bcva	bcva	NOUN
dti-3213	122	3	gains	gain	NOUN
dti-3213	122	4	and	and	CCONJ
dti-3213	122	5	cst	cst	PROPN
dti-3213	122	6	reductions	reduction	NOUN
dti-3213	122	7	observed	observe	VERB
dti-3213	122	8	in	in	ADP
dti-3213	122	9	this	this	DET
dti-3213	122	10	sensitivity	sensitivity	NOUN
dti-3213	122	11	analysis	analysis	NOUN
dti-3213	122	12	were	be	AUX
dti-3213	122	13	consistent	consistent	ADJ
dti-3213	122	14	with	with	ADP
dti-3213	122	15	the	the	DET
dti-3213	122	16	main	main	ADJ
dti-3213	122	17	scenarios	scenario	NOUN
dti-3213	122	18	,	,	PUNCT
dti-3213	122	19	with	with	ADP
dti-3213	122	20	the	the	DET
dti-3213	122	21	weighted	weight	VERB
dti-3213	122	22	treatment	treatment	NOUN
dti-3213	122	23	difference	difference	NOUN
dti-3213	122	24	in	in	ADP
dti-3213	122	25	bcva	bcva	PROPN
dti-3213	122	26	and	and	CCONJ
dti-3213	122	27	cst	cst	PROPN
dti-3213	122	28	equal	equal	ADJ
dti-3213	122	29	to	to	ADP
dti-3213	122	30	+4.0	+4.0	VERB
dti-3213	122	31	letters	letter	NOUN
dti-3213	122	32	and	and	CCONJ
dti-3213	122	33	−71.5	−71.5	NOUN
dti-3213	122	34	μm	μm	NOUN
dti-3213	122	35	,	,	PUNCT
dti-3213	122	36	respectively	respectively	ADV
dti-3213	122	37	,	,	PUNCT
dti-3213	122	38	in	in	ADP
dti-3213	122	39	favor	favor	NOUN
dti-3213	122	40	of	of	ADP
dti-3213	122	41	faricimab	faricimab	NOUN
dti-3213	122	42	.	.	PUNCT
dti-3213	123	1	despite	despite	SCONJ
dti-3213	123	2	the	the	DET
dti-3213	123	3	adjustment	adjustment	NOUN
dti-3213	123	4	for	for	ADP
dti-3213	123	5	the	the	DET
dti-3213	123	6	number	number	NOUN
dti-3213	123	7	of	of	ADP
dti-3213	123	8	injections	injection	NOUN
dti-3213	123	9	,	,	PUNCT
dti-3213	123	10	residual	residual	ADJ
dti-3213	123	11	confounding	confounding	NOUN
dti-3213	123	12	by	by	ADP
dti-3213	123	13	the	the	DET
dti-3213	123	14	different	different	ADJ
dti-3213	123	15	regime	regime	NOUN
dti-3213	123	16	and	and	CCONJ
dti-3213	123	17	protocol	protocol	NOUN
dti-3213	123	18	between	between	ADP
dti-3213	123	19	the	the	DET
dti-3213	123	20	pivotal	pivotal	ADJ
dti-3213	123	21	and	and	CCONJ
dti-3213	123	22	real	real	ADJ
dti-3213	123	23	-	-	PUNCT
dti-3213	123	24	world	world	NOUN
dti-3213	123	25	studies	study	NOUN
dti-3213	123	26	can	can	AUX
dti-3213	123	27	not	not	PART
dti-3213	123	28	be	be	AUX
dti-3213	123	29	excluded	exclude	VERB
dti-3213	123	30	,	,	PUNCT
dti-3213	123	31	which	which	PRON
dti-3213	123	32	may	may	AUX
dti-3213	123	33	limit	limit	VERB
dti-3213	123	34	the	the	DET
dti-3213	123	35	interpretation	interpretation	NOUN
dti-3213	123	36	and	and	CCONJ
dti-3213	123	37	generalizability	generalizability	NOUN
dti-3213	123	38	of	of	ADP
dti-3213	123	39	the	the	DET
dti-3213	123	40	results	result	NOUN
dti-3213	123	41	.	.	PUNCT
dti-3213	124	1	to	to	ADP
dti-3213	124	2	the	the	DET
dti-3213	124	3	best	good	ADJ
dti-3213	124	4	of	of	ADP
dti-3213	124	5	our	our	PRON
dti-3213	124	6	knowledge	knowledge	NOUN
dti-3213	124	7	,	,	PUNCT
dti-3213	124	8	this	this	PRON
dti-3213	124	9	is	be	AUX
dti-3213	124	10	the	the	DET
dti-3213	124	11	first	first	ADJ
dti-3213	124	12	study	study	NOUN
dti-3213	124	13	that	that	SCONJ
dti-3213	124	14	compared	compare	VERB
dti-3213	124	15	faricimab	faricimab	NOUN
dti-3213	124	16	with	with	ADP
dti-3213	124	17	soc	soc	NOUN
dti-3213	124	18	for	for	ADP
dti-3213	124	19	patients	patient	NOUN
dti-3213	124	20	with	with	ADP
dti-3213	124	21	namd	namd	NOUN
dti-3213	124	22	in	in	ADP
dti-3213	124	23	italy	italy	PROPN
dti-3213	124	24	.	.	PUNCT
dti-3213	125	1	first	first	ADJ
dti-3213	125	2	-	-	PUNCT
dti-3213	125	3	line	line	NOUN
dti-3213	125	4	treatment	treatment	NOUN
dti-3213	125	5	with	with	ADP
dti-3213	125	6	faricimab	faricimab	NOUN
dti-3213	125	7	was	be	AUX
dti-3213	125	8	associated	associate	VERB
dti-3213	125	9	with	with	ADP
dti-3213	125	10	greater	great	ADJ
dti-3213	125	11	visual	visual	ADJ
dti-3213	125	12	gain	gain	NOUN
dti-3213	125	13	and	and	CCONJ
dti-3213	125	14	cst	cst	PROPN
dti-3213	125	15	reduction	reduction	NOUN
dti-3213	125	16	,	,	PUNCT
dti-3213	125	17	compared	compare	VERB
dti-3213	125	18	to	to	ADP
dti-3213	125	19	current	current	ADJ
dti-3213	125	20	intravitreal	intravitreal	ADJ
dti-3213	125	21	anti	anti	ADJ
dti-3213	125	22	-	-	ADJ
dti-3213	125	23	vegf	vegf	ADJ
dti-3213	125	24	soc	soc	NOUN
dti-3213	125	25	,	,	PUNCT
dti-3213	125	26	showing	show	VERB
dti-3213	125	27	potential	potential	NOUN
dti-3213	125	28	to	to	PART
dti-3213	125	29	redefine	redefine	VERB
dti-3213	125	30	the	the	DET
dti-3213	125	31	treatment	treatment	NOUN
dti-3213	125	32	landscape	landscape	NOUN
dti-3213	125	33	for	for	ADP
dti-3213	125	34	namd	namd	NOUN
dti-3213	125	35	.	.	PUNCT
dti-3213	126	1	clinicians	clinician	NOUN
dti-3213	126	2	may	may	AUX
dti-3213	126	3	consider	consider	VERB
dti-3213	126	4	faricimab	faricimab	NOUN
dti-3213	126	5	as	as	ADP
dti-3213	126	6	an	an	DET
dti-3213	126	7	effective	effective	ADJ
dti-3213	126	8	option	option	NOUN
dti-3213	126	9	,	,	PUNCT
dti-3213	126	10	particularly	particularly	ADV
dti-3213	126	11	given	give	VERB
dti-3213	126	12	its	its	PRON
dti-3213	126	13	favorable	favorable	ADJ
dti-3213	126	14	outcomes	outcome	NOUN
dti-3213	126	15	in	in	ADP
dti-3213	126	16	comparison	comparison	NOUN
dti-3213	126	17	to	to	ADP
dti-3213	126	18	employed	employ	VERB
dti-3213	126	19	anti	anti	ADJ
dti-3213	126	20	-	-	ADJ
dti-3213	126	21	vegf	vegf	ADJ
dti-3213	126	22	agents	agent	NOUN
dti-3213	126	23	.	.	PUNCT
dti-3213	127	1	itc	itc	PROPN
dti-3213	127	2	of	of	ADP
dti-3213	127	3	faricimab	faricimab	NOUN
dti-3213	127	4	vs.	vs.	X
dti-3213	127	5	soc	soc	NOUN
dti-3213	127	6	for	for	ADP
dti-3213	127	7	namd	namd	ADJ
dti-3213	127	8	patients	patient	NOUN
dti-3213	127	9	in	in	ADP
dti-3213	127	10	italy110	italy110	PROPN
dti-3213	127	11	©	©	PROPN
dti-3213	127	12	2024	2024	NUM
dti-3213	127	13	the	the	DET
dti-3213	127	14	authors	author	NOUN
dti-3213	127	15	.	.	PUNCT
dti-3213	128	1	drug	drug	NOUN
dti-3213	128	2	target	target	NOUN
dti-3213	128	3	insights	insight	NOUN
dti-3213	128	4	issn	issn	VERB
dti-3213	128	5	1177	1177	NUM
dti-3213	128	6	-	-	SYM
dti-3213	128	7	3928	3928	NUM
dti-3213	128	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-3213	128	9	the	the	DET
dti-3213	128	10	limitations	limitation	NOUN
dti-3213	128	11	of	of	ADP
dti-3213	128	12	the	the	DET
dti-3213	128	13	study	study	NOUN
dti-3213	128	14	include	include	VERB
dti-3213	128	15	the	the	DET
dti-3213	128	16	size	size	NOUN
dti-3213	128	17	of	of	ADP
dti-3213	128	18	the	the	DET
dti-3213	128	19	realworld	realworld	PROPN
dti-3213	128	20	cohort	cohort	NOUN
dti-3213	128	21	,	,	PUNCT
dti-3213	128	22	in	in	ADP
dti-3213	128	23	particular	particular	ADJ
dti-3213	128	24	for	for	ADP
dti-3213	128	25	the	the	DET
dti-3213	128	26	analysis	analysis	NOUN
dti-3213	128	27	on	on	ADP
dti-3213	128	28	cst	cst	PROPN
dti-3213	128	29	,	,	PUNCT
dti-3213	128	30	which	which	PRON
dti-3213	128	31	was	be	AUX
dti-3213	128	32	too	too	ADV
dti-3213	128	33	small	small	ADJ
dti-3213	128	34	to	to	PART
dti-3213	128	35	allow	allow	VERB
dti-3213	128	36	subgroup	subgroup	NOUN
dti-3213	128	37	analysis	analysis	NOUN
dti-3213	128	38	by	by	ADP
dti-3213	128	39	anti	anti	ADJ
dti-3213	128	40	-	-	ADJ
dti-3213	128	41	vegf	vegf	ADJ
dti-3213	128	42	agent	agent	NOUN
dti-3213	128	43	,	,	PUNCT
dti-3213	128	44	along	along	ADP
dti-3213	128	45	with	with	ADP
dti-3213	128	46	all	all	DET
dti-3213	128	47	limitations	limitation	NOUN
dti-3213	128	48	associated	associate	VERB
dti-3213	128	49	with	with	ADP
dti-3213	128	50	the	the	DET
dti-3213	128	51	comparison	comparison	NOUN
dti-3213	128	52	of	of	ADP
dti-3213	128	53	clinical	clinical	ADJ
dti-3213	128	54	trial	trial	NOUN
dti-3213	128	55	and	and	CCONJ
dti-3213	128	56	real	real	ADJ
dti-3213	128	57	-	-	PUNCT
dti-3213	128	58	world	world	NOUN
dti-3213	128	59	cohorts	cohort	NOUN
dti-3213	128	60	.	.	PUNCT
dti-3213	129	1	in	in	ADP
dti-3213	129	2	particular	particular	ADJ
dti-3213	129	3	,	,	PUNCT
dti-3213	129	4	the	the	DET
dti-3213	129	5	treatment	treatment	NOUN
dti-3213	129	6	regimens	regimen	VERB
dti-3213	129	7	in	in	ADP
dti-3213	129	8	the	the	DET
dti-3213	129	9	clinical	clinical	ADJ
dti-3213	129	10	trial	trial	NOUN
dti-3213	129	11	setting	setting	NOUN
dti-3213	129	12	are	be	AUX
dti-3213	129	13	more	more	ADV
dti-3213	129	14	controlled	control	VERB
dti-3213	129	15	than	than	ADP
dti-3213	129	16	in	in	ADP
dti-3213	129	17	routine	routine	ADJ
dti-3213	129	18	clinical	clinical	ADJ
dti-3213	129	19	practice	practice	NOUN
dti-3213	129	20	.	.	PUNCT
dti-3213	130	1	although	although	SCONJ
dti-3213	130	2	we	we	PRON
dti-3213	130	3	used	use	VERB
dti-3213	130	4	ps	ps	PROPN
dti-3213	130	5	weighting	weight	VERB
dti-3213	130	6	to	to	PART
dti-3213	130	7	balance	balance	VERB
dti-3213	130	8	potential	potential	ADJ
dti-3213	130	9	confounding	confound	VERB
dti-3213	130	10	factors	factor	NOUN
dti-3213	130	11	,	,	PUNCT
dti-3213	130	12	residual	residual	ADJ
dti-3213	130	13	confounding	confounding	NOUN
dti-3213	130	14	as	as	ADV
dti-3213	130	15	well	well	ADV
dti-3213	130	16	as	as	ADP
dti-3213	130	17	an	an	DET
dti-3213	130	18	impact	impact	NOUN
dti-3213	130	19	of	of	ADP
dti-3213	130	20	unmeasured	unmeasured	ADJ
dti-3213	130	21	confounders	confounder	NOUN
dti-3213	130	22	can	can	AUX
dti-3213	130	23	not	not	PART
dti-3213	130	24	be	be	AUX
dti-3213	130	25	ruled	rule	VERB
dti-3213	130	26	out	out	ADP
dti-3213	130	27	.	.	PUNCT
dti-3213	131	1	in	in	ADP
dti-3213	131	2	addition	addition	NOUN
dti-3213	131	3	,	,	PUNCT
dti-3213	131	4	in	in	ADP
dti-3213	131	5	the	the	DET
dti-3213	131	6	radiance	radiance	NOUN
dti-3213	131	7	cohort	cohort	NOUN
dti-3213	131	8	we	we	PRON
dti-3213	131	9	included	include	VERB
dti-3213	131	10	patients	patient	NOUN
dti-3213	131	11	with	with	ADP
dti-3213	131	12	at	at	ADV
dti-3213	131	13	least	least	ADV
dti-3213	131	14	two	two	NUM
dti-3213	131	15	post	post	ADJ
dti-3213	131	16	-	-	ADJ
dti-3213	131	17	baseline	baseline	ADJ
dti-3213	131	18	endpoint	endpoint	NOUN
dti-3213	131	19	measurements	measurement	NOUN
dti-3213	131	20	,	,	PUNCT
dti-3213	131	21	including	include	VERB
dti-3213	131	22	one	one	NUM
dti-3213	131	23	around	around	ADP
dti-3213	131	24	52	52	NUM
dti-3213	131	25	weeks	week	NOUN
dti-3213	131	26	,	,	PUNCT
dti-3213	131	27	and	and	CCONJ
dti-3213	131	28	this	this	PRON
dti-3213	131	29	could	could	AUX
dti-3213	131	30	have	have	AUX
dti-3213	131	31	introduced	introduce	VERB
dti-3213	131	32	some	some	DET
dti-3213	131	33	selection	selection	NOUN
dti-3213	131	34	bias	bias	NOUN
dti-3213	131	35	if	if	SCONJ
dti-3213	131	36	these	these	DET
dti-3213	131	37	patients	patient	NOUN
dti-3213	131	38	were	be	AUX
dti-3213	131	39	different	different	ADJ
dti-3213	131	40	from	from	ADP
dti-3213	131	41	those	those	PRON
dti-3213	131	42	with	with	ADP
dti-3213	131	43	only	only	ADV
dti-3213	131	44	one	one	NUM
dti-3213	131	45	post	post	ADJ
dti-3213	131	46	-	-	ADJ
dti-3213	131	47	baseline	baseline	ADJ
dti-3213	131	48	measurement	measurement	NOUN
dti-3213	131	49	.	.	PUNCT
dti-3213	132	1	conclusions	conclusion	NOUN
dti-3213	132	2	despite	despite	SCONJ
dti-3213	132	3	limitations	limitation	NOUN
dti-3213	132	4	of	of	ADP
dti-3213	132	5	indirect	indirect	ADJ
dti-3213	132	6	treatment	treatment	NOUN
dti-3213	132	7	comparisons	comparison	NOUN
dti-3213	132	8	,	,	PUNCT
dti-3213	132	9	which	which	PRON
dti-3213	132	10	call	call	VERB
dti-3213	132	11	for	for	ADP
dti-3213	132	12	specific	specific	ADJ
dti-3213	132	13	post	post	ADJ
dti-3213	132	14	-	-	ADJ
dti-3213	132	15	marketing	marketing	ADJ
dti-3213	132	16	real	real	ADJ
dti-3213	132	17	-	-	PUNCT
dti-3213	132	18	world	world	NOUN
dti-3213	132	19	studies	study	NOUN
dti-3213	132	20	,	,	PUNCT
dti-3213	132	21	and	and	CCONJ
dti-3213	132	22	the	the	DET
dti-3213	132	23	possibility	possibility	NOUN
dti-3213	132	24	that	that	SCONJ
dti-3213	132	25	the	the	DET
dti-3213	132	26	difference	difference	NOUN
dti-3213	132	27	may	may	AUX
dti-3213	132	28	be	be	AUX
dti-3213	132	29	due	due	ADJ
dti-3213	132	30	to	to	ADP
dti-3213	132	31	frequency	frequency	NOUN
dti-3213	132	32	and	and	CCONJ
dti-3213	132	33	time	time	NOUN
dti-3213	132	34	of	of	ADP
dti-3213	132	35	treatment	treatment	NOUN
dti-3213	132	36	rather	rather	ADV
dti-3213	132	37	than	than	ADP
dti-3213	132	38	to	to	PART
dti-3213	132	39	type	type	NOUN
dti-3213	132	40	of	of	ADP
dti-3213	132	41	agents	agent	NOUN
dti-3213	132	42	used	use	VERB
dti-3213	132	43	,	,	PUNCT
dti-3213	132	44	the	the	DET
dti-3213	132	45	present	present	ADJ
dti-3213	132	46	analysis	analysis	NOUN
dti-3213	132	47	supports	support	VERB
dti-3213	132	48	potential	potential	ADJ
dti-3213	132	49	benefits	benefit	NOUN
dti-3213	132	50	in	in	ADP
dti-3213	132	51	terms	term	NOUN
dti-3213	132	52	of	of	ADP
dti-3213	132	53	va	va	PROPN
dti-3213	132	54	and	and	CCONJ
dti-3213	132	55	cst	cst	PROPN
dti-3213	132	56	reduction	reduction	NOUN
dti-3213	132	57	in	in	ADP
dti-3213	132	58	naïve	naïve	ADJ
dti-3213	132	59	namd	namd	NOUN
dti-3213	132	60	patients	patient	NOUN
dti-3213	132	61	treated	treat	VERB
dti-3213	132	62	with	with	ADP
dti-3213	132	63	faricimab	faricimab	NOUN
dti-3213	132	64	compared	compare	VERB
dti-3213	132	65	with	with	ADP
dti-3213	132	66	intravitreal	intravitreal	ADJ
dti-3213	132	67	anti	anti	ADJ
dti-3213	132	68	-	-	ADJ
dti-3213	132	69	vegf	vegf	ADJ
dti-3213	132	70	soc	soc	NOUN
dti-3213	132	71	(	(	PUNCT
dti-3213	132	72	aflibercept	aflibercept	ADJ
dti-3213	132	73	,	,	PUNCT
dti-3213	132	74	ranibizumab	ranibizumab	NOUN
dti-3213	132	75	,	,	PUNCT
dti-3213	132	76	and	and	CCONJ
dti-3213	132	77	bevacizumab	bevacizumab	PROPN
dti-3213	132	78	)	)	PUNCT
dti-3213	132	79	.	.	PUNCT
dti-3213	133	1	additional	additional	ADJ
dti-3213	133	2	evidence	evidence	NOUN
dti-3213	133	3	from	from	ADP
dti-3213	133	4	the	the	DET
dti-3213	133	5	real	real	ADJ
dti-3213	133	6	-	-	PUNCT
dti-3213	133	7	world	world	NOUN
dti-3213	133	8	setting	setting	NOUN
dti-3213	133	9	is	be	AUX
dti-3213	133	10	required	require	VERB
dti-3213	133	11	to	to	PART
dti-3213	133	12	confirm	confirm	VERB
dti-3213	133	13	our	our	PRON
dti-3213	133	14	finding	finding	NOUN
dti-3213	133	15	.	.	PUNCT
dti-3213	134	1	acknowledgments	acknowledgment	NOUN
dti-3213	134	2	the	the	DET
dti-3213	134	3	authors	author	NOUN
dti-3213	134	4	acknowledge	acknowledge	VERB
dti-3213	134	5	ombretta	ombretta	PROPN
dti-3213	134	6	bandi	bandi	PROPN
dti-3213	134	7	from	from	ADP
dti-3213	134	8	seed	seed	NOUN
dti-3213	134	9	medical	medical	ADJ
dti-3213	134	10	publishers	publisher	NOUN
dti-3213	134	11	who	who	PRON
dti-3213	134	12	provided	provide	VERB
dti-3213	134	13	writing	writing	NOUN
dti-3213	134	14	assistance	assistance	NOUN
dti-3213	134	15	and	and	CCONJ
dti-3213	134	16	journal	journal	NOUN
dti-3213	134	17	styling	styling	NOUN
dti-3213	134	18	services	service	NOUN
dti-3213	134	19	.	.	PUNCT
dti-3213	135	1	disclosures	disclosure	VERB
dti-3213	135	2	financial	financial	ADJ
dti-3213	135	3	support	support	NOUN
dti-3213	135	4	:	:	PUNCT
dti-3213	135	5	this	this	DET
dti-3213	135	6	study	study	NOUN
dti-3213	135	7	was	be	AUX
dti-3213	135	8	sponsored	sponsor	VERB
dti-3213	135	9	and	and	CCONJ
dti-3213	135	10	financially	financially	ADV
dti-3213	135	11	supported	support	VERB
dti-3213	135	12	by	by	ADP
dti-3213	135	13	roche	roche	PROPN
dti-3213	135	14	s.p.a	s.p.a	PROPN
dti-3213	135	15	.	.	PUNCT
dti-3213	136	1	the	the	DET
dti-3213	136	2	study	study	NOUN
dti-3213	136	3	was	be	AUX
dti-3213	136	4	presented	present	VERB
dti-3213	136	5	as	as	ADP
dti-3213	136	6	a	a	DET
dti-3213	136	7	poster	poster	NOUN
dti-3213	136	8	at	at	ADP
dti-3213	136	9	ispor	ispor	PROPN
dti-3213	136	10	europe	europe	PROPN
dti-3213	136	11	2023	2023	NUM
dti-3213	136	12	(	(	PUNCT
dti-3213	136	13	copenhagen	copenhagen	PROPN
dti-3213	136	14	,	,	PUNCT
dti-3213	136	15	november	november	PROPN
dti-3213	136	16	12	12	NUM
dti-3213	136	17	-	-	SYM
dti-3213	136	18	15	15	NUM
dti-3213	136	19	,	,	PUNCT
dti-3213	136	20	2023	2023	NUM
dti-3213	136	21	)	)	PUNCT
dti-3213	136	22	.	.	PUNCT
dti-3213	137	1	conflict	conflict	NOUN
dti-3213	137	2	of	of	ADP
dti-3213	137	3	interest	interest	NOUN
dti-3213	137	4	:	:	PUNCT
dti-3213	137	5	the	the	DET
dti-3213	137	6	authors	author	NOUN
dti-3213	137	7	declare	declare	VERB
dti-3213	137	8	the	the	DET
dti-3213	137	9	following	follow	VERB
dti-3213	137	10	financial	financial	ADJ
dti-3213	137	11	interests	interest	NOUN
dti-3213	137	12	/	/	SYM
dti-3213	137	13	personal	personal	ADJ
dti-3213	137	14	relationships	relationship	NOUN
dti-3213	137	15	which	which	PRON
dti-3213	137	16	may	may	AUX
dti-3213	137	17	be	be	AUX
dti-3213	137	18	considered	consider	VERB
dti-3213	137	19	as	as	ADP
dti-3213	137	20	potential	potential	ADJ
dti-3213	137	21	competing	compete	VERB
dti-3213	137	22	interests	interest	NOUN
dti-3213	137	23	:	:	PUNCT
dti-3213	137	24	cg	cg	NOUN
dti-3213	137	25	roche	roche	NOUN
dti-3213	137	26	;	;	PUNCT
dti-3213	137	27	ft	ft	PART
dti-3213	137	28	none	none	NOUN
dti-3213	137	29	;	;	PUNCT
dti-3213	137	30	mp	mp	PROPN
dti-3213	137	31	abbvie	abbvie	PROPN
dti-3213	137	32	,	,	PUNCT
dti-3213	137	33	novartis	novartis	PROPN
dti-3213	137	34	,	,	PUNCT
dti-3213	137	35	bayer	bayer	PROPN
dti-3213	137	36	,	,	PUNCT
dti-3213	137	37	roche	roche	PROPN
dti-3213	137	38	,	,	PUNCT
dti-3213	137	39	zeiss	zeiss	PROPN
dti-3213	137	40	;	;	PUNCT
dti-3213	137	41	fv	fv	PROPN
dti-3213	137	42	bayer	bayer	PROPN
dti-3213	137	43	,	,	PUNCT
dti-3213	137	44	novartis	novartis	PROPN
dti-3213	137	45	,	,	PUNCT
dti-3213	137	46	abbvie	abbvie	PROPN
dti-3213	137	47	,	,	PUNCT
dti-3213	137	48	roche	roche	PROPN
dti-3213	137	49	;	;	PUNCT
dti-3213	137	50	mn	mn	PROPN
dti-3213	137	51	roche	roche	PROPN
dti-3213	137	52	;	;	PUNCT
dti-3213	137	53	sv	sv	PROPN
dti-3213	137	54	abbvie	abbvie	PROPN
dti-3213	137	55	,	,	PUNCT
dti-3213	137	56	alimera	alimera	PROPN
dti-3213	137	57	,	,	PUNCT
dti-3213	137	58	apellis	apellis	PROPN
dti-3213	137	59	,	,	PUNCT
dti-3213	137	60	bayer	bayer	PROPN
dti-3213	137	61	.	.	PUNCT
dti-3213	138	1	b&i	b&i	PROPN
dti-3213	138	2	,	,	PUNCT
dti-3213	138	3	novartis	novartis	PROPN
dti-3213	138	4	,	,	PUNCT
dti-3213	138	5	roche	roche	PROPN
dti-3213	138	6	,	,	PUNCT
dti-3213	138	7	zeiss	zeiss	PROPN
dti-3213	138	8	;	;	PUNCT
dti-3213	138	9	lb	lb	PRON
dti-3213	138	10	is	be	AUX
dti-3213	138	11	an	an	DET
dti-3213	138	12	employee	employee	NOUN
dti-3213	138	13	at	at	ADP
dti-3213	138	14	roche	roche	PROPN
dti-3213	138	15	;	;	PUNCT
dti-3213	138	16	es	es	PRON
dti-3213	138	17	is	be	AUX
dti-3213	138	18	an	an	DET
dti-3213	138	19	employee	employee	NOUN
dti-3213	138	20	at	at	ADP
dti-3213	138	21	roche	roche	PROPN
dti-3213	138	22	;	;	PUNCT
dti-3213	138	23	gv	gv	AUX
dti-3213	138	24	is	be	AUX
dti-3213	138	25	an	an	DET
dti-3213	138	26	employee	employee	NOUN
dti-3213	138	27	at	at	ADP
dti-3213	138	28	roche	roche	PROPN
dti-3213	138	29	;	;	PUNCT
dti-3213	138	30	pl	pl	PROPN
dti-3213	138	31	aerie	aerie	PROPN
dti-3213	138	32	,	,	PUNCT
dti-3213	138	33	allergan	allergan	PROPN
dti-3213	138	34	,	,	PUNCT
dti-3213	138	35	annexon	annexon	PROPN
dti-3213	138	36	,	,	PUNCT
dti-3213	138	37	apellis	apellis	PROPN
dti-3213	138	38	,	,	PUNCT
dti-3213	138	39	bausch	bausch	PROPN
dti-3213	138	40	&	&	CCONJ
dti-3213	138	41	lomb	lomb	PROPN
dti-3213	138	42	,	,	PUNCT
dti-3213	138	43	bayer	bayer	PROPN
dti-3213	138	44	,	,	PUNCT
dti-3213	138	45	biogen	biogen	PROPN
dti-3213	138	46	,	,	PUNCT
dti-3213	138	47	boehringer	boehringer	PROPN
dti-3213	138	48	ingelheim	ingelheim	PROPN
dti-3213	138	49	,	,	PUNCT
dti-3213	138	50	eyepoint	eyepoint	NOUN
dti-3213	138	51	pharmaceuticals	pharmaceutical	NOUN
dti-3213	138	52	,	,	PUNCT
dti-3213	138	53	i	i	PRON
dti-3213	138	54	-	-	PUNCT
dti-3213	138	55	care	care	NOUN
dti-3213	138	56	,	,	PUNCT
dti-3213	138	57	genentech	genentech	NOUN
dti-3213	138	58	,	,	PUNCT
dti-3213	138	59	novartis	novartis	PROPN
dti-3213	138	60	,	,	PUNCT
dti-3213	138	61	ocular	ocular	ADJ
dti-3213	138	62	therapeutix	therapeutix	NOUN
dti-3213	138	63	,	,	PUNCT
dti-3213	138	64	outlook	outlook	NOUN
dti-3213	138	65	therapeutics	therapeutic	NOUN
dti-3213	138	66	,	,	PUNCT
dti-3213	138	67	and	and	CCONJ
dti-3213	138	68	roche	roche	PROPN
dti-3213	138	69	authors	author	NOUN
dti-3213	138	70	’	’	PART
dti-3213	138	71	contributions	contribution	NOUN
dti-3213	138	72	:	:	PUNCT
dti-3213	138	73	all	all	DET
dti-3213	138	74	authors	author	NOUN
dti-3213	138	75	contributed	contribute	VERB
dti-3213	138	76	to	to	ADP
dti-3213	138	77	conceptualization	conceptualization	NOUN
dti-3213	138	78	,	,	PUNCT
dti-3213	138	79	writing	writing	NOUN
dti-3213	138	80	—	—	PUNCT
dti-3213	138	81	review	review	NOUN
dti-3213	138	82	and	and	CCONJ
dti-3213	138	83	editing	editing	NOUN
dti-3213	138	84	.	.	PUNCT
dti-3213	139	1	cg	cg	NOUN
dti-3213	139	2	and	and	CCONJ
dti-3213	139	3	ft	ft	PROPN
dti-3213	139	4	performed	perform	VERB
dti-3213	139	5	data	data	NOUN
dti-3213	139	6	management	management	NOUN
dti-3213	139	7	and	and	CCONJ
dti-3213	139	8	statistical	statistical	ADJ
dti-3213	139	9	analysis	analysis	NOUN
dti-3213	139	10	.	.	PUNCT
dti-3213	140	1	lb	lb	X
dti-3213	140	2	,	,	PUNCT
dti-3213	140	3	es	es	NOUN
dti-3213	140	4	,	,	PUNCT
dti-3213	140	5	and	and	CCONJ
dti-3213	140	6	gv	gv	PART
dti-3213	140	7	contributed	contribute	VERB
dti-3213	140	8	to	to	ADP
dti-3213	140	9	funding	funding	NOUN
dti-3213	140	10	acquisition	acquisition	NOUN
dti-3213	140	11	,	,	PUNCT
dti-3213	140	12	project	project	NOUN
dti-3213	140	13	administration	administration	NOUN
dti-3213	140	14	,	,	PUNCT
dti-3213	140	15	resources	resource	NOUN
dti-3213	140	16	,	,	PUNCT
dti-3213	140	17	and	and	CCONJ
dti-3213	140	18	supervision	supervision	NOUN
dti-3213	140	19	.	.	PUNCT
dti-3213	141	1	all	all	DET
dti-3213	141	2	authors	author	NOUN
dti-3213	141	3	have	have	AUX
dti-3213	141	4	read	read	VERB
dti-3213	141	5	and	and	CCONJ
dti-3213	141	6	agreed	agree	VERB
dti-3213	141	7	to	to	ADP
dti-3213	141	8	the	the	DET
dti-3213	141	9	published	publish	VERB
dti-3213	141	10	version	version	NOUN
dti-3213	141	11	of	of	ADP
dti-3213	141	12	the	the	DET
dti-3213	141	13	manuscript	manuscript	NOUN
dti-3213	141	14	.	.	PUNCT
dti-3213	142	1	references	reference	NOUN
dti-3213	142	2	1	1	NUM
dti-3213	142	3	.	.	PUNCT
dti-3213	142	4	colijn	colijn	PROPN
dti-3213	142	5	jm	jm	PROPN
dti-3213	142	6	,	,	PUNCT
dti-3213	142	7	buitendijk	buitendijk	PROPN
dti-3213	142	8	ghs	ghs	PROPN
dti-3213	142	9	,	,	PUNCT
dti-3213	142	10	prokofyeva	prokofyeva	ADJ
dti-3213	142	11	e	e	NOUN
dti-3213	142	12	,	,	PUNCT
dti-3213	142	13	et	et	PROPN
dti-3213	142	14	al	al	PROPN
dti-3213	142	15	;	;	PUNCT
dti-3213	142	16	eye	eye	NOUN
dti-3213	142	17	-	-	PUNCT
dti-3213	142	18	risk	risk	NOUN
dti-3213	142	19	consortium	consortium	NOUN
dti-3213	142	20	;	;	PUNCT
dti-3213	142	21	european	european	ADJ
dti-3213	142	22	eye	eye	NOUN
dti-3213	142	23	epidemiology	epidemiology	NOUN
dti-3213	142	24	(	(	PUNCT
dti-3213	142	25	e3	e3	NOUN
dti-3213	142	26	)	)	PUNCT
dti-3213	142	27	consortium	consortium	NOUN
dti-3213	142	28	.	.	PUNCT
dti-3213	143	1	prevalence	prevalence	NOUN
dti-3213	143	2	of	of	ADP
dti-3213	143	3	age	age	NOUN
dti-3213	143	4	-	-	PUNCT
dti-3213	143	5	related	relate	VERB
dti-3213	143	6	macular	macular	ADJ
dti-3213	143	7	degeneration	degeneration	NOUN
dti-3213	143	8	in	in	ADP
dti-3213	143	9	europe	europe	PROPN
dti-3213	143	10	:	:	PUNCT
dti-3213	143	11	the	the	DET
dti-3213	143	12	past	past	NOUN
dti-3213	143	13	and	and	CCONJ
dti-3213	143	14	the	the	DET
dti-3213	143	15	future	future	NOUN
dti-3213	143	16	.	.	PUNCT
dti-3213	144	1	ophthalmology	ophthalmology	NOUN
dti-3213	144	2	.	.	PUNCT
dti-3213	145	1	2017;124(12):1753	2017;124(12):1753	X
dti-3213	145	2	-	-	SYM
dti-3213	145	3	1763	1763	NUM
dti-3213	145	4	.	.	PUNCT
dti-3213	146	1	crossref	crossref	PROPN
dti-3213	146	2	pubmed	pubmed	PROPN
dti-3213	146	3	2	2	PROPN
dti-3213	146	4	.	.	PUNCT
dti-3213	146	5	flaxman	flaxman	PROPN
dti-3213	146	6	sr	sr	PROPN
dti-3213	146	7	,	,	PUNCT
dti-3213	146	8	bourne	bourne	NOUN
dti-3213	146	9	rra	rra	PROPN
dti-3213	146	10	,	,	PUNCT
dti-3213	146	11	resnikoff	resnikoff	NOUN
dti-3213	146	12	s	s	PROPN
dti-3213	146	13	,	,	PUNCT
dti-3213	146	14	et	et	PROPN
dti-3213	146	15	al	al	PROPN
dti-3213	146	16	;	;	PUNCT
dti-3213	146	17	vision	vision	NOUN
dti-3213	146	18	loss	loss	NOUN
dti-3213	146	19	expert	expert	NOUN
dti-3213	146	20	group	group	NOUN
dti-3213	146	21	of	of	ADP
dti-3213	146	22	the	the	DET
dti-3213	146	23	global	global	ADJ
dti-3213	146	24	burden	burden	NOUN
dti-3213	146	25	of	of	ADP
dti-3213	146	26	disease	disease	NOUN
dti-3213	146	27	study	study	NOUN
dti-3213	146	28	.	.	PUNCT
dti-3213	147	1	global	global	ADJ
dti-3213	147	2	causes	cause	NOUN
dti-3213	147	3	of	of	ADP
dti-3213	147	4	blindness	blindness	NOUN
dti-3213	147	5	and	and	CCONJ
dti-3213	147	6	distance	distance	NOUN
dti-3213	147	7	vision	vision	NOUN
dti-3213	147	8	impairment	impairment	VERB
dti-3213	147	9	1990	1990	NUM
dti-3213	147	10	-	-	SYM
dti-3213	147	11	2020	2020	NUM
dti-3213	147	12	:	:	PUNCT
dti-3213	147	13	a	a	DET
dti-3213	147	14	systematic	systematic	ADJ
dti-3213	147	15	review	review	NOUN
dti-3213	147	16	and	and	CCONJ
dti-3213	147	17	meta	meta	ADJ
dti-3213	147	18	-	-	PUNCT
dti-3213	147	19	analysis	analysis	NOUN
dti-3213	147	20	.	.	PUNCT
dti-3213	148	1	lancet	lancet	NOUN
dti-3213	148	2	glob	glob	PROPN
dti-3213	148	3	health	health	NOUN
dti-3213	148	4	.	.	PUNCT
dti-3213	149	1	2017;5(12):e1221	2017;5(12):e1221	NOUN
dti-3213	149	2	-	-	PUNCT
dti-3213	149	3	e1234	e1234	PROPN
dti-3213	149	4	.	.	PUNCT
dti-3213	149	5	crossref	crossref	PROPN
dti-3213	149	6	pubmed	pubmed	PROPN
dti-3213	149	7	3	3	PROPN
dti-3213	149	8	.	.	PUNCT
dti-3213	150	1	steinmetz	steinmetz	PROPN
dti-3213	150	2	jd	jd	PROPN
dti-3213	150	3	,	,	PUNCT
dti-3213	150	4	bourne	bourne	NOUN
dti-3213	150	5	rra	rra	PROPN
dti-3213	150	6	,	,	PUNCT
dti-3213	150	7	briant	briant	PROPN
dti-3213	150	8	ps	ps	PROPN
dti-3213	150	9	,	,	PUNCT
dti-3213	150	10	et	et	PROPN
dti-3213	150	11	al	al	PROPN
dti-3213	150	12	;	;	PUNCT
dti-3213	150	13	gbd	gbd	NOUN
dti-3213	150	14	2019	2019	NUM
dti-3213	150	15	blindness	blindness	NOUN
dti-3213	150	16	and	and	CCONJ
dti-3213	150	17	vision	vision	NOUN
dti-3213	150	18	impairment	impairment	NOUN
dti-3213	150	19	collaborators	collaborator	NOUN
dti-3213	150	20	;	;	PUNCT
dti-3213	150	21	vision	vision	NOUN
dti-3213	150	22	loss	loss	NOUN
dti-3213	150	23	expert	expert	NOUN
dti-3213	150	24	group	group	NOUN
dti-3213	150	25	of	of	ADP
dti-3213	150	26	the	the	DET
dti-3213	150	27	global	global	ADJ
dti-3213	150	28	burden	burden	NOUN
dti-3213	150	29	of	of	ADP
dti-3213	150	30	disease	disease	NOUN
dti-3213	150	31	study	study	NOUN
dti-3213	150	32	.	.	PUNCT
dti-3213	151	1	causes	cause	NOUN
dti-3213	151	2	of	of	ADP
dti-3213	151	3	blindness	blindness	NOUN
dti-3213	151	4	and	and	CCONJ
dti-3213	151	5	vision	vision	NOUN
dti-3213	151	6	impairment	impairment	VERB
dti-3213	151	7	in	in	ADP
dti-3213	151	8	2020	2020	NUM
dti-3213	151	9	and	and	CCONJ
dti-3213	151	10	trends	trend	NOUN
dti-3213	151	11	over	over	ADP
dti-3213	151	12	30	30	NUM
dti-3213	151	13	years	year	NOUN
dti-3213	151	14	,	,	PUNCT
dti-3213	151	15	and	and	CCONJ
dti-3213	151	16	prevalence	prevalence	NOUN
dti-3213	151	17	of	of	ADP
dti-3213	151	18	avoidable	avoidable	ADJ
dti-3213	151	19	blindness	blindness	NOUN
dti-3213	151	20	in	in	ADP
dti-3213	151	21	relation	relation	NOUN
dti-3213	151	22	to	to	ADP
dti-3213	151	23	vision	vision	NOUN
dti-3213	151	24	2020	2020	NUM
dti-3213	151	25	:	:	PUNCT
dti-3213	151	26	the	the	DET
dti-3213	151	27	right	right	NOUN
dti-3213	151	28	to	to	PART
dti-3213	151	29	sight	sight	NOUN
dti-3213	151	30	:	:	PUNCT
dti-3213	151	31	an	an	DET
dti-3213	151	32	analysis	analysis	NOUN
dti-3213	151	33	for	for	ADP
dti-3213	151	34	the	the	DET
dti-3213	151	35	global	global	ADJ
dti-3213	151	36	burden	burden	NOUN
dti-3213	151	37	of	of	ADP
dti-3213	151	38	disease	disease	NOUN
dti-3213	151	39	study	study	NOUN
dti-3213	151	40	.	.	PUNCT
dti-3213	152	1	lancet	lancet	NOUN
dti-3213	152	2	glob	glob	PROPN
dti-3213	152	3	health	health	NOUN
dti-3213	152	4	.	.	PUNCT
dti-3213	153	1	2021;9(2):e144	2021;9(2):e144	NUM
dti-3213	153	2	-	-	PUNCT
dti-3213	153	3	e160	e160	PROPN
dti-3213	153	4	.	.	PUNCT
dti-3213	153	5	crossref	crossref	PROPN
dti-3213	153	6	pubmed	pubmed	PROPN
dti-3213	154	1	4	4	PROPN
dti-3213	154	2	.	.	PROPN
dti-3213	154	3	ambati	ambati	PROPN
dti-3213	154	4	j	j	PROPN
dti-3213	154	5	,	,	PUNCT
dti-3213	154	6	fowler	fowler	PROPN
dti-3213	154	7	bj	bj	PROPN
dti-3213	154	8	.	.	PUNCT
dti-3213	154	9	mechanisms	mechanism	NOUN
dti-3213	154	10	of	of	ADP
dti-3213	154	11	age	age	NOUN
dti-3213	154	12	-	-	PUNCT
dti-3213	154	13	related	relate	VERB
dti-3213	154	14	macular	macular	ADJ
dti-3213	154	15	degeneration	degeneration	NOUN
dti-3213	154	16	.	.	PUNCT
dti-3213	155	1	neuron	neuron	PROPN
dti-3213	155	2	.	.	PUNCT
dti-3213	156	1	2012;75(1):26	2012;75(1):26	NUM
dti-3213	156	2	-	-	SYM
dti-3213	156	3	39	39	NUM
dti-3213	156	4	.	.	PUNCT
dti-3213	157	1	crossref	crossref	PROPN
dti-3213	157	2	pubmed	pubmed	PROPN
dti-3213	157	3	5	5	PROPN
dti-3213	157	4	.	.	PUNCT
dti-3213	158	1	cheung	cheung	PROPN
dti-3213	158	2	lk	lk	PROPN
dti-3213	158	3	,	,	PUNCT
dti-3213	158	4	eaton	eaton	PROPN
dti-3213	158	5	a.	a.	PROPN
dti-3213	158	6	age	age	PROPN
dti-3213	158	7	-	-	PUNCT
dti-3213	158	8	related	relate	VERB
dti-3213	158	9	macular	macular	ADJ
dti-3213	158	10	degeneration	degeneration	NOUN
dti-3213	158	11	.	.	PUNCT
dti-3213	159	1	pharmacotherapy	pharmacotherapy	NOUN
dti-3213	159	2	.	.	PUNCT
dti-3213	160	1	2013;33(8):838	2013;33(8):838	NUM
dti-3213	160	2	-	-	SYM
dti-3213	160	3	855	855	NUM
dti-3213	160	4	.	.	PUNCT
dti-3213	161	1	crossref	crossref	PROPN
dti-3213	161	2	pubmed	pubmed	PROPN
dti-3213	161	3	6	6	NUM
dti-3213	161	4	.	.	PUNCT
dti-3213	162	1	ferris	ferris	PROPN
dti-3213	162	2	fl	fl	PROPN
dti-3213	162	3	iii	iii	PROPN
dti-3213	162	4	,	,	PUNCT
dti-3213	162	5	wilkinson	wilkinson	PROPN
dti-3213	162	6	cp	cp	PROPN
dti-3213	162	7	,	,	PUNCT
dti-3213	162	8	bird	bird	NOUN
dti-3213	162	9	a	a	PRON
dti-3213	162	10	,	,	PUNCT
dti-3213	162	11	et	et	PROPN
dti-3213	162	12	al	al	PROPN
dti-3213	162	13	;	;	PUNCT
dti-3213	162	14	beckman	beckman	PROPN
dti-3213	162	15	initiative	initiative	NOUN
dti-3213	162	16	for	for	ADP
dti-3213	162	17	macular	macular	ADJ
dti-3213	162	18	research	research	NOUN
dti-3213	162	19	classification	classification	NOUN
dti-3213	162	20	committee	committee	NOUN
dti-3213	162	21	.	.	PUNCT
dti-3213	163	1	clinical	clinical	ADJ
dti-3213	163	2	classification	classification	NOUN
dti-3213	163	3	of	of	ADP
dti-3213	163	4	age	age	NOUN
dti-3213	163	5	-	-	PUNCT
dti-3213	163	6	related	relate	VERB
dti-3213	163	7	macular	macular	ADJ
dti-3213	163	8	degeneration	degeneration	NOUN
dti-3213	163	9	.	.	PUNCT
dti-3213	164	1	ophthalmology	ophthalmology	NOUN
dti-3213	164	2	.	.	PUNCT
dti-3213	165	1	2013;120(4):844	2013;120(4):844	NUM
dti-3213	165	2	-	-	SYM
dti-3213	165	3	851	851	NUM
dti-3213	165	4	.	.	PUNCT
dti-3213	166	1	crossref	crossref	PROPN
dti-3213	166	2	pubmed	pubmed	PROPN
dti-3213	166	3	7	7	PROPN
dti-3213	166	4	.	.	PUNCT
dti-3213	167	1	gheorghe	gheorghe	PROPN
dti-3213	167	2	a	a	X
dti-3213	167	3	,	,	PUNCT
dti-3213	167	4	mahdi	mahdi	PROPN
dti-3213	167	5	l	l	PROPN
dti-3213	167	6	,	,	PUNCT
dti-3213	167	7	musat	musat	VERB
dti-3213	167	8	o.	o.	PROPN
dti-3213	167	9	age	age	NOUN
dti-3213	167	10	-	-	PUNCT
dti-3213	167	11	related	relate	VERB
dti-3213	167	12	macular	macular	ADJ
dti-3213	167	13	degeneration	degeneration	NOUN
dti-3213	167	14	.	.	PUNCT
dti-3213	168	1	rom	rom	INTJ
dti-3213	169	1	j	j	PROPN
dti-3213	169	2	ophthalmol	ophthalmol	PROPN
dti-3213	169	3	.	.	PUNCT
dti-3213	170	1	2015;59(2):74	2015;59(2):74	NUM
dti-3213	170	2	-	-	SYM
dti-3213	170	3	77	77	NUM
dti-3213	170	4	.	.	PUNCT
dti-3213	171	1	pubmed	pubmed	PROPN
dti-3213	171	2	8	8	PROPN
dti-3213	171	3	.	.	PUNCT
dti-3213	172	1	patel	patel	PROPN
dti-3213	172	2	p	p	PROPN
dti-3213	172	3	,	,	PUNCT
dti-3213	172	4	sheth	sheth	PROPN
dti-3213	172	5	v.	v.	ADP
dti-3213	172	6	new	new	ADJ
dti-3213	172	7	and	and	CCONJ
dti-3213	172	8	innovative	innovative	ADJ
dti-3213	172	9	treatments	treatment	NOUN
dti-3213	172	10	for	for	ADP
dti-3213	172	11	neovascular	neovascular	NOUN
dti-3213	172	12	age	age	NOUN
dti-3213	172	13	-	-	PUNCT
dti-3213	172	14	related	relate	VERB
dti-3213	172	15	macular	macular	ADJ
dti-3213	172	16	degeneration	degeneration	NOUN
dti-3213	172	17	(	(	PUNCT
dti-3213	172	18	namd	namd	NOUN
dti-3213	172	19	)	)	PUNCT
dti-3213	172	20	.	.	PUNCT
dti-3213	173	1	j	j	PROPN
dti-3213	173	2	clin	clin	PROPN
dti-3213	173	3	med	med	PROPN
dti-3213	173	4	.	.	PUNCT
dti-3213	174	1	2021;10(11):2436	2021;10(11):2436	NUM
dti-3213	174	2	.	.	PUNCT
dti-3213	174	3	crossref	crossref	PROPN
dti-3213	174	4	pubmed	pubmed	PROPN
dti-3213	174	5	9	9	PROPN
dti-3213	174	6	.	.	PUNCT
dti-3213	175	1	brown	brown	PROPN
dti-3213	175	2	dm	dm	PROPN
dti-3213	175	3	,	,	PUNCT
dti-3213	175	4	kaiser	kaiser	PROPN
dti-3213	175	5	pk	pk	PROPN
dti-3213	175	6	,	,	PUNCT
dti-3213	175	7	michels	michels	PROPN
dti-3213	175	8	m	m	PROPN
dti-3213	175	9	,	,	PUNCT
dti-3213	175	10	et	et	PROPN
dti-3213	175	11	al	al	PROPN
dti-3213	175	12	;	;	PUNCT
dti-3213	175	13	anchor	anchor	NOUN
dti-3213	175	14	study	study	NOUN
dti-3213	175	15	group	group	NOUN
dti-3213	175	16	.	.	PUNCT
dti-3213	176	1	ranibizumab	ranibizumab	NOUN
dti-3213	176	2	versus	versus	ADP
dti-3213	176	3	verteporfin	verteporfin	NOUN
dti-3213	176	4	for	for	ADP
dti-3213	176	5	neovascular	neovascular	NOUN
dti-3213	176	6	age	age	NOUN
dti-3213	176	7	-	-	PUNCT
dti-3213	176	8	related	relate	VERB
dti-3213	176	9	macular	macular	ADJ
dti-3213	176	10	degeneration	degeneration	NOUN
dti-3213	176	11	.	.	PUNCT
dti-3213	177	1	n	n	PROPN
dti-3213	177	2	engl	engl	PROPN
dti-3213	177	3	j	j	PROPN
dti-3213	177	4	med	med	PROPN
dti-3213	177	5	.	.	PUNCT
dti-3213	178	1	2006;355(14):1432	2006;355(14):1432	NUM
dti-3213	178	2	-	-	SYM
dti-3213	178	3	1444	1444	NUM
dti-3213	178	4	.	.	PUNCT
dti-3213	179	1	crossref	crossref	PROPN
dti-3213	179	2	pubmed	pubmed	PROPN
dti-3213	179	3	10	10	PROPN
dti-3213	179	4	.	.	PUNCT
dti-3213	180	1	busbee	busbee	PROPN
dti-3213	180	2	bg	bg	PROPN
dti-3213	180	3	,	,	PUNCT
dti-3213	180	4	ho	ho	PROPN
dti-3213	180	5	ac	ac	PROPN
dti-3213	180	6	,	,	PUNCT
dti-3213	180	7	brown	brown	ADJ
dti-3213	180	8	dm	dm	PROPN
dti-3213	180	9	,	,	PUNCT
dti-3213	180	10	et	et	PROPN
dti-3213	180	11	al	al	PROPN
dti-3213	180	12	;	;	PUNCT
dti-3213	180	13	harbor	harbor	PROPN
dti-3213	180	14	study	study	NOUN
dti-3213	180	15	group	group	NOUN
dti-3213	180	16	.	.	PUNCT
dti-3213	181	1	twelve	twelve	NUM
dti-3213	181	2	-	-	PUNCT
dti-3213	181	3	month	month	NOUN
dti-3213	181	4	efficacy	efficacy	NOUN
dti-3213	181	5	and	and	CCONJ
dti-3213	181	6	safety	safety	NOUN
dti-3213	181	7	of	of	ADP
dti-3213	181	8	0.5	0.5	NUM
dti-3213	181	9	mg	mg	NOUN
dti-3213	181	10	or	or	CCONJ
dti-3213	181	11	2.0	2.0	NUM
dti-3213	181	12	mg	mg	PROPN
dti-3213	181	13	ranibizumab	ranibizumab	NOUN
dti-3213	181	14	in	in	ADP
dti-3213	181	15	patients	patient	NOUN
dti-3213	181	16	with	with	ADP
dti-3213	181	17	subfoveal	subfoveal	NOUN
dti-3213	181	18	neovascular	neovascular	NOUN
dti-3213	181	19	age	age	NOUN
dti-3213	181	20	-	-	PUNCT
dti-3213	181	21	related	relate	VERB
dti-3213	181	22	macular	macular	ADJ
dti-3213	181	23	degeneration	degeneration	NOUN
dti-3213	181	24	.	.	PUNCT
dti-3213	182	1	ophthalmology	ophthalmology	NOUN
dti-3213	182	2	.	.	PUNCT
dti-3213	183	1	2013;120(5):1046	2013;120(5):1046	NUM
dti-3213	183	2	-	-	SYM
dti-3213	183	3	1056	1056	NUM
dti-3213	183	4	.	.	PUNCT
dti-3213	184	1	crossref	crossref	PROPN
dti-3213	184	2	pubmed	pubmed	PROPN
dti-3213	184	3	11	11	NUM
dti-3213	184	4	.	.	PUNCT
dti-3213	185	1	cohen	cohen	PROPN
dti-3213	185	2	sy	sy	PROPN
dti-3213	185	3	,	,	PUNCT
dti-3213	185	4	mimoun	mimoun	VERB
dti-3213	185	5	g	g	NOUN
dti-3213	185	6	,	,	PUNCT
dti-3213	185	7	oubraham	oubraham	PROPN
dti-3213	185	8	h	h	NOUN
dti-3213	185	9	,	,	PUNCT
dti-3213	185	10	et	et	PROPN
dti-3213	185	11	al	al	PROPN
dti-3213	185	12	;	;	PUNCT
dti-3213	185	13	lumiere	lumiere	PROPN
dti-3213	185	14	study	study	PROPN
dti-3213	185	15	group	group	NOUN
dti-3213	185	16	.	.	PUNCT
dti-3213	186	1	changes	change	NOUN
dti-3213	186	2	in	in	ADP
dti-3213	186	3	visual	visual	ADJ
dti-3213	186	4	acuity	acuity	NOUN
dti-3213	186	5	in	in	ADP
dti-3213	186	6	patients	patient	NOUN
dti-3213	186	7	with	with	ADP
dti-3213	186	8	wet	wet	ADJ
dti-3213	186	9	agerelated	agerelate	VERB
dti-3213	186	10	macular	macular	ADJ
dti-3213	186	11	degeneration	degeneration	NOUN
dti-3213	186	12	treated	treat	VERB
dti-3213	186	13	with	with	ADP
dti-3213	186	14	intravitreal	intravitreal	ADJ
dti-3213	186	15	ranibizumab	ranibizumab	NOUN
dti-3213	186	16	in	in	ADP
dti-3213	186	17	daily	daily	ADJ
dti-3213	186	18	clinical	clinical	ADJ
dti-3213	186	19	practice	practice	NOUN
dti-3213	186	20	:	:	PUNCT
dti-3213	186	21	the	the	DET
dti-3213	186	22	lumiere	lumiere	PROPN
dti-3213	186	23	study	study	PROPN
dti-3213	186	24	.	.	PUNCT
dti-3213	187	1	retina	retina	VERB
dti-3213	187	2	.	.	PUNCT
dti-3213	188	1	2013;33(3):474	2013;33(3):474	PROPN
dti-3213	188	2	-	-	PUNCT
dti-3213	188	3	481	481	PROPN
dti-3213	188	4	.	.	PUNCT
dti-3213	189	1	crossref	crossref	PROPN
dti-3213	189	2	pubmed	pubmed	PROPN
dti-3213	189	3	12	12	NUM
dti-3213	189	4	.	.	PUNCT
dti-3213	190	1	dugel	dugel	PROPN
dti-3213	190	2	pu	pu	PROPN
dti-3213	190	3	,	,	PUNCT
dti-3213	190	4	koh	koh	PROPN
dti-3213	190	5	a	a	X
dti-3213	190	6	,	,	PUNCT
dti-3213	190	7	ogura	ogura	PROPN
dti-3213	190	8	y	y	PROPN
dti-3213	190	9	,	,	PUNCT
dti-3213	190	10	et	et	PROPN
dti-3213	190	11	al	al	PROPN
dti-3213	190	12	;	;	PUNCT
dti-3213	190	13	hawk	hawk	NOUN
dti-3213	190	14	and	and	CCONJ
dti-3213	190	15	harrier	harrier	PROPN
dti-3213	190	16	study	study	NOUN
dti-3213	190	17	investigators	investigator	NOUN
dti-3213	190	18	.	.	PUNCT
dti-3213	191	1	hawk	hawk	NOUN
dti-3213	191	2	and	and	CCONJ
dti-3213	191	3	harrier	harrier	NOUN
dti-3213	191	4	:	:	PUNCT
dti-3213	191	5	phase	phase	NOUN
dti-3213	191	6	3	3	NUM
dti-3213	191	7	,	,	PUNCT
dti-3213	191	8	multicenter	multicenter	NOUN
dti-3213	191	9	,	,	PUNCT
dti-3213	191	10	randomized	randomize	VERB
dti-3213	191	11	,	,	PUNCT
dti-3213	191	12	double	double	ADJ
dti-3213	191	13	-	-	PUNCT
dti-3213	191	14	masked	mask	VERB
dti-3213	191	15	trials	trial	NOUN
dti-3213	191	16	of	of	ADP
dti-3213	191	17	brolucizumab	brolucizumab	NOUN
dti-3213	191	18	for	for	ADP
dti-3213	191	19	neovascular	neovascular	NOUN
dti-3213	191	20	age	age	NOUN
dti-3213	191	21	-	-	PUNCT
dti-3213	191	22	related	relate	VERB
dti-3213	191	23	macular	macular	ADJ
dti-3213	191	24	degeneration	degeneration	NOUN
dti-3213	191	25	.	.	PUNCT
dti-3213	192	1	ophthalmology	ophthalmology	NOUN
dti-3213	192	2	.	.	PUNCT
dti-3213	193	1	2020;127(1):72	2020;127(1):72	NUM
dti-3213	193	2	-	-	SYM
dti-3213	193	3	84	84	NUM
dti-3213	193	4	.	.	PUNCT
dti-3213	194	1	crossref	crossref	PROPN
dti-3213	194	2	pubmed	pubmed	PROPN
dti-3213	194	3	13	13	NUM
dti-3213	194	4	.	.	PUNCT
dti-3213	195	1	heier	heier	PROPN
dti-3213	195	2	js	js	PROPN
dti-3213	195	3	,	,	PUNCT
dti-3213	195	4	brown	brown	ADJ
dti-3213	195	5	dm	dm	PROPN
dti-3213	195	6	,	,	PUNCT
dti-3213	195	7	chong	chong	PROPN
dti-3213	195	8	v	v	PROPN
dti-3213	195	9	,	,	PUNCT
dti-3213	195	10	et	et	PROPN
dti-3213	195	11	al	al	PROPN
dti-3213	195	12	;	;	PUNCT
dti-3213	195	13	view	view	NOUN
dti-3213	195	14	1	1	NUM
dti-3213	195	15	and	and	CCONJ
dti-3213	195	16	view	view	VERB
dti-3213	195	17	2	2	NUM
dti-3213	195	18	study	study	NOUN
dti-3213	195	19	groups	group	NOUN
dti-3213	195	20	.	.	PUNCT
dti-3213	196	1	intravitreal	intravitreal	ADJ
dti-3213	196	2	aflibercept	aflibercept	PROPN
dti-3213	196	3	(	(	PUNCT
dti-3213	196	4	vegf	vegf	PROPN
dti-3213	196	5	trap	trap	NOUN
dti-3213	196	6	-	-	PUNCT
dti-3213	196	7	eye	eye	NOUN
dti-3213	196	8	)	)	PUNCT
dti-3213	196	9	in	in	ADP
dti-3213	196	10	wet	wet	ADJ
dti-3213	196	11	agerelated	agerelate	VERB
dti-3213	196	12	macular	macular	ADJ
dti-3213	196	13	degeneration	degeneration	NOUN
dti-3213	196	14	.	.	PUNCT
dti-3213	197	1	ophthalmology	ophthalmology	NOUN
dti-3213	197	2	.	.	PUNCT
dti-3213	198	1	2012;119(12	2012;119(12	NUM
dti-3213	198	2	):	):	PUNCT
dti-3213	198	3	2537	2537	NUM
dti-3213	198	4	-	-	SYM
dti-3213	198	5	2548	2548	NUM
dti-3213	198	6	.	.	PUNCT
dti-3213	199	1	crossref	crossref	PROPN
dti-3213	199	2	pubmed	pubmed	PROPN
dti-3213	199	3	14	14	PROPN
dti-3213	199	4	.	.	PUNCT
dti-3213	200	1	holz	holz	PROPN
dti-3213	200	2	fg	fg	PROPN
dti-3213	200	3	,	,	PUNCT
dti-3213	200	4	tadayoni	tadayoni	PROPN
dti-3213	200	5	r	r	NOUN
dti-3213	200	6	,	,	PUNCT
dti-3213	200	7	beatty	beatty	PROPN
dti-3213	200	8	s	s	PROPN
dti-3213	200	9	,	,	PUNCT
dti-3213	200	10	et	et	PROPN
dti-3213	200	11	al	al	PROPN
dti-3213	200	12	.	.	PUNCT
dti-3213	201	1	multi	multi	ADJ
dti-3213	201	2	-	-	ADJ
dti-3213	201	3	country	country	ADJ
dti-3213	201	4	real	real	ADJ
dti-3213	201	5	-	-	PUNCT
dti-3213	201	6	life	life	NOUN
dti-3213	201	7	experience	experience	NOUN
dti-3213	201	8	of	of	ADP
dti-3213	201	9	anti	anti	ADJ
dti-3213	201	10	-	-	ADJ
dti-3213	201	11	vascular	vascular	ADJ
dti-3213	201	12	endothelial	endothelial	ADJ
dti-3213	201	13	growth	growth	NOUN
dti-3213	201	14	factor	factor	NOUN
dti-3213	201	15	therapy	therapy	NOUN
dti-3213	201	16	for	for	ADP
dti-3213	201	17	wet	wet	ADJ
dti-3213	201	18	age	age	NOUN
dti-3213	201	19	-	-	PUNCT
dti-3213	201	20	related	relate	VERB
dti-3213	201	21	macular	macular	ADJ
dti-3213	201	22	degeneration	degeneration	NOUN
dti-3213	201	23	.	.	PUNCT
dti-3213	202	1	br	br	PROPN
dti-3213	203	1	j	j	PROPN
dti-3213	203	2	ophthalmol	ophthalmol	PROPN
dti-3213	203	3	.	.	PUNCT
dti-3213	204	1	2015;99(2):220	2015;99(2):220	PROPN
dti-3213	204	2	-	-	PUNCT
dti-3213	204	3	226	226	NUM
dti-3213	204	4	.	.	PUNCT
dti-3213	205	1	crossref	crossref	PROPN
dti-3213	205	2	pubmed	pubmed	PROPN
dti-3213	205	3	15	15	PROPN
dti-3213	205	4	.	.	PUNCT
dti-3213	206	1	rosenfeld	rosenfeld	PROPN
dti-3213	206	2	pj	pj	PROPN
dti-3213	206	3	,	,	PUNCT
dti-3213	206	4	brown	brown	PROPN
dti-3213	206	5	dm	dm	PROPN
dti-3213	206	6	,	,	PUNCT
dti-3213	206	7	heier	heier	ADV
dti-3213	206	8	js	js	PROPN
dti-3213	206	9	,	,	PUNCT
dti-3213	206	10	et	et	PROPN
dti-3213	206	11	al	al	PROPN
dti-3213	206	12	;	;	PUNCT
dti-3213	206	13	marina	marina	PROPN
dti-3213	206	14	study	study	PROPN
dti-3213	206	15	group	group	PROPN
dti-3213	206	16	.	.	PUNCT
dti-3213	207	1	ranibizumab	ranibizumab	NOUN
dti-3213	207	2	for	for	ADP
dti-3213	207	3	neovascular	neovascular	NOUN
dti-3213	207	4	age	age	NOUN
dti-3213	207	5	-	-	PUNCT
dti-3213	207	6	related	relate	VERB
dti-3213	207	7	macular	macular	ADJ
dti-3213	207	8	degeneration	degeneration	NOUN
dti-3213	207	9	.	.	PUNCT
dti-3213	208	1	n	n	PROPN
dti-3213	208	2	engl	engl	PROPN
dti-3213	208	3	j	j	PROPN
dti-3213	208	4	med	med	PROPN
dti-3213	208	5	.	.	PUNCT
dti-3213	209	1	2006;355(14):1419	2006;355(14):1419	NUM
dti-3213	209	2	-	-	PUNCT
dti-3213	209	3	1431	1431	NUM
dti-3213	209	4	.	.	PUNCT
dti-3213	210	1	crossref	crossref	PROPN
dti-3213	210	2	pubmed	pubmed	PROPN
dti-3213	210	3	https://doi.org/10.1016/j.ophtha.2017.05.035	https://doi.org/10.1016/j.ophtha.2017.05.035	PROPN
dti-3213	210	4	https://www.ncbi.nlm.nih.gov/pubmed/28712657	https://www.ncbi.nlm.nih.gov/pubmed/28712657	PROPN
dti-3213	210	5	https://doi.org/10.1016/s2214-109x(17)30393-5	https://doi.org/10.1016/s2214-109x(17)30393-5	NOUN
dti-3213	210	6	https://www.ncbi.nlm.nih.gov/pubmed/29032195	https://www.ncbi.nlm.nih.gov/pubmed/29032195	NUM
dti-3213	210	7	https://doi.org/10.1016/s2214-109x(20)30489-7	https://doi.org/10.1016/s2214-109x(20)30489-7	PROPN
dti-3213	210	8	https://www.ncbi.nlm.nih.gov/pubmed/33275949	https://www.ncbi.nlm.nih.gov/pubmed/33275949	NUM
dti-3213	210	9	https://doi.org/10.1016/j.neuron.2012.06.018	https://doi.org/10.1016/j.neuron.2012.06.018	NOUN
dti-3213	210	10	https://www.ncbi.nlm.nih.gov/pubmed/22794258	https://www.ncbi.nlm.nih.gov/pubmed/22794258	X
dti-3213	210	11	https://doi.org/10.1002/phar.1264	https://doi.org/10.1002/phar.1264	NOUN
dti-3213	210	12	https://www.ncbi.nlm.nih.gov/pubmed/23580402	https://www.ncbi.nlm.nih.gov/pubmed/23580402	X
dti-3213	210	13	https://doi.org/10.1016/j.ophtha.2012.10.036	https://doi.org/10.1016/j.ophtha.2012.10.036	PROPN
dti-3213	210	14	https://www.ncbi.nlm.nih.gov/pubmed/23332590	https://www.ncbi.nlm.nih.gov/pubmed/23332590	NUM
dti-3213	210	15	https://www.ncbi.nlm.nih.gov/pubmed/26978865	https://www.ncbi.nlm.nih.gov/pubmed/26978865	NUM
dti-3213	210	16	https://doi.org/10.3390/jcm10112436	https://doi.org/10.3390/jcm10112436	ADJ
dti-3213	210	17	https://www.ncbi.nlm.nih.gov/pubmed/34070899	https://www.ncbi.nlm.nih.gov/pubmed/34070899	NUM
dti-3213	210	18	https://doi.org/10.1056/nejmoa062655	https://doi.org/10.1056/nejmoa062655	NOUN
dti-3213	210	19	https://www.ncbi.nlm.nih.gov/pubmed/17021319	https://www.ncbi.nlm.nih.gov/pubmed/17021319	PROPN
dti-3213	210	20	https://doi.org/10.1016/j.ophtha.2012.10.014	https://doi.org/10.1016/j.ophtha.2012.10.014	PROPN
dti-3213	210	21	https://www.ncbi.nlm.nih.gov/pubmed/23352196	https://www.ncbi.nlm.nih.gov/pubmed/23352196	X
dti-3213	210	22	https://doi.org/10.1097/iae.0b013e31827b6324	https://doi.org/10.1097/iae.0b013e31827b6324	PROPN
dti-3213	210	23	https://www.ncbi.nlm.nih.gov/pubmed/23266880	https://www.ncbi.nlm.nih.gov/pubmed/23266880	NUM
dti-3213	210	24	https://doi.org/10.1016/j.ophtha.2019.04.017	https://doi.org/10.1016/j.ophtha.2019.04.017	NUM
dti-3213	210	25	https://www.ncbi.nlm.nih.gov/pubmed/30986442	https://www.ncbi.nlm.nih.gov/pubmed/30986442	NUM
dti-3213	210	26	https://doi.org/10.1016/j.ophtha.2012.09.006	https://doi.org/10.1016/j.ophtha.2012.09.006	PROPN
dti-3213	210	27	https://www.ncbi.nlm.nih.gov/pubmed/23084240	https://www.ncbi.nlm.nih.gov/pubmed/23084240	NUM
dti-3213	210	28	https://doi.org/10.1136/bjophthalmol-2014-305327	https://doi.org/10.1136/bjophthalmol-2014-305327	PROPN
dti-3213	210	29	https://www.ncbi.nlm.nih.gov/pubmed/25193672	https://www.ncbi.nlm.nih.gov/pubmed/25193672	NUM
dti-3213	210	30	https://doi.org/10.1056/nejmoa054481	https://doi.org/10.1056/nejmoa054481	NOUN
dti-3213	210	31	https://www.ncbi.nlm.nih.gov/pubmed/17021318	https://www.ncbi.nlm.nih.gov/pubmed/17021318	NUM
dti-3213	210	32	galeone	galeone	NOUN
dti-3213	210	33	et	et	NOUN
dti-3213	210	34	al	al	PROPN
dti-3213	210	35	drug	drug	PROPN
dti-3213	210	36	target	target	NOUN
dti-3213	210	37	insights	insight	NOUN
dti-3213	210	38	2024	2024	NUM
dti-3213	210	39	;	;	PUNCT
dti-3213	210	40	18	18	NUM
dti-3213	210	41	:	:	SYM
dti-3213	210	42	111	111	NUM
dti-3213	210	43	©	©	PROPN
dti-3213	210	44	2024	2024	NUM
dti-3213	210	45	the	the	DET
dti-3213	210	46	authors	author	NOUN
dti-3213	210	47	.	.	PUNCT
dti-3213	211	1	published	publish	VERB
dti-3213	211	2	by	by	ADP
dti-3213	211	3	aboutscience	aboutscience	NOUN
dti-3213	211	4	www.aboutscience.eu	www.aboutscience.eu	PROPN
dti-3213	211	5	16	16	NUM
dti-3213	211	6	.	.	PUNCT
dti-3213	212	1	staurenghi	staurenghi	PROPN
dti-3213	212	2	g	g	PROPN
dti-3213	212	3	,	,	PUNCT
dti-3213	212	4	bandello	bandello	PROPN
dti-3213	212	5	f	f	PROPN
dti-3213	212	6	,	,	PUNCT
dti-3213	212	7	viola	viola	PROPN
dti-3213	212	8	f	f	PROPN
dti-3213	212	9	,	,	PUNCT
dti-3213	212	10	et	et	PROPN
dti-3213	212	11	al	al	PROPN
dti-3213	212	12	.	.	PROPN
dti-3213	213	1	effectiveness	effectiveness	NOUN
dti-3213	213	2	of	of	ADP
dti-3213	213	3	antivascular	antivascular	ADJ
dti-3213	213	4	endothelial	endothelial	ADJ
dti-3213	213	5	growth	growth	NOUN
dti-3213	213	6	factors	factor	NOUN
dti-3213	213	7	in	in	ADP
dti-3213	213	8	neovascular	neovascular	NOUN
dti-3213	213	9	age	age	NOUN
dti-3213	213	10	-	-	PUNCT
dti-3213	213	11	related	relate	VERB
dti-3213	213	12	macular	macular	ADJ
dti-3213	213	13	degeneration	degeneration	NOUN
dti-3213	213	14	and	and	CCONJ
dti-3213	213	15	variables	variable	NOUN
dti-3213	213	16	associated	associate	VERB
dti-3213	213	17	with	with	ADP
dti-3213	213	18	visual	visual	ADJ
dti-3213	213	19	acuity	acuity	NOUN
dti-3213	213	20	outcomes	outcome	NOUN
dti-3213	213	21	:	:	PUNCT
dti-3213	213	22	results	result	NOUN
dti-3213	213	23	from	from	ADP
dti-3213	213	24	the	the	DET
dti-3213	213	25	eagle	eagle	PROPN
dti-3213	213	26	study	study	NOUN
dti-3213	213	27	.	.	PUNCT
dti-3213	214	1	khetan	khetan	PROPN
dti-3213	214	2	v	v	PROPN
dti-3213	214	3	,	,	PUNCT
dti-3213	214	4	ed	ed	NOUN
dti-3213	214	5	.	.	PUNCT
dti-3213	215	1	plos	plos	PROPN
dti-3213	215	2	one	one	NUM
dti-3213	215	3	.	.	PUNCT
dti-3213	216	1	2021;16(9):e0256461	2021;16(9):e0256461	X
dti-3213	216	2	.	.	PROPN
dti-3213	216	3	crossref	crossref	PROPN
dti-3213	216	4	pubmed	pubmed	PROPN
dti-3213	216	5	17	17	NUM
dti-3213	216	6	.	.	PUNCT
dti-3213	217	1	martin	martin	PROPN
dti-3213	217	2	df	df	PROPN
dti-3213	217	3	,	,	PUNCT
dti-3213	217	4	maguire	maguire	NOUN
dti-3213	217	5	mg	mg	PROPN
dti-3213	217	6	,	,	PUNCT
dti-3213	217	7	ying	ying	PROPN
dti-3213	217	8	gs	gs	PROPN
dti-3213	217	9	,	,	PUNCT
dti-3213	217	10	grunwald	grunwald	PROPN
dti-3213	217	11	je	je	PROPN
dti-3213	217	12	,	,	PUNCT
dti-3213	217	13	fine	fine	ADJ
dti-3213	217	14	sl	sl	NOUN
dti-3213	217	15	,	,	PUNCT
dti-3213	217	16	jaffe	jaffe	PROPN
dti-3213	217	17	gj	gj	PROPN
dti-3213	217	18	;	;	PUNCT
dti-3213	217	19	catt	catt	PROPN
dti-3213	217	20	research	research	NOUN
dti-3213	217	21	group	group	NOUN
dti-3213	217	22	.	.	PUNCT
dti-3213	218	1	ranibizumab	ranibizumab	NOUN
dti-3213	218	2	and	and	CCONJ
dti-3213	218	3	bevacizumab	bevacizumab	NOUN
dti-3213	218	4	for	for	ADP
dti-3213	218	5	neovascular	neovascular	PROPN
dti-3213	218	6	age	age	NOUN
dti-3213	218	7	-	-	PUNCT
dti-3213	218	8	related	relate	VERB
dti-3213	218	9	macular	macular	ADJ
dti-3213	218	10	degeneration	degeneration	NOUN
dti-3213	218	11	.	.	PUNCT
dti-3213	219	1	n	n	PROPN
dti-3213	219	2	engl	engl	PROPN
dti-3213	219	3	j	j	PROPN
dti-3213	219	4	med	med	PROPN
dti-3213	219	5	.	.	PUNCT
dti-3213	220	1	2011;364(20):1897	2011;364(20):1897	X
dti-3213	220	2	-	-	SYM
dti-3213	220	3	1908	1908	NUM
dti-3213	220	4	.	.	PUNCT
dti-3213	221	1	crossref	crossref	PROPN
dti-3213	221	2	pubmed	pubmed	PROPN
dti-3213	221	3	18	18	NUM
dti-3213	221	4	.	.	PUNCT
dti-3213	222	1	calabria	calabria	PROPN
dti-3213	222	2	s	s	PROPN
dti-3213	222	3	,	,	PUNCT
dti-3213	222	4	ronconi	ronconi	VERB
dti-3213	222	5	g	g	PROPN
dti-3213	222	6	,	,	PUNCT
dti-3213	222	7	dondi	dondi	PROPN
dti-3213	222	8	l	l	PROPN
dti-3213	222	9	,	,	PUNCT
dti-3213	222	10	et	et	PROPN
dti-3213	222	11	al	al	PROPN
dti-3213	222	12	.	.	PUNCT
dti-3213	223	1	la	la	PROPN
dti-3213	223	2	popolazione	popolazione	PROPN
dti-3213	223	3	con	con	PROPN
dti-3213	223	4	degenerazione	degenerazione	PROPN
dti-3213	223	5	maculare	maculare	PROPN
dti-3213	223	6	neovascolare	neovascolare	PROPN
dti-3213	223	7	correlata	correlata	PROPN
dti-3213	223	8	all’età	all’età	PROPN
dti-3213	223	9	trattata	trattata	PROPN
dti-3213	223	10	con	con	PROPN
dti-3213	223	11	anti	anti	PROPN
dti-3213	223	12	-	-	PROPN
dti-3213	223	13	vegf	vegf	ADJ
dti-3213	223	14	attraverso	attraverso	PROPN
dti-3213	223	15	i	i	PROPN
dti-3213	223	16	dati	dati	PROPN
dti-3213	223	17	amministrativi	amministrativi	PROPN
dti-3213	223	18	sanitari	sanitari	PROPN
dti-3213	223	19	.	.	PUNCT
dti-3213	224	1	recenti	recenti	PROPN
dti-3213	224	2	prog	prog	PROPN
dti-3213	224	3	med	med	PROPN
dti-3213	224	4	.	.	PUNCT
dti-3213	225	1	2023;114(7):447	2023;114(7):447	NUM
dti-3213	225	2	-	-	SYM
dti-3213	225	3	461	461	NUM
dti-3213	225	4	.	.	PUNCT
dti-3213	226	1	pubmed	pubmed	PROPN
dti-3213	226	2	19	19	NUM
dti-3213	226	3	.	.	PUNCT
dti-3213	227	1	kodjikian	kodjikian	PROPN
dti-3213	227	2	l	l	PROPN
dti-3213	227	3	,	,	PUNCT
dti-3213	227	4	mehanna	mehanna	PROPN
dti-3213	227	5	cj	cj	PROPN
dti-3213	227	6	,	,	PUNCT
dti-3213	227	7	cohen	cohen	PROPN
dti-3213	227	8	sy	sy	PROPN
dti-3213	227	9	,	,	PUNCT
dti-3213	227	10	et	et	PROPN
dti-3213	227	11	al	al	PROPN
dti-3213	227	12	.	.	PUNCT
dti-3213	228	1	the	the	DET
dti-3213	228	2	role	role	NOUN
dti-3213	228	3	of	of	ADP
dti-3213	228	4	future	future	ADJ
dti-3213	228	5	treatments	treatment	NOUN
dti-3213	228	6	in	in	ADP
dti-3213	228	7	the	the	DET
dti-3213	228	8	management	management	NOUN
dti-3213	228	9	of	of	ADP
dti-3213	228	10	neovascular	neovascular	NOUN
dti-3213	228	11	age	age	NOUN
dti-3213	228	12	-	-	PUNCT
dti-3213	228	13	related	relate	VERB
dti-3213	228	14	macular	macular	ADJ
dti-3213	228	15	degeneration	degeneration	NOUN
dti-3213	228	16	in	in	ADP
dti-3213	228	17	europe	europe	PROPN
dti-3213	228	18	.	.	PUNCT
dti-3213	229	1	eur	eur	PROPN
dti-3213	229	2	j	j	PROPN
dti-3213	229	3	ophthalmol	ophthalmol	PROPN
dti-3213	229	4	.	.	PUNCT
dti-3213	230	1	2021;31(5	2021;31(5	NUM
dti-3213	230	2	):	):	PUNCT
dti-3213	230	3	2179	2179	NUM
dti-3213	230	4	-	-	SYM
dti-3213	230	5	2188	2188	NUM
dti-3213	230	6	.	.	PUNCT
dti-3213	231	1	crossref	crossref	PROPN
dti-3213	231	2	pubmed	pubmed	PROPN
dti-3213	231	3	20	20	PROPN
dti-3213	231	4	.	.	PUNCT
dti-3213	232	1	lanzetta	lanzetta	PROPN
dti-3213	233	1	p.	p.	NOUN
dti-3213	233	2	anti	anti	ADJ
dti-3213	233	3	-	-	ADJ
dti-3213	233	4	vegf	vegf	ADJ
dti-3213	233	5	therapies	therapy	NOUN
dti-3213	233	6	for	for	ADP
dti-3213	233	7	age	age	NOUN
dti-3213	233	8	-	-	PUNCT
dti-3213	233	9	related	relate	VERB
dti-3213	233	10	macular	macular	ADJ
dti-3213	233	11	degeneration	degeneration	NOUN
dti-3213	233	12	:	:	PUNCT
dti-3213	233	13	a	a	DET
dti-3213	233	14	powerful	powerful	ADJ
dti-3213	233	15	tactical	tactical	ADJ
dti-3213	233	16	gear	gear	NOUN
dti-3213	233	17	or	or	CCONJ
dti-3213	233	18	a	a	DET
dti-3213	233	19	blunt	blunt	ADJ
dti-3213	233	20	weapon	weapon	NOUN
dti-3213	233	21	?	?	PUNCT
dti-3213	234	1	the	the	DET
dti-3213	234	2	choice	choice	NOUN
dti-3213	234	3	is	be	AUX
dti-3213	234	4	ours	ours	PRON
dti-3213	234	5	.	.	PUNCT
dti-3213	235	1	graefes	graefes	PROPN
dti-3213	235	2	arch	arch	PROPN
dti-3213	235	3	clin	clin	PROPN
dti-3213	235	4	exp	exp	PROPN
dti-3213	235	5	ophthalmol	ophthalmol	PROPN
dti-3213	235	6	.	.	PUNCT
dti-3213	236	1	2021;259(12	2021;259(12	PROPN
dti-3213	236	2	):	):	PUNCT
dti-3213	236	3	3561	3561	NUM
dti-3213	236	4	-	-	SYM
dti-3213	236	5	3567	3567	NUM
dti-3213	236	6	.	.	PUNCT
dti-3213	237	1	crossref	crossref	PROPN
dti-3213	237	2	pubmed	pubmed	PROPN
dti-3213	237	3	21	21	NUM
dti-3213	237	4	.	.	PUNCT
dti-3213	238	1	daien	daien	PROPN
dti-3213	238	2	v	v	NOUN
dti-3213	238	3	,	,	PUNCT
dti-3213	238	4	finger	finger	NOUN
dti-3213	238	5	rp	rp	NOUN
dti-3213	238	6	,	,	PUNCT
dti-3213	238	7	talks	talk	NOUN
dti-3213	238	8	js	js	PROPN
dti-3213	238	9	,	,	PUNCT
dti-3213	238	10	et	et	PROPN
dti-3213	238	11	al	al	PROPN
dti-3213	238	12	.	.	PROPN
dti-3213	239	1	evolution	evolution	NOUN
dti-3213	239	2	of	of	ADP
dti-3213	239	3	treatment	treatment	NOUN
dti-3213	239	4	paradigms	paradigm	NOUN
dti-3213	239	5	in	in	ADP
dti-3213	239	6	neovascular	neovascular	PROPN
dti-3213	239	7	age	age	NOUN
dti-3213	239	8	-	-	PUNCT
dti-3213	239	9	related	relate	VERB
dti-3213	239	10	macular	macular	ADJ
dti-3213	239	11	degeneration	degeneration	NOUN
dti-3213	239	12	:	:	PUNCT
dti-3213	239	13	a	a	DET
dti-3213	239	14	review	review	NOUN
dti-3213	239	15	of	of	ADP
dti-3213	239	16	real	real	ADJ
dti-3213	239	17	-	-	PUNCT
dti-3213	239	18	world	world	NOUN
dti-3213	239	19	evidence	evidence	NOUN
dti-3213	239	20	.	.	PUNCT
dti-3213	240	1	br	br	PROPN
dti-3213	241	1	j	j	PROPN
dti-3213	241	2	ophthalmol	ophthalmol	PROPN
dti-3213	241	3	.	.	PUNCT
dti-3213	242	1	2021;105(11	2021;105(11	NOUN
dti-3213	242	2	):	):	PUNCT
dti-3213	242	3	1475	1475	NUM
dti-3213	242	4	-	-	SYM
dti-3213	242	5	1479	1479	NUM
dti-3213	242	6	.	.	PUNCT
dti-3213	243	1	crossref	crossref	PROPN
dti-3213	243	2	pubmed	pubmed	PROPN
dti-3213	243	3	22	22	NUM
dti-3213	243	4	.	.	PUNCT
dti-3213	244	1	kertes	kertes	PROPN
dti-3213	244	2	pj	pj	PROPN
dti-3213	244	3	,	,	PUNCT
dti-3213	244	4	galic	galic	ADJ
dti-3213	244	5	ij	ij	NOUN
dti-3213	244	6	,	,	PUNCT
dti-3213	244	7	greve	greve	PROPN
dti-3213	244	8	m	m	PROPN
dti-3213	244	9	,	,	PUNCT
dti-3213	244	10	et	et	PROPN
dti-3213	244	11	al	al	PROPN
dti-3213	244	12	.	.	PROPN
dti-3213	244	13	efficacy	efficacy	NOUN
dti-3213	244	14	of	of	ADP
dti-3213	244	15	a	a	DET
dti-3213	244	16	treat	treat	NOUN
dti-3213	244	17	-	-	PUNCT
dti-3213	244	18	and	and	CCONJ
dti-3213	244	19	-	-	PUNCT
dti-3213	244	20	extend	extend	VERB
dti-3213	244	21	regimen	regiman	NOUN
dti-3213	244	22	with	with	ADP
dti-3213	244	23	ranibizumab	ranibizumab	NOUN
dti-3213	244	24	in	in	ADP
dti-3213	244	25	patients	patient	NOUN
dti-3213	244	26	with	with	ADP
dti-3213	244	27	neovascular	neovascular	PROPN
dti-3213	244	28	agerelated	agerelate	VERB
dti-3213	244	29	macular	macular	ADJ
dti-3213	244	30	disease	disease	NOUN
dti-3213	244	31	:	:	PUNCT
dti-3213	244	32	a	a	DET
dti-3213	244	33	randomized	randomized	ADJ
dti-3213	244	34	clinical	clinical	ADJ
dti-3213	244	35	trial	trial	NOUN
dti-3213	244	36	.	.	PUNCT
dti-3213	245	1	jama	jama	PROPN
dti-3213	245	2	ophthalmol	ophthalmol	PROPN
dti-3213	245	3	.	.	PUNCT
dti-3213	246	1	2020;138(3):244	2020;138(3):244	NUM
dti-3213	246	2	-	-	PUNCT
dti-3213	246	3	250	250	NUM
dti-3213	246	4	.	.	PUNCT
dti-3213	247	1	crossref	crossref	PROPN
dti-3213	247	2	pubmed	pubmed	PROPN
dti-3213	247	3	23	23	NUM
dti-3213	247	4	.	.	PUNCT
dti-3213	248	1	kim	kim	PROPN
dti-3213	248	2	ln	ln	PROPN
dti-3213	248	3	,	,	PUNCT
dti-3213	248	4	mehta	mehta	PROPN
dti-3213	248	5	h	h	PROPN
dti-3213	248	6	,	,	PUNCT
dti-3213	248	7	barthelmes	barthelme	NOUN
dti-3213	248	8	d	d	NOUN
dti-3213	248	9	,	,	PUNCT
dti-3213	248	10	nguyen	nguyen	NOUN
dti-3213	248	11	v	v	NOUN
dti-3213	248	12	,	,	PUNCT
dti-3213	248	13	gillies	gillie	NOUN
dti-3213	248	14	mc	mc	PROPN
dti-3213	248	15	.	.	PROPN
dti-3213	248	16	metaanalysis	metaanalysis	NOUN
dti-3213	248	17	of	of	ADP
dti-3213	248	18	real	real	ADJ
dti-3213	248	19	-	-	PUNCT
dti-3213	248	20	world	world	NOUN
dti-3213	248	21	outcomes	outcome	NOUN
dti-3213	248	22	of	of	ADP
dti-3213	248	23	intravitreal	intravitreal	ADJ
dti-3213	248	24	ranibizumab	ranibizumab	NOUN
dti-3213	248	25	for	for	ADP
dti-3213	248	26	the	the	DET
dti-3213	248	27	treatment	treatment	NOUN
dti-3213	248	28	of	of	ADP
dti-3213	248	29	neovascular	neovascular	NOUN
dti-3213	248	30	age	age	NOUN
dti-3213	248	31	-	-	PUNCT
dti-3213	248	32	related	relate	VERB
dti-3213	248	33	macular	macular	ADJ
dti-3213	248	34	degeneration	degeneration	NOUN
dti-3213	248	35	.	.	PUNCT
dti-3213	249	1	retina	retina	VERB
dti-3213	249	2	.	.	PUNCT
dti-3213	250	1	2016;36(8):1418	2016;36(8):1418	NUM
dti-3213	250	2	-	-	SYM
dti-3213	250	3	1431	1431	NUM
dti-3213	250	4	.	.	PUNCT
dti-3213	251	1	crossref	crossref	PROPN
dti-3213	251	2	pubmed	pubmed	PROPN
dti-3213	251	3	24	24	NUM
dti-3213	251	4	.	.	PUNCT
dti-3213	252	1	okada	okada	PROPN
dti-3213	252	2	m	m	PROPN
dti-3213	252	3	,	,	PUNCT
dti-3213	252	4	kandasamy	kandasamy	ADJ
dti-3213	252	5	r	r	NOUN
dti-3213	252	6	,	,	PUNCT
dti-3213	252	7	chong	chong	PROPN
dti-3213	252	8	ew	ew	PROPN
dti-3213	252	9	,	,	PUNCT
dti-3213	252	10	mcguiness	mcguiness	PROPN
dti-3213	252	11	m	m	PROPN
dti-3213	252	12	,	,	PUNCT
dti-3213	252	13	guymer	guymer	NOUN
dti-3213	252	14	rh	rh	PROPN
dti-3213	252	15	.	.	PUNCT
dti-3213	253	1	the	the	DET
dti-3213	253	2	treat	treat	NOUN
dti-3213	253	3	-	-	PUNCT
dti-3213	253	4	and	and	CCONJ
dti-3213	253	5	-	-	PUNCT
dti-3213	253	6	extend	extend	VERB
dti-3213	253	7	injection	injection	NOUN
dti-3213	253	8	regimen	regiman	NOUN
dti-3213	253	9	versus	versus	ADP
dti-3213	253	10	alternate	alternate	ADJ
dti-3213	253	11	dosing	dosing	NOUN
dti-3213	253	12	strategies	strategy	NOUN
dti-3213	253	13	in	in	ADP
dti-3213	253	14	age	age	NOUN
dti-3213	253	15	-	-	PUNCT
dti-3213	253	16	related	relate	VERB
dti-3213	253	17	macular	macular	ADJ
dti-3213	253	18	degeneration	degeneration	NOUN
dti-3213	253	19	:	:	PUNCT
dti-3213	253	20	a	a	DET
dti-3213	253	21	systematic	systematic	ADJ
dti-3213	253	22	review	review	NOUN
dti-3213	253	23	and	and	CCONJ
dti-3213	253	24	meta	meta	ADJ
dti-3213	253	25	-	-	PUNCT
dti-3213	253	26	analysis	analysis	NOUN
dti-3213	253	27	.	.	PUNCT
dti-3213	254	1	am	be	AUX
dti-3213	254	2	j	j	PROPN
dti-3213	254	3	ophthalmol	ophthalmol	NOUN
dti-3213	254	4	.	.	PUNCT
dti-3213	255	1	2018;192	2018;192	NUM
dti-3213	255	2	:	:	PUNCT
dti-3213	255	3	184	184	NUM
dti-3213	255	4	-	-	SYM
dti-3213	255	5	197	197	NUM
dti-3213	255	6	.	.	PUNCT
dti-3213	256	1	crossref	crossref	PROPN
dti-3213	256	2	pubmed	pubmed	PROPN
dti-3213	256	3	25	25	NUM
dti-3213	256	4	.	.	PUNCT
dti-3213	257	1	silva	silva	PROPN
dti-3213	257	2	r	r	PROPN
dti-3213	257	3	,	,	PUNCT
dti-3213	257	4	berta	berta	PROPN
dti-3213	257	5	a	a	PROPN
dti-3213	257	6	,	,	PUNCT
dti-3213	257	7	larsen	larsen	PROPN
dti-3213	257	8	m	m	PROPN
dti-3213	257	9	,	,	PUNCT
dti-3213	257	10	macfadden	macfadden	PROPN
dti-3213	257	11	w	w	NOUN
dti-3213	257	12	,	,	PUNCT
dti-3213	257	13	feller	feller	NOUN
dti-3213	257	14	c	c	NOUN
dti-3213	257	15	,	,	PUNCT
dti-3213	257	16	monés	monés	PROPN
dti-3213	257	17	j	j	PROPN
dti-3213	257	18	;	;	PUNCT
dti-3213	257	19	trend	trend	NOUN
dti-3213	257	20	study	study	NOUN
dti-3213	257	21	group	group	NOUN
dti-3213	257	22	.	.	PUNCT
dti-3213	258	1	treat	treat	NOUN
dti-3213	258	2	-	-	PUNCT
dti-3213	258	3	and	and	CCONJ
dti-3213	258	4	-	-	PUNCT
dti-3213	258	5	extend	extend	VERB
dti-3213	258	6	versus	versus	ADP
dti-3213	258	7	monthly	monthly	ADJ
dti-3213	258	8	regimen	regiman	NOUN
dti-3213	258	9	in	in	ADP
dti-3213	258	10	neovascular	neovascular	NOUN
dti-3213	258	11	age	age	NOUN
dti-3213	258	12	-	-	PUNCT
dti-3213	258	13	related	relate	VERB
dti-3213	258	14	macular	macular	ADJ
dti-3213	258	15	degeneration	degeneration	NOUN
dti-3213	258	16	:	:	PUNCT
dti-3213	258	17	results	result	VERB
dti-3213	258	18	with	with	ADP
dti-3213	258	19	ranibizumab	ranibizumab	NOUN
dti-3213	258	20	from	from	ADP
dti-3213	258	21	the	the	DET
dti-3213	258	22	trend	trend	NOUN
dti-3213	258	23	study	study	NOUN
dti-3213	258	24	.	.	PUNCT
dti-3213	259	1	ophthalmology	ophthalmology	NOUN
dti-3213	259	2	.	.	PUNCT
dti-3213	260	1	2018;125(1):57	2018;125(1):57	PROPN
dti-3213	260	2	-	-	SYM
dti-3213	260	3	65	65	NUM
dti-3213	260	4	.	.	PUNCT
dti-3213	261	1	crossref	crossref	PROPN
dti-3213	261	2	pubmed	pubmed	PROPN
dti-3213	261	3	26	26	NUM
dti-3213	261	4	.	.	PUNCT
dti-3213	262	1	wykoff	wykoff	PROPN
dti-3213	262	2	cc	cc	PROPN
dti-3213	262	3	,	,	PUNCT
dti-3213	262	4	clark	clark	PROPN
dti-3213	262	5	wl	wl	PROPN
dti-3213	262	6	,	,	PUNCT
dti-3213	262	7	nielsen	nielsen	PROPN
dti-3213	262	8	js	js	PROPN
dti-3213	262	9	,	,	PUNCT
dti-3213	262	10	brill	brill	PROPN
dti-3213	262	11	jv	jv	NOUN
dti-3213	262	12	,	,	PUNCT
dti-3213	262	13	greene	greene	PROPN
dti-3213	262	14	ls	ls	PROPN
dti-3213	262	15	,	,	PUNCT
dti-3213	262	16	heggen	heggen	PROPN
dti-3213	262	17	cl	cl	NOUN
dti-3213	262	18	.	.	PUNCT
dti-3213	263	1	optimizing	optimize	VERB
dti-3213	263	2	anti	anti	ADJ
dti-3213	263	3	-	-	ADJ
dti-3213	263	4	vegf	vegf	ADJ
dti-3213	263	5	treatment	treatment	NOUN
dti-3213	263	6	outcomes	outcome	NOUN
dti-3213	263	7	for	for	ADP
dti-3213	263	8	patients	patient	NOUN
dti-3213	263	9	with	with	ADP
dti-3213	263	10	neovascular	neovascular	NOUN
dti-3213	263	11	age	age	NOUN
dti-3213	263	12	-	-	PUNCT
dti-3213	263	13	related	relate	VERB
dti-3213	263	14	macular	macular	ADJ
dti-3213	263	15	degeneration	degeneration	NOUN
dti-3213	263	16	.	.	PUNCT
dti-3213	264	1	jmcp	jmcp	PROPN
dti-3213	264	2	.	.	PUNCT
dti-3213	265	1	2018	2018	NUM
dti-3213	265	2	;	;	PUNCT
dti-3213	265	3	24(2	24(2	NUM
dti-3213	265	4	-	-	PUNCT
dti-3213	265	5	a	a	DET
dti-3213	265	6	suppl):s3	suppl):s3	NOUN
dti-3213	265	7	-	-	PUNCT
dti-3213	265	8	s15	s15	NOUN
dti-3213	265	9	.	.	PUNCT
dti-3213	266	1	crossref	crossref	PROPN
dti-3213	266	2	pubmed	pubmed	PROPN
dti-3213	266	3	27	27	NUM
dti-3213	266	4	.	.	PUNCT
dti-3213	267	1	aifa	aifa	PROPN
dti-3213	267	2	.	.	PUNCT
dti-3213	268	1	determina	determina	NOUN
dti-3213	268	2	2	2	NUM
dti-3213	268	3	ottobre	ottobre	PROPN
dti-3213	268	4	2023	2023	NUM
dti-3213	268	5	riclassificazione	riclassificazione	NOUN
dti-3213	268	6	del	del	PROPN
dti-3213	268	7	medicinale	medicinale	NOUN
dti-3213	268	8	per	per	ADP
dti-3213	268	9	uso	uso	X
dti-3213	268	10	umano	umano	PROPN
dti-3213	268	11	«	«	PUNCT
dti-3213	268	12	vabysmo	vabysmo	NOUN
dti-3213	268	13	»	»	NOUN
dti-3213	268	14	,	,	PUNCT
dti-3213	268	15	ai	ai	VERB
dti-3213	268	16	sensi	sensi	PROPN
dti-3213	268	17	dell’articolo	dell’articolo	ADJ
dti-3213	268	18	8	8	NUM
dti-3213	268	19	,	,	PUNCT
dti-3213	268	20	comma	comma	NOUN
dti-3213	268	21	10	10	NUM
dti-3213	268	22	,	,	PUNCT
dti-3213	268	23	della	della	PROPN
dti-3213	268	24	legge	legge	PROPN
dti-3213	268	25	24	24	NUM
dti-3213	268	26	dicembre	dicembre	PROPN
dti-3213	268	27	1993	1993	NUM
dti-3213	268	28	,	,	PUNCT
dti-3213	268	29	n.	n.	NOUN
dti-3213	268	30	537	537	NUM
dti-3213	268	31	.	.	PUNCT
dti-3213	269	1	(	(	PUNCT
dti-3213	269	2	determina	determina	NOUN
dti-3213	269	3	n.	n.	NOUN
dti-3213	269	4	602/2023	602/2023	NUM
dti-3213	269	5	)	)	PUNCT
dti-3213	269	6	.	.	PUNCT
dti-3213	270	1	(	(	PUNCT
dti-3213	270	2	23a05528	23a05528	NUM
dti-3213	270	3	)	)	PUNCT
dti-3213	270	4	(	(	PUNCT
dti-3213	270	5	gu	gu	NOUN
dti-3213	270	6	n.235	n.235	NUM
dti-3213	270	7	del	del	PROPN
dti-3213	270	8	7	7	NUM
dti-3213	270	9	-	-	SYM
dti-3213	270	10	10	10	NUM
dti-3213	270	11	-	-	NUM
dti-3213	270	12	2023	2023	NUM
dti-3213	270	13	)	)	PUNCT
dti-3213	270	14	.	.	PUNCT
dti-3213	271	1	2023	2023	NUM
dti-3213	271	2	.	.	PUNCT
dti-3213	272	1	online	online	INTJ
dti-3213	272	2	.	.	PUNCT
dti-3213	273	1	(	(	PUNCT
dti-3213	273	2	accessed	access	VERB
dti-3213	273	3	july	july	PROPN
dti-3213	273	4	2024	2024	NUM
dti-3213	273	5	)	)	PUNCT
dti-3213	273	6	28	28	NUM
dti-3213	273	7	.	.	PUNCT
dti-3213	274	1	aifa	aifa	PROPN
dti-3213	274	2	.	.	PUNCT
dti-3213	275	1	determina	determina	NOUN
dti-3213	275	2	28	28	NUM
dti-3213	275	3	dicembre	dicembre	PROPN
dti-3213	275	4	2020	2020	NUM
dti-3213	275	5	istituzione	istituzione	NOUN
dti-3213	275	6	della	della	PROPN
dti-3213	275	7	nota	nota	PROPN
dti-3213	275	8	aifa	aifa	PROPN
dti-3213	275	9	98	98	NUM
dti-3213	275	10	relativa	relativa	NOUN
dti-3213	275	11	alla	alla	NOUN
dti-3213	275	12	prescrizione	prescrizione	NOUN
dti-3213	275	13	e	e	NOUN
dti-3213	275	14	alla	alla	NOUN
dti-3213	275	15	somministrazione	somministrazione	NOUN
dti-3213	275	16	intravitreale	intravitreale	NOUN
dti-3213	275	17	di	di	X
dti-3213	275	18	anti	anti	ADJ
dti-3213	275	19	-	-	PROPN
dti-3213	275	20	vegf	vegf	ADJ
dti-3213	275	21	nella	nella	PROPN
dti-3213	275	22	amd	amd	PROPN
dti-3213	275	23	e	e	PROPN
dti-3213	275	24	dme	dme	PROPN
dti-3213	275	25	.	.	PUNCT
dti-3213	276	1	(	(	PUNCT
dti-3213	276	2	determina	determina	NOUN
dti-3213	276	3	n.	n.	NOUN
dti-3213	276	4	dg/1379/2020	dg/1379/2020	PROPN
dti-3213	276	5	)	)	PUNCT
dti-3213	276	6	.	.	PUNCT
dti-3213	277	1	(	(	PUNCT
dti-3213	277	2	20a07338	20a07338	NUM
dti-3213	277	3	)	)	PUNCT
dti-3213	277	4	(	(	PUNCT
dti-3213	277	5	gu	gu	NOUN
dti-3213	277	6	n.323	n.323	NUM
dti-3213	277	7	del	del	PROPN
dti-3213	277	8	31	31	NUM
dti-3213	277	9	-	-	SYM
dti-3213	277	10	12	12	NUM
dti-3213	277	11	-	-	PUNCT
dti-3213	277	12	2020	2020	NUM
dti-3213	277	13	)	)	PUNCT
dti-3213	277	14	.	.	PUNCT
dti-3213	278	1	2020	2020	NUM
dti-3213	278	2	.	.	PUNCT
dti-3213	279	1	online	online	INTJ
dti-3213	279	2	.	.	PUNCT
dti-3213	280	1	(	(	PUNCT
dti-3213	280	2	accessed	access	VERB
dti-3213	280	3	july	july	PROPN
dti-3213	280	4	2024	2024	NUM
dti-3213	280	5	)	)	PUNCT
dti-3213	280	6	29	29	NUM
dti-3213	280	7	.	.	PUNCT
dti-3213	281	1	aifa	aifa	NOUN
dti-3213	281	2	.	.	PUNCT
dti-3213	282	1	determina	determina	PROPN
dti-3213	282	2	30	30	NUM
dti-3213	282	3	gennaio	gennaio	PROPN
dti-3213	282	4	2015	2015	NUM
dti-3213	282	5	inserimento	inserimento	ADP
dti-3213	282	6	di	di	X
dti-3213	282	7	una	una	PROPN
dti-3213	282	8	indicazione	indicazione	PROPN
dti-3213	282	9	terapeutica	terapeutica	PROPN
dti-3213	282	10	del	del	PROPN
dti-3213	282	11	medicinale	medicinale	PROPN
dti-3213	282	12	per	per	ADP
dti-3213	282	13	uso	uso	X
dti-3213	282	14	umano	umano	PROPN
dti-3213	282	15	«	«	PUNCT
dti-3213	282	16	bevacizumab	bevacizumab	PROPN
dti-3213	282	17	–	–	PUNCT
dti-3213	282	18	avastin	avastin	PROPN
dti-3213	282	19	»	»	PUNCT
dti-3213	282	20	nell’elenco	nell’elenco	ADV
dti-3213	282	21	ex	ex	PROPN
dti-3213	282	22	lege	lege	NOUN
dti-3213	282	23	n.	n.	NOUN
dti-3213	282	24	648/1996	648/1996	NUM
dti-3213	282	25	–	–	PUNCT
dti-3213	282	26	parziale	parziale	PROPN
dti-3213	282	27	modifica	modifica	PROPN
dti-3213	282	28	alla	alla	PROPN
dti-3213	282	29	determina	determina	PROPN
dti-3213	282	30	n.	n.	PROPN
dti-3213	282	31	622	622	NUM
dti-3213	282	32	dg/2014	dg/2014	PROPN
dti-3213	282	33	del	del	PROPN
dti-3213	282	34	23	23	NUM
dti-3213	282	35	giugno	giugno	NOUN
dti-3213	282	36	2014	2014	NUM
dti-3213	282	37	e	e	NOUN
dti-3213	282	38	sostituzione	sostituzione	NOUN
dti-3213	282	39	della	della	PROPN
dti-3213	282	40	stessa	stessa	NOUN
dti-3213	282	41	.	.	PUNCT
dti-3213	283	1	(	(	PUNCT
dti-3213	283	2	determina	determina	NOUN
dti-3213	283	3	n.	n.	NOUN
dti-3213	283	4	79/2015	79/2015	NUM
dti-3213	283	5	)	)	PUNCT
dti-3213	283	6	.	.	PUNCT
dti-3213	284	1	(	(	PUNCT
dti-3213	284	2	15a01013	15a01013	NUM
dti-3213	284	3	)	)	PUNCT
dti-3213	284	4	(	(	PUNCT
dti-3213	284	5	gu	gu	X
dti-3213	284	6	n.38	n.38	PROPN
dti-3213	284	7	del	del	PROPN
dti-3213	284	8	16	16	NUM
dti-3213	284	9	-	-	PUNCT
dti-3213	284	10	2	2	NUM
dti-3213	284	11	-	-	NUM
dti-3213	284	12	2015	2015	NUM
dti-3213	284	13	)	)	PUNCT
dti-3213	284	14	.	.	PUNCT
dti-3213	285	1	2015	2015	NUM
dti-3213	285	2	.	.	PUNCT
dti-3213	286	1	online	online	INTJ
dti-3213	286	2	.	.	PUNCT
dti-3213	287	1	(	(	PUNCT
dti-3213	287	2	accessed	access	VERB
dti-3213	287	3	july	july	PROPN
dti-3213	287	4	2024	2024	NUM
dti-3213	287	5	)	)	PUNCT
dti-3213	287	6	30	30	NUM
dti-3213	287	7	.	.	PUNCT
dti-3213	288	1	heier	heier	PROPN
dti-3213	288	2	js	js	PROPN
dti-3213	288	3	,	,	PUNCT
dti-3213	288	4	khanani	khanani	PROPN
dti-3213	288	5	am	am	PROPN
dti-3213	288	6	,	,	PUNCT
dti-3213	288	7	quezada	quezada	PROPN
dti-3213	288	8	ruiz	ruiz	PROPN
dti-3213	288	9	c	c	PROPN
dti-3213	288	10	,	,	PUNCT
dti-3213	288	11	et	et	PROPN
dti-3213	288	12	al	al	PROPN
dti-3213	288	13	;	;	PUNCT
dti-3213	288	14	tenaya	tenaya	PROPN
dti-3213	288	15	and	and	CCONJ
dti-3213	288	16	lucerne	lucerne	NOUN
dti-3213	288	17	investigators	investigator	NOUN
dti-3213	288	18	.	.	PUNCT
dti-3213	289	1	efficacy	efficacy	NOUN
dti-3213	289	2	,	,	PUNCT
dti-3213	289	3	durability	durability	NOUN
dti-3213	289	4	,	,	PUNCT
dti-3213	289	5	and	and	CCONJ
dti-3213	289	6	safety	safety	NOUN
dti-3213	289	7	of	of	ADP
dti-3213	289	8	intravitreal	intravitreal	ADJ
dti-3213	289	9	faricimab	faricimab	NOUN
dti-3213	289	10	up	up	ADP
dti-3213	289	11	to	to	ADP
dti-3213	289	12	every	every	DET
dti-3213	289	13	16	16	NUM
dti-3213	289	14	weeks	week	NOUN
dti-3213	289	15	for	for	ADP
dti-3213	289	16	neovascular	neovascular	NOUN
dti-3213	289	17	agerelated	agerelate	VERB
dti-3213	289	18	macular	macular	ADJ
dti-3213	289	19	degeneration	degeneration	NOUN
dti-3213	289	20	(	(	PUNCT
dti-3213	289	21	tenaya	tenaya	NOUN
dti-3213	289	22	and	and	CCONJ
dti-3213	289	23	lucerne	lucerne	NOUN
dti-3213	289	24	):	):	PUNCT
dti-3213	289	25	two	two	NUM
dti-3213	289	26	randomised	randomise	VERB
dti-3213	289	27	,	,	PUNCT
dti-3213	289	28	double	double	ADJ
dti-3213	289	29	-	-	PUNCT
dti-3213	289	30	masked	masked	ADJ
dti-3213	289	31	,	,	PUNCT
dti-3213	289	32	phase	phase	NOUN
dti-3213	289	33	3	3	NUM
dti-3213	289	34	,	,	PUNCT
dti-3213	289	35	non	non	ADJ
dti-3213	289	36	-	-	ADJ
dti-3213	289	37	inferiority	inferiority	ADJ
dti-3213	289	38	trials	trial	NOUN
dti-3213	289	39	.	.	PUNCT
dti-3213	290	1	lancet	lancet	PROPN
dti-3213	290	2	.	.	PUNCT
dti-3213	291	1	2022;399(10326):729	2022;399(10326):729	NUM
dti-3213	291	2	-	-	SYM
dti-3213	291	3	740	740	NUM
dti-3213	291	4	.	.	PUNCT
dti-3213	292	1	crossref	crossref	PROPN
dti-3213	292	2	pubmed	pubmed	PROPN
dti-3213	292	3	31	31	NUM
dti-3213	292	4	.	.	PUNCT
dti-3213	293	1	parravano	parravano	PROPN
dti-3213	293	2	mc	mc	PROPN
dti-3213	293	3	,	,	PUNCT
dti-3213	293	4	viola	viola	PROPN
dti-3213	293	5	f	f	PROPN
dti-3213	293	6	,	,	PUNCT
dti-3213	293	7	nicolo	nicolo	PROPN
dti-3213	293	8	m	m	PROPN
dti-3213	293	9	,	,	PUNCT
dti-3213	293	10	et	et	PROPN
dti-3213	293	11	al	al	PROPN
dti-3213	293	12	.	.	PUNCT
dti-3213	294	1	real	real	ADJ
dti-3213	294	2	-	-	PUNCT
dti-3213	294	3	world	world	NOUN
dti-3213	294	4	evidence	evidence	NOUN
dti-3213	294	5	of	of	ADP
dti-3213	294	6	anti	anti	ADJ
dti-3213	294	7	-	-	ADJ
dti-3213	294	8	vegf	vegf	ADJ
dti-3213	294	9	therapies	therapy	NOUN
dti-3213	294	10	in	in	ADP
dti-3213	294	11	neovascular	neovascular	NOUN
dti-3213	294	12	age	age	NOUN
dti-3213	294	13	-	-	PUNCT
dti-3213	294	14	related	relate	VERB
dti-3213	294	15	macular	macular	ADJ
dti-3213	294	16	degeneration	degeneration	NOUN
dti-3213	294	17	in	in	ADP
dti-3213	294	18	italy	italy	PROPN
dti-3213	294	19	:	:	PUNCT
dti-3213	294	20	the	the	DET
dti-3213	294	21	radiance	radiance	NOUN
dti-3213	294	22	study	study	NOUN
dti-3213	294	23	.	.	PUNCT
dti-3213	295	1	eur	eur	PROPN
dti-3213	295	2	j	j	PROPN
dti-3213	295	3	ophthalmol	ophthalmol	PROPN
dti-3213	295	4	.	.	PUNCT
dti-3213	296	1	(	(	PUNCT
dti-3213	296	2	in	in	ADP
dti-3213	296	3	press	press	NOUN
dti-3213	296	4	)	)	PUNCT
dti-3213	296	5	32	32	NUM
dti-3213	296	6	.	.	PUNCT
dti-3213	297	1	chesnaye	chesnaye	PROPN
dti-3213	297	2	nc	nc	PROPN
dti-3213	297	3	,	,	PUNCT
dti-3213	297	4	stel	stel	NOUN
dti-3213	297	5	vs	vs	ADP
dti-3213	297	6	,	,	PUNCT
dti-3213	297	7	tripepi	tripepi	NOUN
dti-3213	297	8	g	g	NOUN
dti-3213	297	9	,	,	PUNCT
dti-3213	297	10	et	et	PROPN
dti-3213	297	11	al	al	PROPN
dti-3213	297	12	.	.	PUNCT
dti-3213	298	1	an	an	DET
dti-3213	298	2	introduction	introduction	NOUN
dti-3213	298	3	to	to	PART
dti-3213	298	4	inverse	inverse	VERB
dti-3213	298	5	probability	probability	NOUN
dti-3213	298	6	of	of	ADP
dti-3213	298	7	treatment	treatment	NOUN
dti-3213	298	8	weighting	weighting	NOUN
dti-3213	298	9	in	in	ADP
dti-3213	298	10	observational	observational	ADJ
dti-3213	298	11	research	research	NOUN
dti-3213	298	12	.	.	PUNCT
dti-3213	299	1	clin	clin	PROPN
dti-3213	299	2	kidney	kidney	PROPN
dti-3213	299	3	j.	j.	PROPN
dti-3213	299	4	2021;15(1):14	2021;15(1):14	PROPN
dti-3213	299	5	-	-	PUNCT
dti-3213	299	6	20	20	NUM
dti-3213	299	7	.	.	PUNCT
dti-3213	300	1	crossref	crossref	PROPN
dti-3213	300	2	pubmed	pubmed	PROPN
dti-3213	300	3	33	33	NUM
dti-3213	300	4	.	.	PUNCT
dti-3213	301	1	holz	holz	PROPN
dti-3213	301	2	fg	fg	PROPN
dti-3213	301	3	,	,	PUNCT
dti-3213	301	4	tadayoni	tadayoni	PROPN
dti-3213	301	5	r	r	NOUN
dti-3213	301	6	,	,	PUNCT
dti-3213	301	7	beatty	beatty	PROPN
dti-3213	301	8	s	s	PROPN
dti-3213	301	9	,	,	PUNCT
dti-3213	301	10	et	et	PROPN
dti-3213	301	11	al	al	PROPN
dti-3213	301	12	.	.	PUNCT
dti-3213	301	13	determinants	determinant	NOUN
dti-3213	301	14	of	of	ADP
dti-3213	301	15	visual	visual	ADJ
dti-3213	301	16	acuity	acuity	NOUN
dti-3213	301	17	outcomes	outcome	NOUN
dti-3213	301	18	in	in	ADP
dti-3213	301	19	eyes	eye	NOUN
dti-3213	301	20	with	with	ADP
dti-3213	301	21	neovascular	neovascular	PROPN
dti-3213	301	22	amd	amd	PROPN
dti-3213	301	23	treated	treat	VERB
dti-3213	301	24	with	with	ADP
dti-3213	301	25	anti	anti	ADJ
dti-3213	301	26	-	-	ADJ
dti-3213	301	27	vegf	vegf	ADJ
dti-3213	301	28	agents	agent	NOUN
dti-3213	301	29	:	:	PUNCT
dti-3213	301	30	an	an	DET
dti-3213	301	31	instrumental	instrumental	ADJ
dti-3213	301	32	variable	variable	ADJ
dti-3213	301	33	analysis	analysis	NOUN
dti-3213	301	34	of	of	ADP
dti-3213	301	35	the	the	DET
dti-3213	301	36	aura	aura	NOUN
dti-3213	301	37	study	study	NOUN
dti-3213	301	38	.	.	PUNCT
dti-3213	302	1	eye	eye	NOUN
dti-3213	302	2	(	(	PUNCT
dti-3213	302	3	lond	lond	PROPN
dti-3213	302	4	)	)	PUNCT
dti-3213	302	5	.	.	PUNCT
dti-3213	303	1	2016;30(8):1063	2016;30(8):1063	NUM
dti-3213	303	2	-	-	SYM
dti-3213	303	3	1071	1071	NUM
dti-3213	303	4	.	.	PUNCT
dti-3213	304	1	crossref	crossref	PROPN
dti-3213	304	2	pubmed	pubmed	PROPN
dti-3213	304	3	34	34	NUM
dti-3213	304	4	.	.	PUNCT
dti-3213	305	1	li	li	PROPN
dti-3213	305	2	jq	jq	PROPN
dti-3213	305	3	,	,	PUNCT
dti-3213	305	4	welchowski	welchowski	PROPN
dti-3213	305	5	t	t	PROPN
dti-3213	305	6	,	,	PUNCT
dti-3213	305	7	schmid	schmid	PROPN
dti-3213	305	8	m	m	PROPN
dti-3213	305	9	,	,	PUNCT
dti-3213	305	10	mauschitz	mauschitz	PROPN
dti-3213	305	11	mm	mm	PROPN
dti-3213	305	12	,	,	PUNCT
dti-3213	305	13	holz	holz	PROPN
dti-3213	305	14	fg	fg	PROPN
dti-3213	305	15	,	,	PUNCT
dti-3213	305	16	finger	finger	NOUN
dti-3213	305	17	rp	rp	NOUN
dti-3213	305	18	.	.	PUNCT
dti-3213	306	1	prevalence	prevalence	NOUN
dti-3213	306	2	and	and	CCONJ
dti-3213	306	3	incidence	incidence	NOUN
dti-3213	306	4	of	of	ADP
dti-3213	306	5	age	age	NOUN
dti-3213	306	6	-	-	PUNCT
dti-3213	306	7	related	relate	VERB
dti-3213	306	8	macular	macular	ADJ
dti-3213	306	9	degeneration	degeneration	NOUN
dti-3213	306	10	in	in	ADP
dti-3213	306	11	europe	europe	PROPN
dti-3213	306	12	:	:	PUNCT
dti-3213	306	13	a	a	DET
dti-3213	306	14	systematic	systematic	ADJ
dti-3213	306	15	review	review	NOUN
dti-3213	306	16	and	and	CCONJ
dti-3213	306	17	meta	meta	ADJ
dti-3213	306	18	-	-	PUNCT
dti-3213	306	19	analysis	analysis	NOUN
dti-3213	306	20	.	.	PUNCT
dti-3213	307	1	br	br	PROPN
dti-3213	308	1	j	j	PROPN
dti-3213	308	2	ophthalmol	ophthalmol	PROPN
dti-3213	308	3	.	.	PUNCT
dti-3213	309	1	2020;104(8):1077	2020;104(8):1077	NUM
dti-3213	309	2	-	-	SYM
dti-3213	309	3	1084	1084	NUM
dti-3213	309	4	.	.	PUNCT
dti-3213	310	1	crossref	crossref	PROPN
dti-3213	310	2	pubmed	pubmed	PROPN
dti-3213	310	3	35	35	NUM
dti-3213	310	4	.	.	PUNCT
dti-3213	311	1	pina	pina	PROPN
dti-3213	311	2	marín	marín	PROPN
dti-3213	311	3	b	b	PROPN
dti-3213	311	4	,	,	PUNCT
dti-3213	311	5	gajate	gajate	VERB
dti-3213	311	6	paniagua	paniagua	PRON
dti-3213	311	7	nm	nm	NOUN
dti-3213	311	8	,	,	PUNCT
dti-3213	311	9	gómez	gómez	NOUN
dti-3213	311	10	-	-	PUNCT
dti-3213	311	11	baldó	baldó	NOUN
dti-3213	311	12	l	l	NOUN
dti-3213	311	13	,	,	PUNCT
dti-3213	311	14	gallegopinazo	gallegopinazo	PROPN
dti-3213	311	15	r.	r.	NOUN
dti-3213	311	16	burden	burden	NOUN
dti-3213	311	17	of	of	ADP
dti-3213	311	18	disease	disease	NOUN
dti-3213	311	19	assessment	assessment	NOUN
dti-3213	311	20	in	in	ADP
dti-3213	311	21	patients	patient	NOUN
dti-3213	311	22	with	with	ADP
dti-3213	311	23	neovascular	neovascular	NOUN
dti-3213	311	24	age	age	NOUN
dti-3213	311	25	-	-	PUNCT
dti-3213	311	26	related	relate	VERB
dti-3213	311	27	macular	macular	ADJ
dti-3213	311	28	degeneration	degeneration	NOUN
dti-3213	311	29	in	in	ADP
dti-3213	311	30	spain	spain	PROPN
dti-3213	311	31	:	:	PUNCT
dti-3213	311	32	results	result	NOUN
dti-3213	311	33	of	of	ADP
dti-3213	311	34	the	the	DET
dti-3213	311	35	amd	amd	ADJ
dti-3213	311	36	-	-	PUNCT
dti-3213	311	37	manage	manage	NOUN
dti-3213	311	38	study	study	NOUN
dti-3213	311	39	.	.	PUNCT
dti-3213	312	1	eur	eur	PROPN
dti-3213	312	2	j	j	PROPN
dti-3213	312	3	ophthalmol	ophthalmol	PROPN
dti-3213	312	4	.	.	PUNCT
dti-3213	313	1	2022;32(1	2022;32(1	NUM
dti-3213	313	2	):	):	PUNCT
dti-3213	313	3	385	385	NUM
dti-3213	313	4	-	-	SYM
dti-3213	313	5	394	394	NUM
dti-3213	313	6	.	.	PUNCT
dti-3213	314	1	crossref	crossref	PROPN
dti-3213	314	2	pubmed	pubmed	PROPN
dti-3213	314	3	https://doi.org/10.1371/journal.pone.0256461	https://doi.org/10.1371/journal.pone.0256461	PROPN
dti-3213	314	4	https://pubmed.ncbi.nlm.nih.gov/34469431/	https://pubmed.ncbi.nlm.nih.gov/34469431/	PROPN
dti-3213	314	5	https://doi.org/10.1056/nejmoa1102673	https://doi.org/10.1056/nejmoa1102673	PROPN
dti-3213	314	6	https://www.ncbi.nlm.nih.gov/pubmed/21526923	https://www.ncbi.nlm.nih.gov/pubmed/21526923	PRON
dti-3213	314	7	https://www.ncbi.nlm.nih.gov/pubmed/37392108	https://www.ncbi.nlm.nih.gov/pubmed/37392108	NUM
dti-3213	314	8	https://doi.org/10.1177/11206721211018348	https://doi.org/10.1177/11206721211018348	PROPN
dti-3213	314	9	https://www.ncbi.nlm.nih.gov/pubmed/34053331	https://www.ncbi.nlm.nih.gov/pubmed/34053331	NUM
dti-3213	314	10	https://doi.org/10.1007/s00417-021-05451-2	https://doi.org/10.1007/s00417-021-05451-2	NUM
dti-3213	314	11	https://www.ncbi.nlm.nih.gov/pubmed/34669026	https://www.ncbi.nlm.nih.gov/pubmed/34669026	X
dti-3213	315	1	https://doi.org/10.1136/bjophthalmol-2020-317434	https://doi.org/10.1136/bjophthalmol-2020-317434	X
dti-3213	315	2	https://www.ncbi.nlm.nih.gov/pubmed/33130553	https://www.ncbi.nlm.nih.gov/pubmed/33130553	X
dti-3213	316	1	https://doi.org/10.1001/jamaophthalmol.2019.5540	https://doi.org/10.1001/jamaophthalmol.2019.5540	PROPN
dti-3213	316	2	https://www.ncbi.nlm.nih.gov/pubmed/31917441	https://www.ncbi.nlm.nih.gov/pubmed/31917441	PRON
dti-3213	316	3	https://doi.org/10.1097/iae.0000000000001142	https://doi.org/10.1097/iae.0000000000001142	PROPN
dti-3213	316	4	https://www.ncbi.nlm.nih.gov/pubmed/27388744	https://www.ncbi.nlm.nih.gov/pubmed/27388744	X
dti-3213	316	5	https://doi.org/10.1016/j.ajo.2018.05.026	https://doi.org/10.1016/j.ajo.2018.05.026	PROPN
dti-3213	316	6	https://www.ncbi.nlm.nih.gov/pubmed/29885297	https://www.ncbi.nlm.nih.gov/pubmed/29885297	NUM
dti-3213	316	7	https://doi.org/10.1016/j.ophtha.2017.07.014	https://doi.org/10.1016/j.ophtha.2017.07.014	PRON
dti-3213	316	8	https://www.ncbi.nlm.nih.gov/pubmed/28893454	https://www.ncbi.nlm.nih.gov/pubmed/28893454	NUM
dti-3213	316	9	https://doi.org/10.18553/jmcp.2018.24.2-a.s3	https://doi.org/10.18553/jmcp.2018.24.2-a.s3	NUM
dti-3213	316	10	https://pubmed.ncbi.nlm.nih.gov/29383980/	https://pubmed.ncbi.nlm.nih.gov/29383980/	PROPN
dti-3213	316	11	https://www.aifa.gov.it/documents/20142/961234/determina_602-2023_vabysmo.pdf	https://www.aifa.gov.it/documents/20142/961234/determina_602-2023_vabysmo.pdf	NOUN
dti-3213	316	12	https://www.aifa.gov.it/documents/20142/1728119/determina_28-12-2020_nota98.pdf	https://www.aifa.gov.it/documents/20142/1728119/determina_28-12-2020_nota98.pdf	PROPN
dti-3213	316	13	https://www.aifa.gov.it/documents/20142/241028/avastin_amd_648_79_2015.pdf	https://www.aifa.gov.it/documents/20142/241028/avastin_amd_648_79_2015.pdf	NOUN
dti-3213	316	14	https://doi.org/10.1016/s0140-6736(22)00010-1	https://doi.org/10.1016/s0140-6736(22)00010-1	PROPN
dti-3213	316	15	https://www.ncbi.nlm.nih.gov/pubmed/35085502	https://www.ncbi.nlm.nih.gov/pubmed/35085502	PRON
dti-3213	316	16	https://doi.org/10.1093/ckj/sfab158	https://doi.org/10.1093/ckj/sfab158	PROPN
dti-3213	316	17	https://www.ncbi.nlm.nih.gov/pubmed/35035932	https://www.ncbi.nlm.nih.gov/pubmed/35035932	NUM
dti-3213	316	18	https://doi.org/10.1038/eye.2016.90	https://doi.org/10.1038/eye.2016.90	PROPN
dti-3213	316	19	https://www.ncbi.nlm.nih.gov/pubmed/27197868	https://www.ncbi.nlm.nih.gov/pubmed/27197868	PUNCT
dti-3213	316	20	https://doi.org/10.1136/bjophthalmol-2019-314422	https://doi.org/10.1136/bjophthalmol-2019-314422	NUM
dti-3213	316	21	https://www.ncbi.nlm.nih.gov/pubmed/31712255	https://www.ncbi.nlm.nih.gov/pubmed/31712255	NUM
dti-3213	316	22	https://doi.org/10.1177/11206721211001716	https://doi.org/10.1177/11206721211001716	NOUN
dti-3213	316	23	https://www.ncbi.nlm.nih.gov/pubmed/33719641	https://www.ncbi.nlm.nih.gov/pubmed/33719641	NUM